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ABSTRACT
! Myotonic dystrophy (DM) is currently an incurable genetic disease that affects 1 
in 8,000 humans worldwide. Although extensive efforts have been made to understand 
its pathogenesis, the mechanism by which DM causes its symptoms is not fully 
understood. Nevertheless, it is known that the alternative splicing regulator, MBNL1, is 
sequestered by two types of abnormally long RNAs. Specifically there are the tri- and 
tetra-nucleotide repeats, CUG and CCUG, in DM1 and DM2, respectively. This key 
discovery inspired the development of ligands that inhibit MBNL1-RNA complex 
formation, allowing MBNL1 to resume its biological functions. The background to the 
DM disease will be given in Chapter 1.
! In 2009, our group reported a rationally  designed ligand (11) that recognizes the 
base mismatches in CUG repeats found in type 1 myotonic dystrophy (DM1). Although 
little was known about the binding mode, this lead compound disrupts the MBNL1-RNA 
complex in vitro. Attempts to obtain a crystal of the RNA-ligand complex for X-ray 
analysis were unsuccessful. As part of an alternative strategy, we have synthesized a 
small library of lead-like compounds to better understand the structure-activity 
relationship. In Chapter 2, possible binding modes of the lead ligands are elucidated 
using a combination of synthesis, gel shift assay, and molecular dynamics simulation. 
During the course of study, a lead compound for the type 2 myotonic dystrophy (DM2) 
was discovered. The synthesis, biophysical studies, and in vitro activity of this 
compound is described in Chapter 3. A new class of potential DM drugs has been 
discovered using a reported structure of a HIV RNA-ligand complex, combined with the 
knowledge gained in studying ligand 11. These ligands possess better aqueous 
solubility and lower toxicity. More importantly, they are shown to be active in a DM1 
Drosophila model. The design, synthesis, and evaluation of these ligands are described 
in Chapter 4.
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Chapter 1   Introduction
1.1 Background to Myotonic Dystrophy
Myotonic dystrophy (dystrophia myotonica or DM) is currently an incurable, inherited 
neuromuscular disease with a prevalence of 1 in 8,500 worldwide.1 DM is characterized 
by its highly variable age of disease onset with a wide range of multisystemic symptoms 
(Table 1). Medical managements such as physiotherapy and supportive devices are 
available for only some of the symptoms. In some cases, surgery  is required for 
example for drooping eyelids (ptosis) and cataracts. There are a limited number of 
drugs available for relieving symptoms; mexiletine2 was recently found to be effective in 
reducing myotonia but none of them cures the disease (Chart 1). Currently, two major 
types of DM have been identified: type 1 (DM1) and type 2 (DM2). One major difference 
between the two types is the lack of congenital form in DM2. The symptoms for DM2 are 
1
Table 1. Common clinical features of DM1 and DM2 and their management.
Symptom DM1 DM2 Management
Muscle weakness + + + Drugs for symptoms; occupational therapy; physiotherapy
Myotonia + + + + Mexiletine; heated gloves
Calf hypertrophy – + No specific management
Cataract + + Eye assessment; cataract removal
Diabetes + + Glucose measurement; diet modification
Cardiac problems + + ± Annually to hourly electrocardiography (ECG); pacemakers
Respiratory failure + + – Respiratory assessment; nocturnal non-invasive ventilation
Gastrointestinal symptoms + + – Cholestyramine; gastroenterology assessment
Dysphagia + – Speech therapy
Developmental disability + + – Physiotherapy; occupational therapy; pre-natal testing
+ +: present and prominent; +: present; –: not present; ±: minor
often milder compared to those for DM1 and the disease progresses more slowly.3 
Unlike DM1 which is present in all most countries, DM2 was mainly  found in Europe. It 
was further suggested that the prevalence of DM2 in Germany could be as high as that 
of DM1.4 Like DM1, DM2 is also incurable.
1.2 Disease Mechanism and RNA Gain-of-Function Toxicity
The discovery of the mutated genes for DM1 and DM2, in 19925 and 2001,6 
respectively, has led to a burgeoning research effort focused on understanding the 
disease mechanism and development of therapeutic strategies. It was discovered that 
DM1 and DM2 are caused by unstable nucleotide repeat expansions in DNA.7,8 DM1 is 
caused by the trinucleotide CTG expansion, from a normal length of <37 up to 2,000 or 
higher in those with the disease.9 The expansion is located in the 3’-untranslated region 
(3’-UTR) of the dystrophia myotonica protein kinase (DMPK) gene (Figure 1a), whereas 
DM2 is associated with a tetranucleotide CCTG repeat expansion (from <30 to 11,000 
repeats) in the intron 1 of the zinc-finger 9 (ZNF9) gene (Figure 1b).6 It was shown that 
the severity of the disease increases and the age of onset decreases with increasing 
number of repeats of the genes.10 The expansion also grows progressively longer 
during the patients lifetime.5 Several disease mechanisms have been proposed;11-13 
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Chart 1. Drugs for relieving some of the DM symptoms.
currently, the generally accepted hypothesis is a toxic RNA gain-of-function model14,15 
for the non-coding RNA transcripts of the expanded DNA (Figure 1c). These mutant 
RNA sequences, (CUG)n and (CCUG)n for DM1 and DM2, respectively, form nuclear 
inclusions which in turn sequester an alternative splicing protein, muscleblind-like 1 
(MBNL1) (Figure 1d). These MBNL1-RNA complexes were observed as nuclear foci in 
both DM1 and DM2 cells using immunofluorescence and fluorescence in situ 
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Figure 1. (a) Location of trinucleotide CTG repeats in the 3’-UTR of the DMPK gene on chromosome 19. 
(b) Location of tetranucleotide CCTG repeats within intron 1 of the ZNF9 gene on chromosome 3. (c) 
Expanded transcripts from these genes form stable stem-loop structures with U-U mismatch in DM1 and 
C-U mismatch in DM2. (d) MBNL1 proteins were sequestered by the expanded RNAs inside the nucleus 
and the resulting foci can be seen as green spots under confocal microscope using immunofluorescence 
staining. (e) MBNL1 sequestration leads to misregulated alternative splicings of > 100 pre-mRNAs.
hybridization (FISH) techniques.16 The depletion of MBNL proteins leads to global mis-
regulated alternative splicings of >100 pre-mRNAs, which in turn leads to the 
multisystemic symptoms of the DM diseases (Figure 1e).17
! What is the mechanism for repeat expansion? Most studies suggest the 
formation of unusual DNA structures during DNA metabolism that are the key 
determinants of the expansion.8 The exact mechanisms of how these unusual structures 
lead to repeat expansion beyond the normal range (< 30–40 repeats) remains 
controversial; different or even contradictory results have been obtained across different 
organisms, such as yeast, mouse, and human models.18 The repeat expansion is also 
found to be depending on the specific tissue- and cell-type within an individual as well 
as the stages of development.19 This complexity is further increased by the number of 
proteins and pathways involved during DNA replication, repair, recombination, and 
transcription. Investigations of the expansion mechanism are ongoing but, at this 
writing, targeting the expanded DNA with the hope of slowing, or even reversing the 
CTG expansion, is yet to be a viable strategy.18
1.3 RNA as a Viable Target for Treating DM
As described previously, although the DNA expansion mechanism is not known, most 
results suggest a toxic gain-of-function of the non-coding, expanded RNA as the cause 
of multisystemic symptoms of DM.15 There are multiple strategies that can be applied at 
the RNA level including degrading or repairing the expanded RNA.20 Among these 
strategies, inhibiting the MBNL1-RNA interaction, thereby releasing MBNL1 to resume 
its biological functions, is perhaps one the of most promising approaches. In 2006, 
4
Swanson and co-workers reported a significant reversal of missplicing of a major 
skeletal muscle chloride channel (Clcn1) by  overexpression of the Mbnl1 protein in 
mouse muscle.21 A substantial reduction of myotonia was observed using 
electromyography. This result clearly  indicated the importance of having a significant 
level of free MBNL1 inside the cells and suggested the idea of inhibiting the MBNL1-
RNA interaction as a therapeutic strategy.
1.4 Antisense Strategy
One of the appealing approaches is the use of antisense oligonucleotides (AONs) to 
hybridize with the mutant RNA to release MBNL1 from the foci.22,23 Whereas common 
antisense strategies involve RNase H or other nuclease-mediated pathways to cleave 
the tareget RNA, Thornton and co-workers reported the use of the antisense morpholino 
oligonucleotide agent, CAG25, to inhibit MBNL1-CUG interaction without triggering the 
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Figure 2. Comparative structure of CAG antisense oligonucleotide: (a) phosphorodiamidate morpholino 
oligonucleotide (PMO), (b) 2’-O-methylated phosphorothiolate (2’-OMe-PT), (c) r(CAG) segment in hU7-
snRNA, and (d) locked nucleic acid (LNA) with phosphorothiolate linkage.
cleavage of the expanded RNA, thereby lowering the risk of degrading other CUG-
containing transcripts (Note: CAG25 is a 25-nt antisense morpholino oligonucleotides 
containing 7 CAG repeats).24 CAG25 (Figure 2a) not only dispersed the nuclear foci but 
also restored the expression of ClC-1 channels in tibialis anterior (TA) muscle of HSALR 
transgenic mice. Similar effects were also observed by Wansink and co-workers using 
an 2’-O-methyl phosphorothioate (PT) (CAG)7 antisense oligonucleotide (Figure 2b).25 It 
is noteworthy that both PMO and 2’-OMe-PT AONs are not expected to mediate RNase-
based degradation because of their structures. Therefore, the mechanism for the 
unpredicted reduction of the expanded transcripts using these AONs remains unclear. 
Furling and co-workers reported the transduction of an engineered human U7 small 
nuclear RNAs (hU7-snRNAs) containing a (CAG)15 segment into human DM1 muscle 
cell (Figure 2c).26 The transduced DM cells expressed the hU7-(CAG)15 which in turn 
inhibited the MBNL1-CUG interaction, thereby removing the need of repeated 
administration of AONs. Recently, Thornton and co-workers showed that locked-nucleic 
acid (LNA)-based AONs (Figure 2d) not only  reduced the amount of nuclear foci but 
also reduced the average length of CTG repeats.27 However, the mechanism that led to 
the contraction is still unknown.
! Although antisense technology yielded promising results in cell and animal 
models, there are still several limitations that need to be addressed before entering 
clinical trials, namely, delivery, distribution, and toxicity.20 The current results with AONs 
have relied on local injection into a particular muscle, so reversal of the phenotype in an 
organism as a whole has yet to be demonstrated. It is also observed that the inter-tissue 
spreading is minimal for 2’-OMe-PT-(CAG)7 suggesting the difficulty of achieving a 
6
global phenotype reversal through single injection.25 This low dispersion rate is not 
surprising given the high molecular weights of these AONs (6,400–7,500 Da). These 
challenges are not unique to the treatment of DM, given the history of issues associated 
with the safe and selective delivery of AONs in the treatment of other diseases.22 Oral 
administration has yet to be shown as a viable strategy. Another major concern is the 
long-term toxicity  profile of these AONs. Commonly observed toxicities are resulted from 
off-targeting binding and undesirable immune activation.28 Like other drugs, the toxicity 
of AONs was observed at higher doses. The question remains whether one can treat 
DM with antisense technology with selective delivery at a safe dose range.
1.5 Inhibition by Small Molecules Discovered from Screening
While this project was ongoing, Miller and co-workers reported the first small molecule 
inhibitors for treating myotonic dystrophy  in 2008.29 By screening a resin-bound dynamic 
combinatorial library (RBDCL) of 11,325 members, the authors discovered three lead 
compounds capable of inhibiting MBNL1-CUG interaction in vitro with low micromolar Kd 
and Ki values (Chart 2). In 2012, the same group reported a new series of compounds 
from RBDCL  and found that derivatives 4 and 5 are stronger CUG binders and partially 
restore missplicing in a DM1 mouse model.30
! By a screening of 26 known nucleic acid binders, Berglund and co-workers 
discovered that both pentamidine (6) and neomycin B (7) disrupt the MBNL1-CUG 
interaction in vitro but only  pentamidine reversed the missplicing of cardiac troponin T 
(cTNT) and insulin receptor (IR) pre-mRNAs in HeLa cells (Chart 3).31 The authors also 
found that pentamidine partially reversed the missplicing of the chloride-1 (Clc-1) and 
7
sarco/endoplasmic reticulum Ca2+-ATPase-1 (Serca1) pre-mRNAs in DM1 mouse 
model and, thus, pentamidine became the first small molecule that was shown to be 
active in animal model. Unfortunately, the therapeutic window was narrow because of 
pentamidine’s high toxicity.32 For example, a treatment of 30 mg/kg dosage twice a day 
was lethal to mice while 40 mg/kg per day partially reversed the missplicing of the Clc-1 
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Chart 2. Lead compounds discovered for DM1 from a RBDCL by Miller and co-workers.
and Serca1 mRNAs. Pentamidine is also known to bind to various protein33,34 and 
nucleic acid targets.35-38 Although the selectivity of pentamidine is poor, the report 
indicated that small molecule inhibition is a viable approach for the treatment of DM1 in 
animal model.
! Artero and co-workers identified a D-amino acid hexapeptide (8; Ac-ppyawe-NH2) 
from a combinatorial peptide library that suppressed DM1 phenotypes in both 
Drosophila and mouse models (Chart 4).39 It was observed that the hexapeptide and 
Drosophila muscleblind (Mbl) aggregate with the r(CUG)23 which prevented the authors 
from quantifying the binding and inhibiting activities in vitro. Based on the circular 
dichroism (CD) studies, it was suggested that the hexapeptide destabilized the duplex 
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Chart 4. Structure of the D-amino acid hexapeptide (8) discovered by Artero and co-workers.
region of the r(CUG)60 hairpin thereby reducing the affinity of the RNA towards the Mbl 
protein.
1.6 Oligomerization of CUG-binders
In principle, an oligomeric ligand has a higher affinity  toward the target because of the 
multivalent binding.40 Oligomeric ligands are also expected to provide better inhibition 
because of a larger steric coverage of the target. By taking advantage of the repetitive 
nature of the toxic RNA, Disney and co-workers reported a repertoire of peptoid-based 
oligomeric ligands for inhibiting MBNL1-RNA interactions for DM141 and DM242 (Figure 
3). As expected, these oligomers bind much more strongly to the toxic RNA than the 
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Figure 3. Disney’s oligomeric binders for (a) CUG repeats in DM1 and (b) CCUG repeats in DM2.
corresponding monomers. For example, pentamer 9 and hexamer 10 bind to CUG and 
CCUG repeats, respectively, with low nanomolar Kd values. These tighter RNA binders 
are also better inhibitors of the MBNL1-RNA interaction with IC50 in the low nanomolar 
range. Although these oligomers have high molecular weights (MW = 5,122 for 9 and 
3,438 for 10), they are shown to be cell-permeable to mouse myoblasts.41,42 In both 
series of oligomers, the Kd and IC50 values improves with increasing number of 
repeating units. To further improve the bioavailability of these oligomers, the authors 
reported the use of D-Arg9-conjugated peptoids to facilitate the cellular uptake.43 
Substantial improvements in IC50 and splicing correction were observed with the D-Arg9-
conjugated oligomers.43 In Chapter 4, we proposed an “in situ” ligand oligomerization 
approach that takes advantages of both the higher bioavailability of monomers and the 
high potency of the resulting oligomers.
1.7 Lead Development in Our Laboratory
Based on an X-ray  structure (PDB: 1ZEV) reported by Berglund in 2005 (Figure 4a),44 
we reported a class of ligands consisting of an intercalator (11) linked to a “Janus-
wedge”45 recognition unit that showed low micromolar affinity  to CTG and CUG repeats 
(Figure 4b).46 By linking a recognition unit (a triaminotriazine in this system) to the 
acridine unit by a short tetramethylene linker with the hope of reducing non-selective 
intercalation by the formation of a π-stacked conformation in aqueous medium (Figure 
5a). The triaminotriazine moiety is designed to function as a Janus-wedge being 
capable of binding two thymine or uracil units simultaneously from the major or minor 
groove if the hydrogen bonding complementarity is the only consideration (Figure 5b). 
11
T h e π - s t a c k e d a c r i d i n e r i n g 
intercalates between the mismatch 
and the neighbor Watson-Crick base 
pair (Figures 4b and 5c). The study 
of binding mode of ligand 11 to CTG 
and CUG repeats will be presented 
in Chapter 2. Using isothermal 
titration calorimetry (ITC), ligand 11 
was shown to bind to CTG and CUG 
repeats with low-micromolar affinity 
(0.5–0.7 µM).46 In addition, ligand 11 
exhibited moderate to high selectivity 
(8-fold weaker CCG and >70-fold weaker to CAG and CGG). More importantly, it was 
shown by electrophoretic mobility shift assay (EMSA) that the ligand inhibited MBNL1 
protein from binding to r(CUG)12 with low-micromolar Ki (~ 7 µM). However, moderate 
toxicity  and non-selectivity  intercalation were observed in various cellular studies 
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(a) (b)
Figure 4. (a) X-ray structure r(CUG)6 duplex (PDB: 1ZEV) 
showing the characteristic U-U mismatches (in white) 
sandwiched between CG steps (in green). (b) Molecular 
modeling of ligand 11 (in blue) binding to r(CUG)6 duplex.
11
N
N
N
HN
NH
NH2H2N
N Cl
MeO
(a) (b)
preferred conformation 
in aqueous medium
N
N
N
N
N
HH
H
N
HN
MeO
Cl
NH
H
5'
3'
C
G
C
G
U
G
C
G
C
UN
Cl
OMe
HN
N N
NN N
N
H
HH
H
H
NN
O
H
O
N N
O
H
O
R R
Thymine: R = Me
     Uracil: R = H
(c)
Figure 5. (a) Ligand 11 contains a triaminotriazine unit designed for selective targeting T-T and U-U 
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conducted in the Hergenrother group at UIUC. Solubility  problems were also 
encountered in several ITC and EMSA assays. Nonetheless, ligand 11 is a good lead 
compound because of its high affinity and merits further structural modifications to 
achieve better properties. In fact, we discovered two lead ligands that are structurally 
similar to ligand 11 for potential treatment of DM2 and the results will be presented in 
Chapter 3. In 2011, a promising lead was designed based on the knowledge and results 
generated in the past. In collaborations with other research groups in the United States 
and Hong Kong, the biological activity of the new lead compounds has been extensively 
studied. Many of these results will be presented in Chapter 4.
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2.1 Introduction
As mentioned in Section 1.6, our first lead compound (11) was designed based on the 
crystal structure of r(CUG)6 duplex reported by Berglund in 2005.44 We believe that we 
can design better compounds if we have a better understanding of how the ligands 
interact with the CUG repeats. After our first report of ligand 11 in 2009, we initiated a 
collaboration with the Berglund lab  attempting to grow a crystal for solving the structure 
14
1 This chapter includes previously published material. The other contributors were Stacie L. Richardson, 
Yen-Jun Ho, Alex M. H. Lucas, Tiziano Tuccinardi, Anne M. Baranger, and Steven C. Zimmerman. 
Reused with permission from: Wong, C.-H.; Richardson, S. L.; Ho, Y.-J.; Lucas, A. M. H.; Tuccinardi, T.; 
Baranger, A. M.; Zimmerman, S. C. ChemBioChem 2012, 13, 2505–2509.
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Chart 5. Derivatives of ligand 11 with improved aqueous solubility.
of the RNA-ligand complex. Unfortunately, we cannot obtain any crystal and we believe 
that one of the reasons for the failure is the high percentage (5%) of DMSO used in the 
crystallization settings. Although the in vitro properties of ligand 11 are promising, we 
need to prepare derivatives with better aqueous solubility not only for preparing crystal 
structures but also for cellular and animal studies. Thus, after modifying the acridine ring 
of 11 to carry an ammonium ion, we are able to obtain several derivatives (e.g., 12 and 
13) with improved aqueous solubilities (~0.5 vs. <0.1 mg/mL). These compounds have 
activities comparable to that of ligand 11 in terms of RNA binding and inhibition of the 
MBNL1-CUG complexation. Only 1% (v/v) of DMSO was used in those assays (vs 5–
10% DMSO for ligand 11). In collaboration with Professor Raven Huang at UIUC, we 
attempted to grow co-crystals of the ligand 11 with CTG duplexes (i.e., DNA sequences) 
along with its aqueous soluble derivatives 12 and 13. We were able to obtain crystals 
with ligand 12 but the quality  was not suitable for X-ray crystallography. We are currently 
solving an NMR solution structure with compounds 11–13 in collaboration with 
Professor Sherlock Lam at the Chinese University of Hong Kong.
! In the absence of structural information, we set out to establish the structure-
activity  relationship  using an indirect approach.47 Using a combination of biophysical 
and molecular dynamics (MD) simulations, this study supports distinct binding modes 
for the recognition of CUG sites in RNA and CTG sites in DNA. More importantly, we 
discovered a number of ligands that are CTG-selective but show no measurable affinity 
for RNA, potentially opening an avenue for a DNA-targeted molecular therapy for DM1.
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2.2 Structures of the CUG Repeats
At this writing, there are a total of 6 reports on the structures of CUG repeats (5 reports 
on X-ray44,48-51 and 1 on NMR structures).52 All CUG-containing structures generally 
adopted standard A-form RNA duplex conformations with a shallow and wide minor 
groove and a deep and narrow major groove (Figure 6).53 Three of the representative 
CUG structures are shown in Figures 6b–d showing the characteristic A-form features. 
All of them contain U-U mismatches sandwiched between CG steps. The U-U 
mismatches have a C1’-C1’ distance (~10.4 Å) that is close to the average value of a 
standard A-form duplex.51 Interestingly, this type of U-U mismatch appears to be an 
intermediate structure between the cis-U-U54 and trans-U-U pairs (Figure 7).55,56 The U-
U mismatch in CUG repeats has more hydrogen bonding sites available for recognition 
16
Standard A-form 
RNA duplex
(PDB: 1QC0; 19 bp) 
(a) (b) (c) (d)
Major 
groove
Minor 
groove
2005
[r(CUG)6]2
(PDB: 1ZEV; 18 bp) 
2012
[r(UUGGGC(CUG)3GUCC)]2
(PDB: 3SZX; 17 bp) 
2012
[rG(CUG)6C]2
(PDB: 4E48; 20 bp) 
Figure 6. (a) Structure of a typical A-form RNA duplex (PDB: 1QC0). Three representative CUG repeats 
structures adopting A-form RNA conformation (b)–(d).
than a cis-U-U pair but the C1’-C1’ distance is not so lengthened that will distort the 
helical backbone. Thus, the overall structure of CUG repeats do not deviate from a 
typical A-form helix even with the recurring U-U mismatches.
! The dynamics of the U-U pairs was reported by Disney and co-workers in 2011.52 
Combined with NMR and molecular dynamics (MD) simulations, the authors suggested 
that these U-U pairs are weakly paired and the majority  (relative populations = 76.5%) 
of the mismatches are singly hydrogen bonded. This result is in good agreement with 
the crystal structures described above (see Figure 7b; PDB: 3GM7). Very few doubly 
hydrogen bonded U-U pairs were observed (7.6%) and the pairs showed relatively short 
C1’-C1’ distance (8.9 Å) signifying a distortion in the RNA helical backbone. 
Interestingly, a substantial number (15.9%) of the observed U-U pairs are not hydrogen 
bonded. They are water-bridged and have a similar C1’-C1’ distance to standard A-
helix. Similar results were also seen in the MD simulations performed by our 
collaborator, Professor Tiziano Tuccinardi at the University of Pisa, Italy (vide infra).
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trans-U-U paircis-U-U pair
All the observed C–G base pairs form Watson–Crick
interactions, while all the U–U pairs interact via only
one hydrogen bond between the carbonyl O4 atom of
one base and the N3 amino group of the second U. The
residue accepting the H-bond is inclined towards the
minor groove, as indicated by angle ! (between the glyco-
sidic bond and th line joini g the base-pa red C10 atoms)
(Figure 2A). The value for the inclined bases is small, 308,
compared to the average value for nucleotides of 558. The
inter-strand distance measured between the C10 atoms of
the paired uridines remained typical for A-RNA—about
10.4 A˚ (the average for the analysed duplexes is 10.5 A˚,
with standard deviation of 0.2 A˚). The base pair opening
for all U–U pairs is !7.58, irrespective of which U is
inclined (Supplementary Table 2). The above features
are preserved in all the observed U–U pairs. According
to the nomenclature introduced by Le ntis and Westhof
(40) the pairing of uridines could be described as ‘U"U
cis (wobble) W+C+/W+C+’, with the additional
clarification that there is only one hydrogen bond between
the bases. This base pairing can be described as ‘stretched
U–U wobble’.
Overall, each CUG repeat assumes one of two distinct
conformations depending on whether the uridine is
inclined towards the minor groove (low !) or not. In the
A+B duplex, both uridines on strand A are inclined, thus
the two strands are structurally different. Similarly, in the
C+D duplex both uridines of strand D are inclined.
The duplex E+E# is crystallographically symmetric and
has the second U inclined. In the rhombohedral structure
the first and the third U of strand G are inclined (and the
remaining four U of strand H).
RNA hydration and ligand interactions
Ordered water molecules are associated with the U–U
pairs, forming a characteristic pattern in both grooves
(Figure 2A). In the minor groove one water molecule
H-bonds with the N3 amino group of the inclined uridine
(low !) and with O2 of the other U. This pattern is
observed for all six U–U pairs in the monoclinic structure
and for four of the six U–U pairs in the detwinned rhom-
bohedral structure. In the major groove, a water molecule
is bound to the O4 carbonyl of the non-inclined U and to
the O6 carbonyl of the nearest guanosine on the opposite
strand. These interactions are observed in all cases in the
monoclinic s ructure and in three U–U pairs in the rhom-
bohedral structure.
C–G hydration also exhibits regularity (Supplementary
Figure 2). Most guanosines in the high resolution struc-
ture are observed to interact with four ordered water
molecules. Two of them are in the major groove: one
H-bonded to the N7 group and the other to the O6 car-
bonyl atom. The two water molecules in the minor groove
interact with the exo-amino and the imine groups.
The cytosines are typically associated with two water
molecules, one in each groove. In three cases the C exo-
amino group in the major groove interacts with a sulphate
anion or a glycerol molecule instead of water. One of the
sulphate ions is located between the A+B duplex and its
symmetry-equivalent d plex, in the space between two
sugar moieties. Two of its oxygen atoms interact each
with a different O20 atom: from 3U of chain B, and 2C,
chain A#. Another sulphate oxygen is H-bonded to the N2
exo-amino group of 1G A#.
Two ligands bind in the major groove in an ordered
manner: a glycerol molecule is bound to duplex A+B
and the second sulphate ion interacts with C+D. Each
ligand forms two hydrogen bonds: with the amino group
of 2C (chain A for glycerol or D for sulphate) and with the
nearby ‘U–G water’ of the major groove, associated with
3U–6U pair. Each ligand is half-occupied and associated
with a local disorder in the RNA strands (sulphate with
chain C and glycerol with B) and interacts with one of two
distinct conformers. The two strands are in contact in the
crystal lattice and their conformations are co-related.
In consequence, either the sulphate can bind to A+B
duplex or glycerol to C+D (Supplementary Figure 3).
In addition, the third OH group of glycerol interacts
with the exo-amino group of 5C in chain B.
Figure 2. A representative ‘stretched U–U pair’ with a single H-bond
N3-O4, as observed in the monoclinic structure (A). All the pairs i both
analysed crystal forms show the same conformation. One of the uridines
is inclined towards the minor groove, and the ! angle, between the
glycosidic bond and the line connecting C10 atoms (green line), is 308
or less, as opposed to the typical value of 558. The distance C10–C10
for the ‘stretched U–U pair’ is about 10.4 A˚, similar to the average
value for an A-helix. The corresponding distance for standard U–U
pair (B), calculated from all 582 available U(anti)-U(anti) pairs in
the SwS server, is 8.6 A˚, and the uridines interact via two H-bonds.
Each type of U–U pair is solvated by two water molecules, one in
each groove. The interactions of the water in the minor groove are
very different between the two types of U–U pairs. The environment
of the water in the major groove also changes due to the inclination
of one U.
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Intermediate (in CUG repeats)
C1’-C1’ = 8.1 Å 10.4 Å 11.2 Å
PDB: 280D PDB: 3GM7 PDB: 1OSU
(a) (b) (c)
Figure 7. Three different types of conformations observed in U-U mismatches of different C1’-C1’ 
distances. Reprinted with permissions from Refs. 51 and 56.
2.3 Elucidating the Modes of Binding
Although there is a lack of X-ray or NMR structure of the RNA-ligand complex, we have 
evidence of the intercalative mode of binding from a circular dichroism (CD) titration of 
ligand 11 to r(CUG)12 (Figure 8). The CD spectra showed an increase in CD signal from 
negative to positive from 280–300 nm and a decrease in signal <260 nm to more 
negative indicating of an intercalation of the acridine moiety to an A-form duplex.57 An 
intriguing question how the triaminotriazine moiety interact with the RNA remains 
unanswered. As reported in 2009, the mismatch in the DNA duplex is important for 
binding suggesting the triaminotriazine is interacting with the mismatch.46 In addition, in 
a thermal denaturation study  the binding of ligand 11 is substantially weakened when 
the triaminotriazine moiety is replaced by  a 2-aminopyridine unit.46 Very recently, one of 
our collaborators, Professor Sherlock Lam at the Chinese University  of Hong Kong, 
observed a perturbation in NOE signal of the imino proton of a T-T mismatch upon 
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Figure 8. CD titration of ligand 11 to r(CUG)12.
titration of ligand 11 (unpublished result). We expect that the triaminotriazine unit is 
likely interacting the U-U pairs in CUG repeats.
! With the reported CUG repeat structures (Figure 6), we considered two possible 
triplet modes of binding of ligand 11 to CUG repeats (Figures 9a,b). Simple modeling 
suggested that binding of ligand from the minor groove would require a lengthening of 
the C1’-C1’ distance of the U-U pair from 10.4 to 13.8 Å. Although the RNA minor 
groove is readily accessible by small molecules, 3.4 Å is a significant increase in the 
C1’-C1’ distance (Figure 9a) and may signal a distortion in the DNA or RNA backbone 
that is energetically  unfavorable.58,59 This distance is even longer than that of a G-A 
purine-purine pair (12.5 Å) in a DNA duplex.60 In fact, repeated attempts to model 
[r(CUG)6]2⋅11 with the ligand in the minor groove in failed to yield a stable complex. On 
the other hand, modeling of a major groove base-triplet suggested a C1’-C1’ distance 
fairly close to that in the X-ray  structure (10.1 vs 10.4 Å; Figure 9b). Indeed, an 
unconstrained 10 ns MD simulation showed ligand 1 could fit satisfactorily  in the major 
groove (Figure 10a). The average C1’-C1’ distance of the complexed U-U pair was also 
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Figure 9. Three potential modes of binding: (a) Minor groove triplet binding. (b) Major groove triplet 
binding. (c) Minor groove stretched wobble binding. (d) A ChemDraw representation of Figure 7b  (PDB: 
3GM7). R = CH3 (DNA) or H (RNA).
analyzed (Figure 10b). Clearly, this binding mode does not introduce significant 
deviation in the C1’-C1’ distance.
! The de-twinned CUG repeat structure (PDB: 3MG7) with high-resolution 
hydration details (Figure 7b) led us to consider another possible binding mode (Figure 
9c). Modeling showed that the water molecule bridging the two uracil bases in a 
stretched wobble pair (Figure 9d) could be replaced by the triazine unit in the minor 
groove (Figure 9c). The C1’-C1’ distance of the binding mode is moderately lengthened 
by 1.4 Å (11.8 vs 10.4 Å). The MD simulation of this minor groove stretched wobble 
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Figure 10. Snapshot from a 10 ns MD simulations showing ligand 11 binding to [r(CUG)6]2 (a) from the 
major groove via a triplet formation. (b) The average C1’-C1’ distance of the interacting U-U pair is 
reported in red, whereas the C1’-C1’ distance of all the base pairs is reported in black. (c) Snapshot from 
the 10 ns MD simulations of ligand 11 interacting a U-U pair via a minor groove stretched wobble binding. 
(d) The corresponding average C1’-C1’ distance of the interacting U-U pair is reported in red, whereas 
the C1’-C1’ distance of all the base pairs is reported in black
binding was also performed (Figure 10c). Although fewer hydrogen bonds are formed, 
the unconstrained simulation led to a stable structure. The average C1’-C1’ distance of 
the U-U mismatch is moderately lengthened by 1.4 Å (11.8 vs 10.4 Å, see Figure 10d).
2.4 Methyl Scanning Approach
To distinguish between these models, an extended “methyl scanning” approach61 
appeared to be an ideal approach because the number of hydrogen bonds differ 
significantly in the base triplet (Figures 9a,b) and the stretched wobble binding modes 
(Figure 9c). In particular, the wobble binding mode has two, possibly three free N–H 
group whereas only a single N–H group  is free in the triplet binding modes. Thus, five 
N-methylated analogs 14–18 were synthesized (Chart 6) and tested the binding using 
ITC with both d(CTG)2 and r(CUG)2 to establish a structure-activity relationship (SAR).
! Ligands 14–18 were prepared using the same synthetic sequence for preparing 
ligand 11. Thus, a linker is first attached to the Janus wedge followed by the acridine 
moiety.46 For example, ligands 15 and 16 were prepared from the corresponding 
methylated wedges (19 and 20) , which in turn, were prepared from 
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Chart 6. A series of N-methylated versions (14–18) of ligand 11, and RNA and DNA duplexes containing a 
r(CUG)2 and d(CTG)2 motifs, respectively, for SAR studies.
aminodichlorotriazine 21 (Scheme 1).62 The linker was attached to the wedge by 
heating 19 or 20 with an excess of 1,4-diaminobutane to afford intermediates 22 and 23, 
respectively. The intercalator unit was attached to the linker using an activated acridine 
2463 with catalytic amount of trifluoroacetic acid (TFA) to yield ligands 15 and 16. 
Ligands 14, 17, and 18 containing a methyl group at nitrogen position of the linker 
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30: R1 = R2 = H
20: R1 = Me;  R2 = H
19: R1 = R2 = Me
24
I N3
required the corresponding precursor 2564 that is prepared from tetrahydrofuran (THF)65 
in 6 steps (Scheme 2). Similarly, intermediates 34–36 were prepared from the 
corresponding wedges using precursor 25 followed by Pd-catalyzed hydrogenolysis 
(Scheme 3). Attempts to purify  these intermediates (34–36) resulted in low yields (20–
40%). For example, compound 35 was isolated in only 39% yield. They were used 
directly in the subsequent steps to afford ligands 14, 17, and 18, respectively.
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Figure 11. ITC profiles for complexation of d(CTG)2 with (a) ligand 14 and (b) ligand 15.
Table 2. Kd values (in µM) of ligands 11, 14–18 with T-T (DNA) and U-U (RNA) mismatches.
Target
N
N
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NMe Me
N
N
N
N
N
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N
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NH H
N
N
N
N
N
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H
N
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11 14 15
N
N
N
N
N
HH
Me
N
HNMeO
Cl
NMe Me
N
N
N
N
N
HH
Me
N
HNMeO
Cl
NH Me
N
N
N
N
N
HH
H
N
HNMeO
Cl
NH Me
16 17 18
T-T 0.39 ± 0.08 0.8 ± 0.4 0.12 ± 0.04 2.2 ± 0.5 50 ± 30 nb
U-U 2.1 ± 0.2 nb nb 14 ± 5 nb nb
nb: no measurable binding and a lower limit of Kd > 200 µM is assigned.
! The d(CTG)2 recognition by 14–18 was measured by ITC and all Kd values are 
collected in Table 2. Ligand 15 was found to bind >3-fold stronger than ligand 11 (Kd = 
0.12 µM for 15 vs 0.39 µM for 11), whereas ligands 14, 16, and 17 each bound d(CTG)2 
progressively  more weakly than 11. The fact that the affinities of these methylated 
ligands binding to d(CTG)2 compared to that of 11 ruled out the possibility of a triplet 
formation, irrespective of the groove preference. Figure 11 showed the ITC profiles of 
ligands 14 and 15 binding to a (CTG)2-containing duplex. Ligand 18, carrying three 
methyl groups, showed no measurable binding to d(CTG)2. Because of the limited 
aqueous solubility, we were only able to assign a lower limit of Kd > 200 µM. The 
combined ITC and modeling results is consistent with Watson-Crick-type recognition of 
the stretched wobble pair (Figure 12). This binding mode also explains the decreased 
binding to the T-T pair by 17 (Kd = 50 µM for 17 vs 0.39 µM for 11) because of the 
presence of rotamers that interrupt the hydrogen bonding interaction. An unconstrained 
10 ns MD simulation further suggested that the weakly  bound thymine unit could be 
24
N
N
OH
C1'O
N
N
N H
Me
N
H
H
T
NN
O
HC1'
O
T
N
Me
Me
Me
N
N
N
OH
C1'O
N
N
N H
Me
N
H
H
T
NN
O
HC1'
O
T
N
N
H
Me
Me
N
N
OH
C1'O
N
N
N H
H
N
H
H
T
NN
O
HC1'
O
T
N
N
H
Me
Me
N
N
OH
C1'O
N
N
N H
H
N
H
H
T
NN
O
HC1'
O
T
N
Me
Me
Me
N
N
N
OH
C1'O
N
N
N H
Me
N
H
H
T
NN
O
HC1'
O
T
N
N
Me
Me
Me
11
15
14
16
17
Figure 12. Proposed minor groove stretched wobble binding for ligands 11, 14–17.
flipped-out from the dsDNA (Figure 13). 
Base flipping is often observed with DNA 
modifying and error repairing enzymes66 
and there are precedents for base-
flipping induced by small molecules.67-69 
Yen-Jun Ho in our group  attempted to 
use potassium permanganate (KMnO4) 
as a probe for flipped-out thymines and 
observe by electrophoresis but unsuccessful. 
! The most interesting finding came from the ITC  results of the ligand-RNA binding. 
In contrast to the results with d(CTG)2, ligand 15 did not bind under similar conditions to 
r(CUG)2 (Figure 14a, Table 2) and, indeed, the single N-methyl group  in 14 was enough 
to eliminate the ligand binding (Kd > 200 µM). The only CUG-binding N-methylated 
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Figure 14. ITC profiles for complexation of the complexation of r(CUG)2 to (a) ligand 15 and (b) ligand 16.
Figure 13. Snapshot from a 10 ns MD simulation of 
a complex of d(CTG)12·15 showing one of the 
thymines was flipped-out from the helix.
ligand was 16 and even its Kd was 7-fold weaker in comparison to 11 (Figure 14b, Table 
2). One of the possible explanations is that only  ligands 11 and 16 allow the formation of 
triplet with a U-U mismatch (cf. Figures 9a,b). Again, the weaker binding of 16 to U-U 
mismatch can be explained by the presence of a rotamer that disfavors the triplet 
formation. 
! The ability of ligands 11, 14–18 to inhibit MBNL1 binding to r(CUG)12 was 
measured by EMSA and the results paralleled the ITC  data. Thus, only  ligands 11 and 
16 showed inhibition (Figure 15). Although nothing can be said about the groove 
preference from this experiment, the MD simulations favor major groove triplet formation 
(vide supra), and it is also known that loop  and mismatch structures can enhance the 
accessibility of the major groove.70
! To get a complete picture of the binding selectivity, the affinity of the ligand to 
other mismatches was also measured (Table 3). In general, these ligands exhibited high 
selectivity (7- to 1,600-fold) for DNA over RNA mismatches. The ligands were also found 
to bind weakly to purine-purine mismatches. Interestingly, all the methylated ligands 
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10% DMSO, Tris⋅borate (pH 8.3)
[(CUG)12] = 0.2 nM; [Ligand] = 100 µM; [MBNL1] = 0.46 µM
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Figure 15. EMSA screening of ligands 11, 14–18 showing only ligands 11 and 16 inhibit MBNL1⋅CUG 
interaction. The structure of r(CUG)12 used in the assay is shown on the right.
bind quite strongly (Kd = 0.13–2.0 µM) to d(CCG)2 (sequence shown in Table 3), a 
trinucleotide repeat sequence associated with Fragile XE syndrome71,72 and chronic 
lymphocytic leukemia,73 suggesting a potential molecular therapeutic approach to these 
diseases that warrants additional study. More importantly, all methylated ligands showed 
reduced affinity toward normally paired duplex DNA (i.e., no mismatch), including 
herring sperm DNA. We believe that the ability of the recognition unit to stack on the 
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Table 3. Kd values (in µM) of ligands 11, 14–18 with various oligonucleotides.
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16 17 18
RNA
Duplex A > 200 > 200 > 200 > 200 > 200 > 200
U-U 2.1 ± 0.2a > 200 > 200 14 ± 5 > 200 > 200
C-C 14 ± 2a > 200 > 200 > 200 > 200 > 200
A-A > 300a > 200 > 200 > 200 > 200 > 200
G-G > 300a > 200 > 200 > 200 > 200 > 200
DNA
Duplex B > 200 > 200 > 200 > 200 > 200 > 200
Duplex C 173 ± 21 > 200 > 200 > 200 > 200 > 200
hsDNAb 55 ± 16 > 200 > 200 > 200 > 200 > 200
T-T 0.39 ± 0.08a 0.83 ± 0.36 0.12 ± 0.04 2.2 ± 0.5 49 ± 35 > 200
C-C 5.0 ± 0.2a 2.0 ± 1.5 0.13 ± 0.05 0.64 ± 0.11 1.9 ± 1.7 0.71 ± 0.16
A-A 66 ± 8.0a 32 ± 17 6.7 ± 2.5 32 ± 20 108 ± 33 57 ± 33
G-G 30 ± 26a 19 ± 23 21 ± 10 14 ± 8 40 ± 27 56 ± 18
aArambula, J. F.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. Proc. Natl. Acad. Sci. U.S.A. 2009, 106, 
16068. bHerring sperm DNA.
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intercalator is enhanced by methylation which in turn reduced the non-specific 
intercalative binding to duplex DNA.74,75
! The combined experimental and computational approach described herein 
suggests that this class of ligands bind DNA and RNA by significantly different modes. 
Thus, it is proposed that ligands 11 and 16 recognize the U-U mismatch in RNA through 
formation of a major groove base triplet whereas ligands 11, 14–17 bind the T-T 
mismatch in DNA via the stretched wobble pair (Figure 16). These binding modes also 
explain the decreased binding to U-U by 16 (Kd = 14 vs 2.1 µM for 11) and to T-T by 17 
(Kd = 50 µM for 17 vs 0.39 µM for 11). Thus, the C–NH(Me) bond rotation leads to 
unfavorable binding for one or more of the rotamers.76
2.5 Conclusions
We have used the methyl scanning method combined with MD simulations to indirectly 
investigate the possible binding modes by  which ligands 11, 14–17 recognize CUG and 
CTG sites in RNA and DNA, respectively. Beyond informing on the binding mode, the 
ability  to substitute the amino groups of ligand 11 suggests these as sites for further 
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Figure 16. Proposed binding modes for the (a) U-U and (b) T-T mismatches.
modifications that may enhance the selectivity and efficacy of these lead compounds in 
treating DM1. 
! More significant was the unexpected discovery of DNA-selective ligands for CTG. 
Compared to the ligand 11, which binds both CUG and CTG with similar strength, ligand 
15 showed a >3-fold increase in affinity to CTG relative to ligand 11 with negligible 
binding to RNA. It was also found that these ligands showed reduced binding toward 
DNA and RNA duplexes (i.e., without mismatches) upon methylation, potentially open 
an avenue for a DNA-targeted molecular therapy of DM1.8,18,77 Competitive binding to 
the corresponding CUG transcript would be expected to reduce the effectiveness of this 
approach and could also complicate efforts to assess the DNA-targeted approach. More 
broadly, this study increases our knowledge of how small molecules can selectively 
recognize nucleic acids.
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Chapter 3   Lead Discovery for DM22
“I and others with DM2  appreciate the research being done to develop a potential 
treatment in DM2 by you and other researchers at the University of Illinois. Although DM2 
is very rare in the States, in Germany it is much more common. Thank you.”
A DM2 patient in Germany
DM1 (CUG) DM2 (CCUG)
N
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N HH
HNH H NHOH N
N
42
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N
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H
N
HNMeO
Cl
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11
Serendipity
3.1 Introduction
DM2 is a second form of myotonic dystrophy, one that caused by  the expansion of a 
CCTG repeat of the ZNF9 gene on chromosome 3.6 Like DM1, DM2 is an incurable 
neuromuscular disease. As we can see in Table 1, the severity of DM2 is considered to 
be milder than that of DM1. Although DM2 patients do not suffer from the severe 
congenital form of disorder that occurs in DM1, the prevalence of DM2 is predicted to be 
at least as high as DM1 depending on the geographical location (1 in 8,000).4 Our 
preliminary results on targeting CTG/CUG repeats suggested the use of the stacked 
intercalator approach to target CCTG/CCUG repeats in DM2. Targeting CCTG (or 
CCUG) repeats represents a challenge because their secondary  structures are not well-
studied.78,79 In addition, structural changes in DNA and RNA upon binding of small 
30
2 This chapter includes previously published material. The other contributors were Yuan Fu, Sreenivasa 
R. Ramisetty, Anne M. Baranger, and Steven C. Zimmerman. Reused with permission from: Wong, C.-H.; 
Fu, Y.; Ramisetty, S. R.; Baranger, A. M.; Zimmerman, S. C. Nucleic Acids Res. 2011, 39, 8881–8890.
molecules are always possible.80,81  Indeed, such structural 
changes are usually substrate-dependent as is observed in 
riboswitches.81 Thus, conformations (a) and (b) are 
possible with different ligands. There are two limiting 
conformations for CCTG repeats that may be considered 
upon binding (Figure 17). As both CUG and CCUG repeats 
are able to sequester MBNL proteins with high affinities (Kd = 0.26–0.07 µM),82 this 
suggests the structural similarities between the two repeats in which conformation (b) 
with a T-T mismatch might be operating. Thus, we set out to examine a number of π-
stacked ligands with the goal of therapeutic agents discovering of DM2 lead.
3.2 Targeting C-T and C-U Mismatches
! In comparison to CUG repeats, targeting CCUG repeats represents a particular 
challenge because neither an NMR nor X-ray structure of RNA containing CCUG 
repeats is available. However, the encouraging results with DM1 prompted us to design 
analogous π-stacked ligands that can bind to CCTG (or CCUG) repeats in DM2. Thus, 
we designed the 2,6-diaminopyrimidinone-based intercalator (37) to recognize the C-T 
mismatch with complementary  hydrogen bonding on both edges forming a base triplet 
(Figure 18). Indeed, both C-U and C-T 
mismatches have been successfully 
targeted by 2,6-diaminopyrimidinone-
based compounds by Lehn45 and 
McLaughlin,83 respectively. It should be 
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binding mode to a C-T mismatch in CCTG repeats.
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Figure 17. Possible CCTG 
repeat structures with (a) two 
C-T mismatches or (b) one T-T 
mismatch and two C-bulges.
noted that Lehn used cytosine and uracil nucleobases instead of nucleotides in their 
studies. Nevertheless, all reported ligands were based on a 2,6-diaminopyrimidinone 
moiety. Ligand 37 was prepared to determine whether it can inhibit the MBNL1-RNA 
interactions (Scheme 4). Removal of a t-butyl group of known compound 3883 by  TFA 
gave compound 39 in 72% yield. Coupling of compounds 39 and 4084 using EDCI 
provided ligand 37 in 83% yield. It is well known that DNA predominantly adopts a B-
form conformation in solutions, which has wide major groove, it is worth to test the idea 
whether an aminoisocytosine-containing intercalator will bind to a C-T mismatch (Figure 
18). Thus, preliminary binding studies were performed on duplex containing two 
complimentary strands containing a d(CCTG)2 unit (Figure 19a). It was found that ligand 
37 bound to the sequence in an expected 2:1 ratio with Kd(1) = 3 µM and Kd(2) = 8 µM. 
The third binding (Kd(3) = 0.3 mM) was attributed to non-specific binding. These results 
also suggest that π-stacking may still occur even if there is an amide bond in the linker. 
Unfortunately, the strong binding of ligand 37 for CCTG-containing DNA did not 
translate into strong binding for an RNA oligonucleotide containing a CCUG repeat 
(Figure 19b). The reason of this distinct difference on binding to RNA and DNA is still 
unknown. In a gel-shift assay performed by Dr. Yuan Fu in the Baranger group, ligand 
37 also did not show any  inhibition in good agreement with the ITC result (Figure 20). 
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Nevertheless, in the absence of an NMR or X-ray structure, the binding mode remains 
unknown.
! In principle, inhibition may still be observed if a ligand such as 11 or its 
derivatives can recognize the uracil unit in a C-U mismatch. Previous results indicated 
that ligand 11 is capable to bind to U-U mismatch in r(CUG)4 with low micromolar affinity 
(Kd = 0.43 µM) and bind to C-C mismatch with moderately  reduced affinity (Kd = 13.5 
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Figure 20. Gel-shift assay showing ligand 37 could not interrupt the MBNL1-RNA complex. Lane 1: 
CCUG RNA only; Lane 2: RNA + MBNL without ligand 37.
Conditions:
[Ligand]0 = 500 µM
[Duplex]0 = 10 µM
[MOPS] = 20 mM
[NaCl] = 300 mM
Temperature = 25 °C
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Figure 19. ITC binding studies of ligand 37 using (a) a DNA sequence containing CCTG repeat and (b) a 
µM). Compared to the Kd values measured 
for A-A and G-G mismatches (Kd > 300 
µM), ligand 11 showed strong preference 
toward pyrimidine-pyrimidine mismatches. 
Therefore, we attempted to use ligand 11 
to target CCUG repeat for DM2. 
! The biophysical studies were first 
carried out on the same CCTG sequence 
with ligand 11 (Figure 21). A Job  plot 
analysis at a total concentration of 60 µM indicated a stoichiometry  of 2:1 (ligand to 
DNA). When the concentration is increased to 120 µM, 2.5:1 was obtained suggesting a 
third binding site with a Kd in the µM range. Such a shift in Job plot was not observed at 
these concentrations with CTG 
repeats indicating the observed 
shift was not a result of non-
specific intercalation.
! The thermodynamic aspects 
of binding were studied using 
isothermal titration calorimetry 
(ITC). A 3:1 stoichiometry was also 
observed at the equivalence point 
of the isotherm (Figure 22). The 
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Figure 22. ITC profile of complexation of ligand 11 to the 
d(CCTG)2-containing duplex.
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Figure 21. Job  analysis of the stoichiometry of the 
d(CCTG)2-containing DNA complex with ligand 11 
with total concentrations of 60 µM (▲) and 120 µM 
(◆).
stoichiometry  determined by ITC is usually more accurate than those obtained from 
other methods because of the precise computer-controlled injections.85 The ITC  data 
were therefore fit using a three-sequential binding sites model. The ITC  data suggests a 
relative weak first binding (14 µM) followed by a strong binding (108 nM) and a third 
weak binding (37 µM) which is consistent with the Job analysis. The positive 
cooperativity could result from the first ligand inducing formation of two C-bulges and a 
central T-T mismatch (see Figure 17b), the latter site providing the same tight binding 
observed at CTG sites, whereas the C-bulge recognition would be comparatively 
weaker. This C-bulge and T-T mismatch structure, which is suggested to be a potential 
drug target, was recently observed by NMR spectroscopy for CCTG repeats.78 A CD 
titration was also performed (Figure 23). The increase in the CD signal at about 290 nm 
and the small positive induced CD (ICD) signal indicates intercalative binding of ligand 
11 to the d(CCTG)2-containing duplex (Figure 23a).86 A plot of CD signal at 288 nm 
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Figure 23. (a) CD spectra showing the change in CD signal upon ligand binding (Conditions: [duplex] = 
25 µM, [MOPS] = 20 mM, [NaCl] = 300 mM, temperature = 25 °C, pH = 7). (b) A plot of CD signal at 288 
nm versus the mole ratio of ligand to duplex indicating the saturation of binding sites at about 3 
equivalents of ligand 11. 
versus mole ratio of ligand indicated that the stoichiometry is about 3:1 (Figure 23b). 
Again, if non-specific intercalation would have occurred, the CD signal would not be 
saturated at 3:1 stoichiometry. However, a closer look at the CD titration curve suggests 
a strong binding event and relatively weaker second and third binding events as the 
slope is steeper until the first equivalence is reached. Overall, Job  plot, CD, and ITC 
studies suggested a 3:1 binding stoichiometry of ligand 11 to the CCTG duplex but the 
disagreement in the cooperativity  (ITC vs. CD) needs to be reconciled with additional 
experiments including ESI-MS or fluorescence titration that might be capable of 
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Figure 25. Two possible stem–loop structures for CCUG repeats with two consecutive C–U mismatches 
(left) or alternating C–C and U–U mismatches in the slipped form (right).
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Figure 24. ITC binding studies of ligand 11 using a RNA sequence containing (a) a r(CCUG)2 and (b) a 
slipped-CCUG unit.
establishing the correct binding sequence. The binding to RNA was examined using a 
RNA duplex containing a r(CCUG)2 unit as shown in Figure 24a. In contrast to the 
results with the DNA oligonucleotide, ligand 11 binds CCUG comparatively weakly; a 
single Kd = 79 µM was obtained. This CCUG repeat structure is predicted by m-fold to 
be comprised of two C-G base pairs and two C-U mismatches, although alternative 
structures cannot be ruled out.87 The slipped CCUG structure contains U-U and C-C 
mismatches separated by C-G base-pairs as shown in Figure 25.82  Although a less 
stable form, it was found that MBNL1 bound this slipped structure with ~1.5-fold higher 
affinity  than to the structure containing two C-U mismatches.82 For this reason, the 
binding of ligand 11 to the slipped sequence was also investigated by ITC using the 11-
mer shown in Figure 24b. A 2:1 complex was observed with low-micromolar Kd values: 
Kd(1) = 3.5 µM and Kd(2) = 7.0 µM.
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Figure 26. (a) Gel electrophoretic mobility shift assay of MBNL1 binding to r(CCUG)6 RNA. (b) MBNL1 
binding to r(CCUG)6 in the presence of 100 nM tRNA. Control lane 1 (C1): RNA only. Control lane 2 (C2): 
RNA + MBNL1. (c) Plots of fractions of r(CCUG)6 bound as a function of MBNL1 concentration in the 
presence (green) and absence (blue) of 100 nM tRNA.
! To determine whether ligand 11 can inhibit the MBNL1-CCUG interaction, an 
electrophoretic mobility shift assay (EMSA) was performed by Dr. Sreeni Ramisetty in 
the Baranger group  using a r(CCUG)6 RNA. The Kd values for the complexes formed 
between r(CCUG)6 and MBNL1 were determined in the absence and presence of 100 
nM of competitor tRNA to be 15 ± 2 nM and 30 ±  4 nM, respectively  (Figure 26). These 
values are in good agreement with literature values.82 No significant inhibition of the 
MBNL1-RNA interaction was observed with ligand 11 up to a concentration of 250 µM 
(Figure 27). Therefore, an accurate IC50 cannot be obtained and a upper limit of 250 µM 
was assigned.
3.3 Discovery of DM2 Lead Compounds
The discovery of compounds 41 and 42 turned out to be serendipitous. During a 
screening of a series of compounds for inhibition of MBNL1-CCUG interaction, we found 
that ligands 11, 41, and 42 can inhibit the toxic protein-RNA interaction (Figure 28). The 
ability  of simple triaminopyrimidine ligands 45 and 46 and triaminotriazine ligands 47 
and 48 to inhibit MBNL1 binding was examined (Figure 28a). Consistent with our 
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Figure 27. EMSA of ligand 11 in the presence of 100 nM tRNA. Control lane 1 (C1): RNA only. Control 
lane 2 (C2): RNA + MBNL1.
previous results for DM1, wedges without tethered intercalators did not destabilize the 
MBNL1-CCUG complexes (Figure 28b). Again, simple intercalators such as 40 do show 
inhibition. Originally, ligands 
41 and 42 were synthesized 
as structural derivatives of 11 
(Scheme 5). Ligand 41 is 
identical to 11, but with a 
triaminopyrimidine moiety that 
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Figure 28. (a) Chemical structures of screened molecules. (b) Gel electrophoretic mobility shift assay 
showing that only π-stacked intercalators inhibit the MBNL1-CCUG complex. Control lane 1 (C1): RNA 
only. Control lane 2 (C2): RNA+MBNL1. Control lane 3 (C3): RNA+MBNL1 with 10% DMSO. Except 
when otherwise noted, all lanes contain 350 nM MBNL1, 100 mM ligands and 10% DMSO.
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forms a C-linked Janus-wedge. It was an appealing recognition unit to explore because 
5-(4-aminobutyl)-2,4,6-triaminopyrimidine88 was a known compound, allowing 41 to be 
easily  synthesized by the same route as used for ligand 11. The triaminopyrimidine ring 
also has an extra N–H group  for post-synthesis modification. Unfortunately  and 
somewhat surprisingly, ligand 41 exhibited very limited water solubility compared to the 
structurally similar ligand 11. The limited solubility  of 41 prevented it from being studied 
by ITC  with less than 10% DMSO. Ligand 42 was prepared with a more water-soluble 
intercalator, N-(2-(dimethylamino)ethyl)acridine-4-carboxamide (DACA)89 in place of the 
9-amino-6-chloro-2-methoxyacridine unit and this allowed the triaminopyrimidine moiety 
to be examined (Scheme 5).
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Figure 29. (a) Gel electrophoretic mobility shift assay of ligand 41 with r(CCUG)6 RNA in the presence of 
100 nM tRNA. Control lane 1 (C1): RNA only. Control lane 2 (C2): RNA+MBNL1. Conditions: [MBNL1] = 
100 nM, [RNA] = 0.1 nM, [NaCl] = 175 mM, [MgCl2] = 5 mM, [BME] = 1.25 mM. (b) Gel electrophoretic 
mobility shift assay of ligand 42 with (CCUG)6 RNA in the presence of 100 nM tRNA. Control lane 1 (C1): 
RNA only. Control lane 2 (C2): RNA+MBNL1. (c) Plots illustrating inhibition of MBNL1-(CCUG)6 complex 
with ligand 41 (green) and 42 (blue).
3.4 MBNL1-CCUG Inhibition by DM2 Lead Compounds
Using EMSA, both ligands 41 and 42 showed good inhibition of the MBNL1-CCUG 
interaction in concentration-dependent studies (Figure 29; see Figure 27 for 11). 
Despite the limited solubility  of ligand 41, its ability to inhibit MBNL1 binding to RNA 
could be determined because of the lower concentrations required for electrophoretic 
mobility  shift assays. Both ligands 41 and 42 were found to significantly destabilize the 
MBNL1-CCUG complex. The IC50 of ligands 41 and 42 were determined by incubating 
varying concentrations of the ligands with a constant concentration of MBNL1-CCUG 
complex and evaluating the results using gel shift assays. The apparent inhibition 
constant (Ki) of these ligands was determined using the equation Ki = IC50 × (Kd/
[MBNL1]total), in which Kd is the dissociation constant of the MBNL1-RNA complex and 
the concentration of MBNL1 is in large excess of the Kd value. The comparison of Ki 
values, rather than the IC50 values, under different conditions is important in order to 
compare the effects of the conditions on the behavior of the ligands independently of 
41
Table 4. Summary of inhibition studies of various RNAs with ligands 41 and 42.a
RNAb tRNA (nM) Kd (nM) [MBNL1] (nM) 41 42
IC50 (µM) Ki (µM) IC50 (µM) Ki (µM)
r(CCUG)6 – 15 ± 2 350 59 ± 5 2.5 ± 0.2 52 ± 8 2.2 ± 0.3
100 30 ± 4 350 40 ± 11 3.4 ± 0.9 35 ± 3 3.0 ± 0.3
r(CUG)12 – 150 ± 20 1000 37 ± 11 5.5 ± 1.4 118 ± 40 18 ± 5
cTNTc – 1.0 ± 0.2 15 101 ± 26 6.7 ± 1.6 >250 >17
a Conditions: [MBNL1] = 100 nM, [RNA] = 0.1 nM, [NaCl] = 175 mM, [MgCl2] = 5 mM, [BME] = 1.25 mM.  
Errors are reported as the standard deviation (SD) of 3 or more trials. b RNA concentrations were 0.1 nM. 
c 18-nt fragment of the cTNT pre-mRNA.
the effects of the varying conditions on the Kd of the MBNL1-CCUG complex. 
Importantly, ligands 41 and 42 do not bind to MBNL1 as measured by ITC.
! To evaluate the specificity  of ligands 41 and 42 for CCUG RNA, the inhibition 
experiments were performed in the presence of competitor RNA sequences. For ligand 
41, the Ki value is increased only slightly  to 3.4 ± 0.9 µM in the presence of 100 nM 
tRNA (Figure 29a,c). Evaluation of ligand 42 provided IC50 values of 52 ± 8 µM and 35 ± 
3 µM in the absence and presence of 100 nM tRNA, respectively, with a Ki of 2.2 ± 0.3 
µM and 2.8 ±  0.3 µM, respectively (Figure 29b,c). The selectivity of ligand 41 and 42 for 
the target sequences r(CCUG)6 relative to r(CUG)12 (i.e., DM2 vs. DM1) and their 
relative abilities to inhibit MBNL1 binding to the same sequences were also evaluated. 
Ligand 41 inhibited binding to r(CCUG)6 and r(CUG)12 with similar Ki values of 2.4 µM 
and 4.8 µM, respectively, whereas ligand 42 exhibited a ~7-fold higher inhibition of the 
MBNL1-CCUG interaction compared to the MBNL1-CUG interaction. The ability of 
ligand 42 to destabilize complexes formed between MBNL1 and cTNT (RNA I, Figure 
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Figure 30. Nucleic acids studied in ITC experiments (tRNA and herring sperm DNA are not shown). The 
structures shown represent the most stable structures predicted by m-fold. Note that RNA I is most likely 
single stranded under the conditions used to perform the binding or complex inhibition experiments.
30) was also evaluated. cTNT is the 18-nt fragment82 of the human cardiac troponin T 
(hcTNT) pre-mRNA, which is a natural target of MBNL1. Ligand 42 only weakly inhibited 
the MBNL1-cTNT interaction. Table 4 summarizes the inhibition studies of ligands 41 
and 42.
3.5 Biophysical Studies of the DM2 Lead Compounds
The ability of ligands 41 and 42 to bind CCUG and CCTG repeats was examined by 
ITC. However, the studies with 41 were hampered by its poor water-solubility. To 
achieve the high ligand concentration needed for ITC  studies, ligand 41 required more 
than 10% (v/v) DMSO. With as little as 1% (v/v) DMSO, a 500 µM solution of ligand 42 
could be prepared in a 300 mM NaCl solution (MOPS buffer; pH 7), presumably 
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Table 5. Dissociation constants (Kd) and Tm values for all tested nucleic acids with ligand 42.a
Nucleic acids Specific target Tm (°C)b Kd(1) Kd(2) Kd(3) Selectivityc
r(CCUG)6 C-U pairsd 61 5.2 ± 0.6 478 ± 85 – 1.4
A C-U pairs 53 3.6 ± 0.8 258 ± 37 – 1.0
B C-C and U-U 54 0.13 ± 0.04 10 ± 5 202 ± 14 0.04
C Single C-U pair 62 85 ± 30 231 ± 55 – 24
D U-U 63 25 ± 13 271 ± 83 – 6.9
E C-C 62 0.77 ± 0.28 162 ± 8 – 0.2
F A-A 62 118 ± 8 2270 ± 360 – 33
G G-G 67 103 ± 26 7690 ± 280 – 29
H T-T 51 1.4 ± 1.5 102 ± 25 – 0.4
I – – 334 ± 11 – – 93
tRNA – – 2400 ± 2100 – – 670
hsDNA – – 36 ± 7e – – 10
aKd values are reported in µM. Errors are reported as the standard deviation (SD) of 3 or more trials. 
bConcentrations of duplexes are 10 µM; additional 1% (v/v) DMSO has negligible effect on the stability of 
the duplexes (∆Tm < 2 °C). cSelectivity is the ratio of Kd(1) of the particular nucleic acid to that of RNA A. 
dmfold predicts two 2×2 nucleotide internal loops. eLigand 42 bound to about every 10 base pairs.
because it contains a water-solubilizing substituent (Scheme 5). Thus, only  the affinity 
and selectivity of ligand 42 for binding to CCUG RNA was evaluated by measuring the 
affinity  of ligand 42 for several oligonucleotides (Figure 30). The stabilities of these 
RNAs were evaluated by melting curves obtained by UV spectroscopy and are reported 
in Table 5. The duplexes containing C-U (RNA C), U-U (RNA D), C-C (RNA E), A-A 
(RNA F), and G-G (RNA G) were designed to evaluate the ability  of ligand 42 to 
selectively recognize the mismatches that are most likely found in the poly(CCUG) RNA 
compared to related mismatched sequences. The binding of ligand 42 to the DNA 
analog of the DM1 sequence containing a T-T mismatch (DNA H) and the 18-nt 
fragment of the human cardiac troponin T (hcTNT) pre-mRNA, a natural target of 
MBNL1 (RNA I) was also evaluated. To investigate the non-specific binding of ligand 42 
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Figure 31. ITC profiles of ligand 42 binding to (a) r(CCUG)6 and (b) an RNA duplex containing a single 
r(CCUG)2 unit.
to nucleic acids in general, its affinity  toward 
tRNA and herring sperm DNA (hsDNA) was 
measured (Table 5).
! ITC  was used to measure the affinity  of 
ligand 42 for the duplexes (Table 5). Ligand 42 
bound to r(CCUG)6 and RNA A with similar 
affinity and stoichiometry. Specifically, both 
sequences fit a binding model with a single, 
reasonably tight binding site (3–5 µM) and a 
second, significantly weaker binding site (250–
480 µM). The tighter binding is presumably 
associated with one of the two CCUG sites in 
(CCUG)6 and the single CCUG site in RNA A (Figure 31a). Potential weaker sites in 
r(CCUG)6 include the remaining CCUG site, (CCUG)2 loop region, and GC stem 
regions. In fact, titration with RNA A, lacking the second CCUG site and loop, give an 
ITC  curve with better curvature (Figure 31b). These results suggest that the residual 
heat at the end of the titration for r(CCUG)6 likely  arises from a general, nonspecific 
binding of the weaker sites. Indeed, the affinity  is similar to that observed for ligand 42 
binding to the single stranded human cardiac troponin T (hcTNT) pre-mRNA (RNA I). 
Overall the data are consistent with ligand 42 binding to only one of the two C-U 
mismatches and a single CCUG site when two sites are neighboring. The origin of this 
latter effect is unclear.
45
C
G
C
C
  U
G
  C
C
C
A
G
  G
  C
  G
  G
U
  C
C
  G
  G
  U
  C
5'
•
•
B
0 1 2 3 4 5 6
-6
-4
-2
-0.8
-0.6
-0.4
-0.2
0.0
0 20 40 60 80 100 120 140 160 180 200 220
Data: CHW02046A_NDH
Model: SequentialBindingSites
Chi^2 = 2393.06
K1 5.396E6 ±1.297E6
H1 -4888 ±50.92
S1 14.41
K2 2.771E5 ±5.655E4
H2 -4648 ±210.0
S2 9.312
K3 5442 ±401.0
H3 -3.204E4 ±1684
S3 -90.36
Time (min)
c
al
/s
ec
Molar Ratio
kc
al
/m
ol
e 
of
 in
je
ct
an
t
Figure 32. ITC profile of ligand 42 binding to 
RNA duplex B containing a slipped CCUG 
unit.
! Similar to the preference exhibited by MBNL1,82 ligand 42 binds with ca. 40-fold 
higher affinity  to the slipped-CCUG structure (RNA B; Figure 32) than to the duplex 
containing adjacent C-U mismatches (RNA A). These results are in good agreement 
with the Kd values for the duplexes containing the single U-U (RNA D) and C-C 
mismatches (RNA E), suggesting that ligand 42 binds strongly to the C-C mismatch in 
the slipped structure and to the U-U with a reduced affinity.
! Surprisingly, ligand 42 does not bind strongly (Kd = 85 ± 30 µM) to RNA C, which 
contains a single C-U step with two adjacent CG steps. Ligand 42 also binds weakly (Kd 
> 100 µM) to the purine-purine mismatches in duplexes F and G. The binding of ligand 
42 to DNA containing a CTG sequence (DNA H), which is one of the targets of DM1, 
occurs with low micromolar affinity (Kd = 1.4 ± 1.5 µM). The difference in binding affinity 
of ligand 42 toward analogous RNA and DNA duplexes (RNA D, U-U; Kd = 25 µM) and 
(DNA H, T-T; Kd = 1.4 µM) may result from structural differences between B-form DNA 
and A-form RNA.
! Importantly, ligand 42 not only binds CCUG, it inhibits the formation of MBNL1-
CCUG complex with low micromolar Ki values. Together with the ITC results, these data 
suggest that ligand 42 is a good lead ligand for targeting either the CCUG or CCUG-
slipped repeat structures implicated as the causative agent of DM2. Finding agents that 
complex CCUG and inhibit MBNL1 binding is a challenge, but finding agents that are 
highly selective is perhaps even more difficult and likely more important given the 
difficulty in developing highly selective agents targeted to nucleic acids. The selectivity 
profile of ligand 42 has been examined in several different contexts and these data can 
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be found in Tables 4 and 5. For example, it is notable that ligand 42 binds r(CCUG)6 
>600-fold tighter than it does tRNA. Thus, even in the presence of tRNA, ligand 42 is 
capable of disrupting the MBNL1-CCUG interaction with minimally diminished Ki values. 
It is also significant that ligand 42 does not inhibit the interaction between MBNL1 and 
its natural target, the 18-nt fragment of human cardiac troponin T (hcTNT) pre-mRNA 
(IC50 > 250 µM). 
! The RNA hydrolytic properties of ligands 11, 41, and 42 were also investigated. 
The stability of the RNA was found to be identical within experimental error in the 
presence of 1–10% DMSO. In addition, the Tm of r(CCUG)6 was concentration-
independent suggesting the formation of a hairpin not a duplex. The hydrolytic stability 
of r(CCUG)6 RNA in the presence of ligands 41 and 42 was also evaluated by Dr. Yuan 
Fu from the Baranger Group. The r(CCUG)6 
RNA was incubated with ligands 41 and 42 
for at least 4 hours at room temperature and 
the RNA was evaluated by denaturing 
polyacrylamide gel electrophoresis (Figure 
33). No cleavage of the RNA was observed 
under these conditions. Therefore, the RNA is 
stable to hydrolytic cleavage in all of the 
binding and inhibition experiments reported 
herein.
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Figure 33. The EMSA studies showed that 
ligands 11, 41, and 42 were not cleaving the 
target r(CCUG)6 RNA.
3.6 Conclusions
Although we did not establish a systematic structure-activity  relationship for this DM2 
study, but the data from the gel electrophoretic mobility shift assays using simple wedge 
recognition compounds 11, 41, and 42 indicate that the acridine unit is critically 
important. These results agree with the previously proposed π-stacked intercalator 
model wherein the acridine is responsible for affinity whereas the selectivity is dictated 
by the nature of the wedge unit. In this regard, it is intriguing that the small structural 
difference between triaminotriazine and triaminopyrimidine units leads to the preferential 
binding to CUG for the former and to CCUG for the latter. It is likely  that the basicity 
difference between triaminotriazine (pKa ~ 5)90 and triaminopyrimidine (pKa ~ 6.7)91 
plays an important role and this is an aspect that merits additional study (Figure 34). At 
pH 7, a substantial amount of protonated triaminopyrimidine may present. As we have 
seen in the previous chapter, this may allow favorable interaction with the C-U mismatch 
from the major groove without serious distortion in the RNA backbone (Figure 35).
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Figure 34. The difference in pKa values of triaminotriazine (in ligand 11) and triaminopyrimidine (in 
ligands 41 and 42).
! Finally, the broadest finding from the current 
study is that ligands 41 and 42 exhibit among the 
highest documented selectivity  for CCUG and, 
thus, represent an excellent starting point for the 
development more selective and potent inhibitors 
of MBNL1 binding. Because of the presence of 
multiple repeating units in the toxic RNAs that 
cause DM1 and DM2, an obvious approach 
involves oligomerization of these or analogous ligands.41,42 This is an approach that has 
already proven effective. For example, Disney reported that the oligomerization of a 
DNA dye (Hoechst 33258) and kanamycin A, ligands that exhibit only  moderate 
selectivity for the CUG and CCUG sequence, respectively, result in oligomers of better 
affinity  and selectivity.41,42,92 The use of intercalators presents an inherent limitation on 
selectivity because an unstacked intercalator can nonselectively  complex a wide range 
of duplex DNAs and RNAs. Developing new ligands where the recognition wedge 
remains stacked or in close proximity to the intercalator, or where the intercalator is 
replaced by a different unit that provides affinity, may obviate this potential source of 
poor selectivity. Regarding to the latter, we have developed a new generation of ligands 
without intercalating moiety which is described in the following chapter.
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4.1 Introduction
Inhibitors 11, 42, and their analogs offered promising activities as were described in the 
previous chapters. After the extensive in vitro studies of these ligands,46,47,93 we began 
to ask if these ligands are also bioactive in DM1 cell models or even in animal models. 
As pointed out in Chapter 1, a reversal of DM phenotype may be achieved by disrupting 
the toxic MBNL1-RNA foci, which in turn, rescues the mis-regulated splicing. The goal is 
to develop  a small molecule that is of low-toxicity and can enter the nucleus readily  to 
disrupt the toxic MBNL1-RNA aggregates. Sulforhodamine B (SRB) toxicity studies 
indicated a relatively high level of cytotoxicity of ligand 11 (IC50 = 20.4 ±  0.5 µM in a 24-
hour assay). The IC50 value is further reduced to 4.2 ±  0.2 µM in a 3-day SRB assay. 
Aggregation of 11 was also observed in cell culture media as a result of its relatively  low 
solubility. In cell culture assays performed by Jessie Peh using confocal microscopy, it 
appeared that ligand 11 concentrated in the cytoplasm of HeLa cells (Figure 36). 
Intercalators that are inherently  charged, such as phenanthridinium and TO-PRO dyes, 
or have solubilizing groups are known to enter the nucleus.94-96 So it is possible that 
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3 This chapter contains materials that are being patented. The other contributors were Jessie Peh, Lien T. 
T. Nguyen, Long M. Luu, Jeannette S. Sanchez, Stacie L. Richardson, Tiziano Tuccinardi, Ho Tsoi, Wood-
Yee Chan, Edwin H. Y. Chan, Anne M. Baranger, Paul J. Hergenrother, and Steven C. Zimmerman. 
ligand 11 can be further developed for example ligands 12 and 13 are much more 
aqueous-soluble and deserve further investigations. Very recently, Amin Jahromi has 
developed derivatives of 12 and 13 that disrupt MBNL1-CUG foci and partially restore 
misregulated splicing. Incidentally we have set out to search for new scaffolds that 
provide satisfactory not only good aqueous solubility but also interact selectively  with 
the A-form RNA duplex.
4.2 Rational Design of the Bisamidinium Inhibitors
In 2011, Butcher and co-workers reported an NMR solution structure of an RNA frame-
shift site stimulator, ligand 49, which was labeled DB213. Ligand 49 was found to reside 
in the stem-loop region of the HIV-1 frameshift site (FS) RNA (Figure 37).97 Similar to 
CUG repeats, the stem-loop  region of HIV-1 FS RNA is essentially an A-form helix.98 
Figure 38a shows the superposition of the [r(CUG)6]2 structure (PDB: 3GM7)51 with the 
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Figure 36. Confocal images of HeLa cells after treatment of ligand 11 (25 µM) for 18 h. (a,b) 
Fluorescent signals from ligand 11. (c,d) TOPO nuclear dye. (e,f) Merge images. Data obtained by 
Jessie Peh.
stem-loop region of the HIV-1 FS RNA 
(PDB: 2L94).97 It was observed that the 
two ammonium ions in ligand 49 spanned 
a distance of about 7 base pairs; i.e., from 
U17-A45 to U23-A40, Figure 38b, which is 
the distance between every other U-U 
mismatch in a CUG repeat sequence 
(Figure 38c). Although ligand 49 bound only weakly to the HIV-1 FS RNA (Kd ~ 360 µM 
by NMR),97 we believed that the bis-amidine moiety would serve as a ds-RNA-binding 
scaffold and also provide satisfactory aqueous solubility  because the two amidinium 
groups would be positively-charged at physiological pH. Thus, we designed ligand 50 by 
replacing the two dimethylamino groups of ligand 49 with two triaminotriazine-based 
recognition units (Figure 38c). In comparison to ligand 11, the additional triaminotriazine 
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Figure 38. (a) Superposition of the structures of the [r(CUG)6]2 duplex (blue; PDB: 3GM7) and the HIV-1 
FS RNA (gray; PDB: 2L94). (b) The binding site of the HIV-1 FS RNA for ligand 49. (c) The proposed 
binding site of the CUG repeats for the bis-amidinium ligands (50–52).
Figure 37. NMR solution structure of DB213 (49) 
binding to the HIV-1 FS RNA in the major groove. 
Copyright (2011) American Chemical Society.
unit was designed to provide enhanced affinity and selectivity by the simultaneous 
recognition of the two U-U mismatches. Molecular modeling provided insight into the 
optimum linker length for ligand binding (Figure 39). It is clear that ligand 50 containing 
two tri-methylene (C3) linkers is too short to allow the triaminotriazine units to form base 
triplets with the U-U mismatches (Figure 39a). Thus, the triaminotriazine units are 
almost perpendicular to the U-U pairs. On the other hand, ligand 51, which has two C4 
linkers, can interact with the U-U pair to form a base triplet. In this binding mode, ligand 
51 spans a distance of three r(CUG)2 repeats (Figure 38c). One triaminotriazine binds a 
U-U mismatch as a base triplet while the bisamidine linker covers the adjacent CUG site 
and the other triaminotriazine binds the third U-U mismatch (Figures 39c,d). The C5 
derivative (52) also showed similar results in both molecular modeling and MD 
simulations which were carried out by Prof. Tiziano Tuccinardi at University of Pisa. 
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Figure 39. Energy minimized structure (Amber) showing (a) ligand 50 and (b) ligand 51 binding to a 
r(CUG)6 duplex in the major groove and the recognition of two of the U-U pairs of ligand 51 through 
hydrogen bonding (c and d). Triaminotriazine-interacting U-U pairs in green and the internal U-U pair in 
gray.
Thus, these results suggested that the one or two extra methylene units in ligands 51 
and 52, respectively, are necessary to allow effective recognition of the U-U pairs.
4.3 Synthesis of Bisamidinium Inhibitors
The synthesis of the bisamidinium-based inhibitors was thought to be straightforward 
based on the reported synthesis of ligand 49 (Scheme 6).97 The synthesis requires a 
bisimino-ester intermediate (53), which 
was prepared from the treatment of 1,4-
dicyanobenzene with dry HCl gas. This 
intermediate was reacted with the 
corresponding amine (54) to afford ligand 
49 as a free base. The ligand was 
subsequently  converted to a tetra-HCl salt upon treatment of hydrogen chloride gas in 
ethanol. The resulting solid was simply filtered off to afford ligand 49 (as tetra-HCl salt) 
of high purity  based on 1H NMR spectroscopy. Unfortunately, the first few attempts to 
synthesize the bisamidine ligands using the same strategy turned out to be problematic. 
The required amine (55), the same intermediates for preparing inhibitor 11, was 
prepared by refluxing diaminochlorotriazine in an excess of 1,4-diaminobutane (Scheme 
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7). A detailed analysis of the this synthetic step  revealed the formation of a small 
amount (5–10%) of dimeric compound 56. During the synthesis and purification of 
ligand 11, this dimeric compound can be effective removed by column chromatography. 
Compound 56 was prepared independently and was found to be highly insoluble in 
water. It is anticipated that the differences in solubility and polarity  of ligands 51 and 56 
will allow simple purification of ligand 51, for example by filtration. Unfortunately, after 
experimenting with different purification techniques, such as HPLC, sephadex, ion 
exchange, and recrystallization, we were unable to obtain a satisfactory 1H NMR 
spectrum of ligand 51. From both the ESI-MS and NMR spectrum, we identified 
compound 56 as one of the impurities in the sample. We set out to dissolve the sample 
in minimum amount of water and filter the insoluble compound 56. Surprisingly, a 
sample containing up  to 10% of compound 56 is still fully  water soluble and this is 
attributed to the formation of supramolecular interactions between compounds 51 and 
56 (Figure 40). Not only could this contribute to the difficulty in purification, some 
identified mono-functionalized intermediates (such as 57) can also form this kind of 
donor-acceptor-donor-acceptor (DA·DA) hydrogen bonding with ligand 51. To solve this 
purification problem, a pure form of compound 55 is required (i.e., without carrying 56 
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Figure 40. (a) Proposed supramolecular interactions between compounds 51 and 56. (b) Structure of a 
mono-functionalized intermediate (57).
into the subsequent step). Secondly, a technique that allows the separation of any 
mono-functionalized intermediates is needed. Removing 56 from 55 turned out to be 
relatively straightforward by careful column chromatography in silica gel using 1–5% of 
ammonium hydroxide in a methanol/dichloromethane eluent. As expected, a relatively 
pure sample of ligand 51 can be obtained with pure amine 55. Careful examination of 
the HPLC trace reveals that there are still impurities appeared as a shoulder peak 
(Figure 41a). Past experience in purifying supramolecular polymers suggests the use of 
highly polar solvents.99 In particular, one must prevent the hydrogen-bond mediated 
self-assembly by using an acidic eluent. Using acidic eluent in silica gel chromatography 
for purifying highly polar compounds is not uncommon.100 After experimenting with 
many combinations of eluent mixture and acids (e.g., HCl and acetic acid), we found the 
best eluent to be a mixture of MeOH, CH2Cl2, and HCl (in the form of 4 M HCl in 
dioxane; see experimental section for details). With this procedure, a pure sample of 
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Figure 41. HPLC traces of (a) crude ligand 51 and (b) purified 51. Conditions: 95% water (0.1% formic 
acid) to 95% acetonitrile (0.1% formic acid) over 10 min using a reverse-phase HPLC column.
ligand 51 can be obtained (Figure 41b). It is noteworthy that there is a change in 
retention time for ligand 51 which is typical for supramolecular aggregates. The pure 
sample also gave a narrower peak width at half height (wh ≈ 0.3 min for crude vs 0.04 
min for pure 51). The reaction conditions were also optimized and is shown in Scheme 
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8. The reaction yield is typical between 70–80%. The reaction has also been scaled up 
from milligram to gram scale. Figure 42 shows the 1H NMR spectrum of ligand 51. Using 
the same experimental conditions, ligands 50 and 52, containing C3 and C5 linkers, 
respectively, were also prepared.
4.4 Foci Disruption and Splicing Correction by Bisamidinium Inhibitors
To test whether these new ligands can disrupt MBNL1-CUG foci in cell culture, Jessie 
Peh and Lien Nguyen transfected HeLa cells with a DMPK plasmid containing a 
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Figure 43. Confocal images of untreated DM1 HeLa cells (a) and a time-course assay with treatment of 
ligand 49 (100 µM) from 24–72 h (c–d). No reduction of foci number was observed up  to 72 h. Scale bar 
= 10 µm. Nuclei was stained by Hoechst 33342; MBNL1 was immunofluorescent (IF) stained by mouse 
anti-MBNL1 antibody followed by goat anti-mouse AlexaFluor 488 antibody; r(CUG)960 was visualized 
with Cy3-(CAG)10. Data obtained by Jessie Peh.
d(CTG)960 repeat which produced expanded CUG transcripts that in turn colocalized 
with MBNL1 (Figure 43a).31 Treatment of the control ligand 49 at 100 µM does not 
disrupt foci appreciably even up  to a 72 h incubation (Figures 43b–d). On the other 
hand, significant reduction in number of foci with treatment of ligand 51 (100 µM) in the 
first 24 h (Figure 44a). Indeed, most foci were dissolved from 48–72 h (Figures 44b,c). 
These results highlighted the importance of the recognition units in ligand 51. Ligand 52, 
containing penta-methylene linkers, also showed disruption but not as effectively as 51. 
In a dose-dependent study, ligand 51 was shown to be effective in reducing the number 
of foci with as little as 5 µM (Figure 45). In agreement with the time-course experiment, 
ligand 51 is more effective then control 49.
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Figure 44. Confocal images from a time-course assay with treatment of ligand 51 (100 µM) from 24–72 
h (a–c). Significant reduction of foci number was observed in the first 24 h (a) when compared to 
untreated cells in Figure 43a. Disruption of most foci from 48–72 h (c,d). Scale bar = 10 µm. Nuclei was 
stained by Hoechst 33342; MBNL1 was immunofluorescent (IF) stained by mouse anti-MBNL1 antibody 
followed by goat anti-mouse AlexaFluor 488 antibody; r(CUG)960 was visualized with Cy3-(CAG)10. Data 
obtained by Jessie Peh.
! The next important step  was to test the potential of ligand 51 to restore 
misregulated splicing in DM1 cells. The splicing assays of cardiac troponin T (cTNT) 
and insulin receptor (IR) pre-mRNA were studied by Jessie Peh and Lien Nguyen, 
respectively. The required DM1 cell culture models were generated by transfecting 
HeLa cells with CTG960 and cTNT (or IR) plasmids. Untransfected cells (i.e., CUG0) 
were used as controls for normal cells. The cTNT,  (CUG)0 and (CUG)960 plasmids were 
obtained from Prof. Thomas Cooper (Baylor College of Medicine) and the IR plasmid 
from Prof. Nicholas Webster (University of California, San Diego). In a splicing assay, 
one determines the ratio of the two isoforms of the mRNA of interest. This ratio is 
different between a healthy  adult and a DM1 patient and the amount of free MBNL1 is a 
key determinant of this ratio. DM patients generally produce a larger number of fetal 
isoform mRNAs. For example in the alternative cTNT splicing, the production of the 
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Figure 45. Dose-dependent foci disruption (48 h treatment) by ligand 51 and comparison of % cell with 
foci for ligands 51 and 49 at 100 µM. P values reaching statistical significance are marked (2 tailed t-test 
with unequal variance). Error bars represent standard errors of the mean. Data obtained by Jessie Peh.
embryonic mRNA (exon 5 included) is enhanced in DM patients (Figure 46a).101 It is 
suggested that the correct splicing ratio can be restored if the MBNL1 protein is 
released from the foci.102 Thus we treated the transfected HeLa cells with ligand 51 at 
100 µM and the ratio of the two isoforms were observed over 3 days (Figure 46b). 
Although there is no observable difference in the ratio from 24–48 h, a significant 
amount of adult isoform (i.e., without exon 5) was observed after treatment of ligand 51 
for 72 h. On the other hand, control 49 did not show any restoration during the same 
period of time. In addition, the amount of exon 5-excluded mRNA increases with 
increasing ligand 51 concentration in a dose-dependent study (Figure 46c).
! Similar results were obtained with HeLa cells transfected with IR plasmid (Figure 
47). In DM, the production of IR-B isoform (exon 11 included) is limited (Figure 47a). 
Results from both time- and dose-dependent assays suggested that ligand 51 
enhanced the production of IR-B mRNA (Figures 47b,c). Again, control 49 showed no 
61
(CU
G)0
(CU
G)9
60
24 h 48 h 72 h 72 h
51 (100 M) 49 (100 M)
(CU
G)0
(CU
G)9
60
25 M 50 M 75 M 100 M
51 (72 h)
+ Exon 5
– Exon 5
+ Exon 5
– Exon 5
4 5 6
+ exon 5 (DM1)
 exon 5 (normal)
cTNT
pre-mRNA
embryonic
adult
5 64
64
(a) (b)
(c)
Figure 46. (a) Alternative splicing of cardiac troponin (cTNT) pre-mRNA. (b) Time-dependent splicing 
correction for cTNT pre-mRNA by treatment of ligand 51 (100 µM) for 24–72 h and the comparison with 
ligand 49 at 100 µM (c) Dose-dependent treatment of ligand 51 for 72 h at the indicated concentrations. 
Data obtained by Jessie Peh.
effect on splicing rescue (Figure 47b). In conclusions, these splicing assays suggest 
that ligand 51 can partially restore the mis-regulated splicing processes in DM.
! These results above also pointed out the low cytotoxicity  profile of ligand 51. All 
HeLa cells remained healthy with dosing at 100 µM for more than 3 days. In fact, the 
cytotoxicity  of ligand 51 was also found to be quite low (IC50 > 100 µM) with two other 
cell lines, DM1 fibroblasts and 3T3 mouse fibroblasts, using SRB or MTT assays. With 
the assistance from Rachel Botham in the Hergenrother group, we also studied the 
toxicity  by measuring the maximum tolerated dose (MTD) in C57BL6 mice. The 
compound was dissolved in water and administrated by intraperitoneal (IP) injection. 
The MTD was found to be between 50 and 100 mg/kg. At 50 mg/kg, the mice showed 
mild neurotoxicity and fatigue in hind limb; improvement in motion was seen after 1 h. 
All mice appeared to be fully  recovered by the next day. At 100 mg/kg, mice were 
sacrificed because of the severe seizures.
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Figure 47. (a) Alternative splicing of insulin receptor (IR) pre-mRNA. (b) Time-dependent splicing 
correction for IR pre-mRNA by treatment of ligand 51 (100 µM) for 24–72 h and the comparison with 
ligand 49 at 100 µM (c) Dose-dependent treatment of ligand 51 for 72 h at the indicated concentrations. 
Data obtained by Lien Nguyen.
4.5 Biophysical Studies of the Bisamidinium Inhibitors
Isothermal titration calorimetry (ITC) was used to study the affinity and selectivity of 
these ligands binding to various targets. It was found that ligand 51 binds to r(CUG)12 
with low micromolar affinity (Kd ~ 8 µM) (Figure 48a). On the other hand, the binding 
affinity  of 51 to bulk tRNA and GST-tagged MBNL1 was too low to be measured. Thus, 
an upper limited of Kd > 200 µM is assigned (Figures 48b,c). These results indicated 
that 51 inhibits the MBNL1-RNA complex by targeting the CUG not by binding the 
protein. The importance of the triaminotriazine units in 51 is also highlighted when 
comparing the ITC  profiles for control 49 and pentamidine (58) (Figure 49). Again, only 
an upper limit of Kd > 200 µM can be assigned for both 49 and 58. This is also 
consistent with the Kd value (~ 360 µM) of control 49 binding to A-form RNA duplexes 
reported by Butcher.97 An electrophoretic mobility shift assay (EMSA) was performed to 
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Figure 48. ITC profiles of ligand 51 binding to (a) r(CUG)12, (b) bulk tRNA, and (c) GST-tagged MBNL1.
measure the strength by which 51 inhibits the MBNL1-CUG interaction (Figure 50). The 
EMSA was performed under stringent conditions with Kd ~ 7 nM for the MBNL1-CUG 
complex. Thus, the measured IC50 was ~115 µM, corresponding to an inhibition constant 
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Figure 49. ITC profiles of (a) control 49 and (b) pentamidine (58) binding to r(CUG)12.
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Figure 50. A electrophoretic gel showing the inhibition of MBNL1-(CUG)12 by ligand 51. Conditions: 
[MBNL1] = 100 nM, [RNA] = 0.2 nM, [NaCl] = 175 mM, [MgCl2] = 5 mM, [BME] = 1.25 mM, 0.05% 
Triton-X. IC50 and Ki were presented as mean ± SD of 4 trials. Data obtained by Lien Nguyen and Stacie 
Richardson.
(Ki) = 2.6 µM for ligand 51, which is comparable to its Kd = 8 µM for r(CUG)12. In 
addition, ligand 50, containing C3 linkers, inhibits MBNL1-CUG interaction very weakly 
and thus an upper limit of IC50 > 6.8 mM.
4.6 Activity in a DM1 Drosophila Model
Drosophila has been a valuable animal model to study neurodegenerative diseases 
including human trinucleotide repeat disorders.103 Several Drosophila models of DM1 
have been reported.39,104-106 Cataract in humans is a common symptom of DM. In 
Drosophila genetically modified with CTG repeats eye defects develop  that are easily 
visualized by microscopy. The Drosophila models are advantageous for multiple 
reasons. In particular, the invertebrates are fast-growing and provide a rapid way to 
study the phenotypic change upon therapeutic treatment.
! Given the promising in vivo results with ligand 51, we were interested in pursuing 
their application in the Drosophila models. Thus, in collaboration with Prof. Woody Chan 
and Prof. Edwin Chan at the Chinese University of Hong Kong, we tested ligand 51 with 
a Drosophila model of DM1 expressing 480 interrupted CUG repeats i(CUG)480.39,104 To 
our delight, ligand 51 reduced the toxic effect from the expanded CUG repeats as seen 
in the improvement in the DM1 eye histology under light microscope (Figure 51a). The 
glossy appearance of untreated flies is visible representing a severe phenotype. Upon 
treatment of ligand 51 (from 200 to 800 µM), the glossy  phenotype is suppressed, 
presenting a less severe rough eye phenotype. Preliminary scanning electron 
microscope (SEM) images of these eyes provided further details on the eye structure 
(Figures 51b,c). Untreated DM1 fly eyes showed substantial fusion and disorganization 
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of ommatidia with a loss of inter-ommatidial bristles (Figure 51c). Upon treatment of 
ligand 51 at 200 µM, the number of fused ommatidia is significantly reduced. At 400 and 
800 µM, the individual ommatidium are further patterned in a more organized way with 
more increased number of inter-ommatidial bristles indicating a protective role for ligand 
51 in preventing the DM phenotype.
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Figure 51. Phenotypic change in eyes of DM1 Drosophila model upon treatment of ligand 51 from 200 
to 800 µM observed under (a) light microscope (✕ 230), (b) SEM (✕ 230), and (c) SEM (✕ 700). Data 
obtained from Dr. Ho Tsoi, Prof. Edwin Chan, and Prof. Woody Chan.
4.7 Conclusions and Outlook
Through rational design, we developed a new generation of ligands (50–52) that has a 
very  low toxicity  profile and high aqueous solubility. In particular, ligand 51, containing 
C4 linkers, showed the most promising activity  among others. Ligand 51 inhibits foci 
formation in DM1 cell culture and partially corrects splicing defects in a DM1 Drosophila 
model. All these results suggested that ligand 51 is a promising lead ligand for 
developing new approach to better inhibit the MBNL1-CUG interaction.
! In this regard, we propose a new therapeutic strategy using template-assisted 
“click chemistry.” As explained in the Background (see also Figure 1), the toxic RNA 
involved in DM is an expanded CUG or CCUG repeat range from 100 to >10,000 
repeating units (i.e., up  to 30,000–40,000 nt in length). Thus, the use of oligomeric 
ligands should provide better inhibition because of a larger steric coverage of the RNA. 
In principle, an oligomeric ligand also has a higher affinity toward the RNA because of 
the multivalent binding.40 As discussed in Section 1.5, Disney and co-workers have put 
this concept forward to target both CUG and CCUG repeats using oligomeric peptoids.
41-43,92,107 We believe that this in vivo click approach is benefited by both the repetitive 
nature of the RNA and high selectivity of the lead ligands. In essence, the expanded 
RNA will not only be the substrate of the ligands but also a template for “in situ” ligand 
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oligomerization. This approach will bypass the difficulty  of cellular uptake of high MW 
ligands yet providing a stronger binding and inhibition. Ligand 59 was thus synthesized 
for this purpose (Scheme 9). Preliminary studies indicated that ligand 59 possesses 
RNA-binding affinity and inhibitory activity comparable to that of 51. The two acetylene 
groups in 59 would allow oligomerization using in situ click chemistry. 
! Finally, it is hoped that the compounds and concepts developed in this 
dissertation will contribute to the development of therapeutic strategy  for curing the 
myotonic dystrophy disease.
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Chapter 5   Materials and Methods
Materials. Single-stranded oligodeoxynucleotides (purified by  standard desalting) were 
purchased from Integrated DNA Technologies (Coralville, IA). The DNA sample 
solutions were prepared using TE buffer (pH 7.6) and the concentrations were 
determined by performing absorbance measurements at 25 °C on a Shimadzu 
UV-2501PC spectrophotometer (Kyoto, Japan). The concentration of each single-
stranded DNA was calculated using Beer’s law with the extinction coefficient (ε260) 
provided by the supplier. The double-stranded DNA solution was freshly prepared by 
mixing required volumes of the corresponding ssDNA. The dsDNA was then annealed 
by heating in a water bath at 90 °C for 5 min and slow cooling to room temperature. 
MOPS buffer solution (100 mM), NaCl solution (3.0 M), and Millipore water were added 
to make up a DNA solution with 20 mM MOPS (pH 7.0 ± 0.2) and 300 mM NaCl.
Thermal denaturation studies.  The melting temperatures of the duplexes were 
measured on a Shimadzu UV-2501PC spectrometer equipped with a temperature-
controller. The absorbance of each DNA solution (12 µM duplex) with 20 mM MOPS (pH 
7.0 ±  0.2), 300 mM NaCl, and 10 mM EDTA was annealed and cooled to 0 °C. The 
absorbance of each sample was monitored at 260 nm from 0 °C to 90 °C  at a ramp rate 
1 °C/min. The melting temperature (Tm) of each sample was determined from the 
maximum point of the first derivative of the melting curve with Origin 7.0 (Northampton, 
MA).
Isothermal titration calorimetry (ITC) studies. ITC measurements were performed at 
25 °C  on a MicroCal VP-ITC calorimeter (Northampton, MA). A typical experiment 
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consisted of titrating 10 µL of a ligand solution (500 µM) from a 250 µL syringe (stirred at 
300 rpm) into a sample cell containing 1.42 mL of a DNA solution (10–20 μM) with total 
28 injections. The initial delay prior to the first injection was 60 s. The duration of each 
injection was 24 s and the delay between injections was 300 s. The heat of dilution was 
determined using a blank solution containing no DNA. The ITC data was then 
subtracted from the blank. All experiments were repeated at least twice. Data analysis 
was carried out with Origin 5.0 software (MicroCal). Binding parameters such as the 
dissociation constant (Kd), enthalpy change (∆H), and entropy change (∆S) were 
determined by fitting the experimental binding isotherms with appropriate models. The 
ligand stock solution was 10 mM in DMSO. The buffer solution for ITC experiments was 
MOPS (20 mM; pH 7.0 ±  0.2), NaCl (300 mM) and 5–10% (v/v) DMSO to balance the 
residual DMSO in the ligand solution.
Job Plot Analysis. Fluorescence measurements were carried out at 25 °C on a 
HORIBA Jobin Yvon (Edison, NJ) FluoroMax-3 spectrofluorometer using a 250 μL 
quartz cell with 0.1 cm path length. The concentrations of the DNA and ligand were 
varied in each sample whereas the sum of the concentrations (c0) was kept constant. All 
solution contained MOPS (20 mM; pH 7.0 ± 0.2) and NaCl (300 mM). The blanks 
consisted of the same solutions with no DNA were used to correct the dilution effect. 
The fluorescence signal was measured with an excitation wavelength of 310 nm and 
emission wavelength was collected from 470 to 530 nm. The fluorescence intensity of 
the sample (F) and the blank (F0) at 495 nm for each mole fraction of ligand (χL) was 
used for the Job plot analysis. A  Job plot was constructed by plotting the change in 
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fluorescence (∆F = F0 – F) versus the mole fraction. The stoichiometry was determined 
from the intercept of the two tangents aligned at the positions χL = 0.0 and 1.0.
Circular dichroism (CD) studies. The CD measurements were carried at 25 °C on a 
Jasco J-715 spectropolarimeter (Easton, MD) using a cylindrical quartz cell with 1 mm 
path length. A  solution of DNA (50 μM duplex, 20 mM MOPS, pH 7.0 ±  0.2, and 300 mM 
NaCl) was titrated with a concentrated ligand solution (10 mM in DMSO). The titration 
was carried out with injection of 5 μL of the ligand solution until a saturation of CD signal 
was reached. The CD signals were collected from 400 to 240 nm. A titration curve was 
then constructed by plotting the CD signal at 288 nm versus the mole ratio of ligand to 
duplex.
Synthetic procedures.  1H and 13C NMR spectra for structural characterization were 
recorded on a Varian Unity  Inova 500 spectrometer (1H: 500 MHz; 13C: 125 MHz). 
Unless otherwise stated, all NMR measurements were carried out in CDCl3 at room 
temperature. Chemical shifts were reported as parts per million (ppm) in scale using 
residual peaks of CDCl3 (1H: 7.26; 13C: 77.16) or DMSO-d6 (1H: 2.50; 13C: 39.52) as 
internal standards. Coupling constants (J) were reported in hertz. Mass spectra were 
obtained by the Mass Spectrometry Laboratory, School of Chemical Sciences, 
University  of Illinois. High performance liquid chromatography (HPLC) was performed 
by a Dynamax SD-200 system with a UV, detector set at 254 nm, using an Alltech 
Denali C-18 column (250 × 10 mm) using a dual solvent system of 0.1% (v/v) formic 
acid/H2O (Solvent A) and 0.1% (v/v) formic acid/MeCN (Solvent B). Melting points were 
measured on a Thomas Hoover capillary melting point apparatus (Philadelphia, PA) and 
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were uncorrected. Elemental analyses were performed in the Microanalysis Laboratory, 
School of Chemical Sciences, University of Illinois.
! All non-aqueous reactions were carried out under dry  N2 atmosphere with oven-
dried (115 °C) glassware. Unless otherwise stated, all solvents and reagents were of 
reagent quality, purchased commercially, and used without further purification. 
Tetrahydrofuran (THF) was freshly distilled from Na/benzophenone ketyl under N2. 
Toluene was freshly  distilled from Na sphere under N2. Dichloromethane (CH2Cl2) was 
freshly distilled from CaH2 under N2. The progress of reaction was monitored by  thin 
layer chromatography (TLC) performed on Merck pre-coated silica gel 60F254 plates, 
and compounds were visualized with a spray of 5% (w/v) phosphomolybdic acid hydrate 
in ethanol with subsequent heating. Flash chromatography was carried out on columns 
of Macherey-Nagel MN Kieselgel 60 M (230–400 mesh) silica gel.
! The synthetic procedures for unpublished compounds (i.e., 37, 43, 44, 50, 51, 
52, 59, and 63) published will be reported below:
Ligand 37:
N
N
H
OH2N
NH2
OH
O
• TFA
N
HN
Cl
MeO
NH2
EDCI, HOBt, DIPEA
DMF, 0−25 °C, 24 h
(60%)
N
HN
MeO
Cl
N
N
O
HH
H
NH
N
HO
HN
3739
40
To a stirred mixture of 91 mg (0.32 mmol) of compound 39, 98 mg (0.32 mmol) of 
compound 40, 81 mg (0.42 mmol) of EDCl, and 25 mg (0.19 mmol) of HOBt in 10 mL of 
DMF was added 0.14 mL of DIPEA (0.80 mmol) at 0 °C. The temperature was raised to 
25 °C  after the addition. The reaction mixture was stirred for 24 h. The solvent was 
removed in vacuo and the residue was dissolved in MeOH and dry-packed for flash 
column chromatography (MeOH:CH2Cl2:NH4OH) to give 90 mg (60%) of ligand 37 as a 
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yellow solid. 1H NMR (DMSO-d6): δ 9.90 (br s, 1 H, NH), 8.59 (d, J = 9.5 Hz, 1 H, ArH), 
8.50 (s, 1 H, ArH), 8.01 (s, 1 H, ArH), 7.90 (d, J = 4.5 Hz, 1 H, ArH) 7.89 (br s, 1 H, NH), 
7.65 (dd, J = 1.5 Hz and 9 Hz, 1 H, ArH), 7.46 (d, J = 9 Hz, 1 H, ArH), 7.06 (br s, 4 H, 
NH2), 4.17 (br s, 2 H, CH2), 3.96 (s, 3 H, OCH3), 3.58 (m, 2 H, CH2), 3.17 (s, 2 H, 
CH2CO).
N-(6-aminopentyl)melamine (63):
N
N
N
Cl
NH2H2N
H2N(CH2)5NH2
130 °C, 5 h
(22%)
N
N
N
NH
NH2H2N
NH2
63
A mixture of 1.24 g (8.52 mmol) of chlorodiaminotriazine and 4.39 g (42.9 mmol) of 1,5-
diaminopentane was heated in an oil bath at 130 °C for 5 h. The reaction mixture was 
cooled to room temperature. A solution of 10 mL of 35% NH4OH aqueous solution was 
added. The precipitated was filtered and triturated with 50 mL of EtOH. The suspension 
was filtered and dried in vacuo to give 0.402 g (22%) of compound 63 as a pale yellow 
solid. 1H NMR (DMSO-d6): δ 6.43 (t, J = 5.5 Hz, 1 H, MelNHCH2), 6.10 (br s, 2 H, NH2), 
5.93 (br s, 2 H, NH2), 4.84 (br s, 2 H, CH2NH2), 3.15 (q, J = 6.5 Hz, 2 H, MelNHCH2), 
2.62–2.59 (m, 2 H, CH2), 1.45–1.40 (m, 4 H, CH2), 1.06–1.03 (m, 2 H, CH2).
Ligand 43:
N
N
N
NH
NH2H2N
NH2
63
N
OMe
Cl
OPh
24
TFA, MeCN
reflux, 6 h
(28%)
N
N
N
N
N
HH
H
N
HN
MeO
Cl
NH
H
43
• 2 TFA
A mixture of 0.402 g (1.89 mmol) of compound 63, 0.667 g (1.99 mmol) of compound 
24, and 0.20 mL of TFA in 20 mL of acetonitrile was refluxed to reflux for 6 h. The 
reaction mixture was cooled to room temperature and concentrated in vacuo. The 
residue was dry-packed with silica gel and purified by  flash column chromatography 
(10% MeOH in CH2Cl2) to afford a yellow solid. The solid was treated with excess TFA 
and the dried in vacuo to afford 0.36 g (28%) compound 43 as a TFA salt. 1H NMR of 
the free base (DMSO-d6): δ 8.31 (d, J = 9 Hz, 1 H, ArH), 7.87–7.82 (m, 2 H, ArH), 7.60 
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(s, 1 H, ArH), 7.40 (d, J = 8.5 Hz, 1 H, ArH), 7.30 (d, J = 8.5 Hz, 1 H, ArH), 6.80 (br s, 1 
H, AcrNH), 6.42 (t, J = 6 Hz, 1 H, MelNH), 6.11 (br s, 2 H, NH2), 5.95 (br s, 2 H, NH2), 
3.92 (s, 3 H, OCH3), 3.72 (t, J = 7 Hz, 2 H, AcrNHCH2), 3.12 (q, J = 6 Hz, 2 H, 
MelNHCH2), 1.75–1.69 (m, 2 H, CH2), 1.46–1.41 (m, 2 H, CH2), 1.35–1.30 (m, 2 H, 
CH2). Anal. calcd for C26H27N8O5F6Cl: C, 45.86; H, 4.00; N, 16.45. Found: C, 46.12; H, 
3.86; N, 16.30.
Ligand 44:
N
N
N
HN
NH2
NH2 N
N
N
N
N
HH
H
N
HN
Cl
NH
H
PhOH, 140 °C, 12 h
(90%)
N
Cl
Cl
H2N
4455
64
A mixture of 0.367 g (1.86 mmol) of compound 55, 0.367 g (1.85 mmol) of compound 
64, and 1.10 g (11.7 mmol) of phenol was heated in an oil bath at 140 °C for 12 h. The 
reaction mixture was cooled to room temperature and dissolved in 20 mL of MeOH. The 
solution was dry-packed with silica gel and purified by flash column chromatography 
(MeOH:CH2Cl2:NH4OH = 2:10:0.1) to give 0.602 g (90%) of compound 44 as a pale 
yellow solid. 1H NMR (DMSO-d6): δ 8.37 (d, J = 5.5 Hz, 1 H, ArH), 8.25 (d, J = 9 Hz, 1 
H, ArH), 7.77 (d, J = 2 Hz, 1 H, ArH), 7.42 (dd, 2.5 Hz and 9 Hz, ArH, 1H), 7.29 (t, J = 5 
Hz, 1 H, QCNHCH2), 6.48 (t, 6 Hz, 1 H, MelNHCH2), 6.45 (d, J = 5.5 Hz, 1 H, ArH, 1H), 
6.10 (br s, 2 H, NH2), 5.93 (br s, 2 H, NH2), 3.29–3.22 (m, 4 H, CH2), 1.68–1.63 (m, 2 H, 
CH2), 1.60–1.56 (m, 2 H, CH2). ESI-MS (m/z): 359.1 ([M + H]+, 60%). ESI-HRMS (m/z): 
[M + H]+ calcd for C16H20N8Cl, 359.1499, found, 359.1501.
Ligand 50:
EtO
HN NH
OEt
⋅ 2 HCl
N
N
N
H2N NH
NH2
NH2
1)
    DIPEA,EtOH
    0−25 °C, 18 h
2) HCl
               (86%)65 50
53
NH
HN
NH
HN
⋅ 4 HCl
NH2
NN
N
NH2
N
H
N
N N
HN
NH2
H
N
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A 25-mL, two-necked, round-bottomed flask equipped with a magnetic stir bar 
containing a white suspension of 0.124 g (0.423 mmol) of compound 53 in 10 mL of 
anhydrous EtOH is cooled in an ice-water bath under a nitrogen atmosphere. To the 
suspension was added 0.30 mL (1.722 mmol) of DIPEA to produce a colorless clear 
solution. A solution of 0.175 g (0.953 mmol) of compound 65 in 5 mL of ethanol was 
added dropwise using a pipette. The reaction mixture was allowed to warm to 25 °C 
slowly  and stirred for 18 h. The reaction was monitor by TLC (n-BuOH:AcOH:H2O = 
3:1:4; Rf = 0.15). The white suspension was filtered and washed with EtOH (20 mL). 
The white solid was dissolved in 15 mL of 1:9 (v/v) H2O/MeOH mixture and 
chromatographed on short silica gel (~200 mL) column starting with CH2Cl2:n-
BuOH:MeOH mixture (gradient from 1:5:4 to 1:3:6). Once the impurities were removed, 
the eluent was acidified with a gradient of 0.10–0.15 mL of 4 M HCl in dioxane (per liter 
of eluent) to afford the desired product. The product-containing fractions were 
combined, filtered, and concentrated in vacuo to afford 0.180 g (86%) of product as a 
white tetra·HCl salt. Rf(AcOH:H2O:MeOH = 3:6:1) = 0.25. 1H NMR (DMSO-d6): 10.20 (s, 
2 H, NH), 9.76 (s, 2 H, NH), 9.36 (s, 2 H, NH), 7.99 (s, 4 H, ArH), 7.34 (br s, 2 H, Het-
NH), 6.77 (br s, 8 H, Het-NH), 3.49 (br s, 4 H, N=CNHCH2), 3.32 (overlap with H2O, 4 H, 
Het-NHCH2), 1.89 (q, 4 H, J = 10 Hz, CH2). ESI-MS [M+H]+:10% [M+2H]2+: 100%.
Ligand 51:
EtO
HN NH
OEt
⋅ 2 HCl
N
N
N
H2N NH
NH2
NH2
1)
    Et3N, HOCH2CH2OH
    EtOH, 0−25 °C, 18 h
2) HCl
               (77%)55 51
53
NH
HN
NH
HN NH2N
N N
H
N
NH2N
N
N
H2N NH
H2N
⋅ 4 HCl
A 50-mL, two-necked, round-bottomed flask equipped with a magnetic stir bar 
containing a white suspension of 1.11 g (3.79 mmol) of compound 53 in 50 mL of 
anhydrous EtOH is cooled in an ice-water bath under a nitrogen atmosphere. To the 
suspension was added 1.10 mL (7.89 mmol) of Et3N to produce a colorless clear 
solution. A solution of 1.54 g (7.81 mmol) of compound 55 in 5 mL of ethylene glycol 
was added dropwise using a pipette. The reaction mixture was allowed to warm to 25 
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°C  slowly and stirred for 18 h. The reaction was monitor by TLC (n-BuOH:AcOH:H2O = 
3:1:4; Rf = 0.1). The white suspension was filtered and washed with EtOH (20 mL). The 
white solid was dissolved in 15 mL of 1:9 (v/v) H2O/MeOH mixture and 
chromatographed on short silica gel (~200 mL) column starting with CH2Cl2:n-
BuOH:MeOH mixture (gradient from 1:5:4 to 1:3:6). Once the impurities were removed, 
the eluent was acidified with a gradient of 0.10–0.15 mL of 4 M HCl in dioxane (per liter 
of eluent) to afford the desired product. The product-containing fractions were 
combined, filtered, and concentrated in vacuo to afford 1.95 g (77%) of product as a 
white tetra·HCl salt (m.p. > 230 °C (decomp.)). Rf(AcOH:H2O:MeOH = 3:6:1) = 0.30. 1H 
NMR (DMSO-d6): 10.25 (s, 2 H, NH), 9.81 (s, 2 H, NH), 9.43 (s, 2 H, NH), 7.98 (s, 4 H, 
ArH), 6.61 (s, 2 H, Het-NH), 6.19 (s, 4 H, Het-NH), 6.03 (s, 4 H, Het-NH), 3.47 (m, 4 H, 
N=CNHCH2), 3.22 (q, 4 H, J = 10 Hz, Het-NHCH2), 1.66 (q, 4 H, J = 10 Hz, CH2), 1.56 
(q, 4 H, J = 10 Hz, CH2). 13C NMR (DMSO-d6): 167.2, 166.9, 166.4, 161.5, 133.0, 128.6, 
42.7, 26.6, 24.8 (one overlapped). HR-ESI-MS for C22H35N16: 523.3231 found: 
523.3233. ESI-MS [M+H]+:30% [M+2H]2+: 100%. Elemental analysis for C22H34N16⋅4HCl 
C:39.53, H:5.73, N:33.53, Cl:21.21 found: C:39.32, H:5.89, N:31.96, Cl:21.77.
Ligand 52:
EtO
HN NH
OEt
⋅ 2 HCl
N
N
N
H2N NH
NH2
1)
    DIPEA,EtOH
    0−25 °C, 18 h
2) HCl
               (73%)63 52
53
NH
HN
NH
HN
⋅ 4 HCl
NH2
NH2
NN
N
NH2
N
H
N
N N
HN
NH2
H
N
A 25-mL, two-necked, round-bottomed flask equipped with a magnetic stir bar 
containing a white suspension of 0.435 g (1.48 mmol) of compound 53 in 10 mL of 
anhydrous EtOH is cooled in an ice-water bath under a nitrogen atmosphere. To the 
suspension was added 0.60 mL (3.44 mmol) of DIPEA to produce a colorless clear 
solution. A solution of 0.658 g (3.11 mmol) of compound 63 in 10 mL of ethanol was 
added dropwise using a pipette. The reaction mixture was allowed to warm to 25 °C 
slowly  and stirred for 18 h. The reaction was monitor by TLC (n-BuOH:AcOH:H2O = 
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3:1:4; Rf = 0.1). The white suspension was filtered and washed with EtOH (20 mL). The 
white solid was dissolved in 15 mL of 1:9 (v/v) H2O/MeOH mixture and 
chromatographed on short silica gel (~200 mL) column starting with CH2Cl2:n-
BuOH:MeOH mixture (gradient from 1:5:4 to 1:3:6). Once the impurities were removed, 
the eluent was acidified with a gradient of 0.10–0.15 mL of 4 M HCl in dioxane (per liter 
of eluent) to afford the desired product. The product-containing fractions were 
combined, filtered, and concentrated in vacuo to afford 0.751 g (73%) of product as a 
white tetra·HCl salt (m.p. > 260 °C (decomp.)). Rf(AcOH:H2O:MeOH = 3:6:1) = 0.35. 1H 
NMR (DMSO-d6): 10.20 (s, 1 H, NH), 9.74 (s, 1 H, NH), 9.36 (s, 1 H, NH), 8.21 (br s, 2 
H, Het-NH), 7.97 (s, 4 H, ArH), 7.89 (s, 8 H, Het-NH), 3.45 (q, 4 H, J = 5 Hz, 
N=CNHCH2), 3.29 (q, 4 H, J = 10 Hz, Het-NHCH2), 1.68 (q, 4 H, J = 10 Hz, CH2), 1.54 
(q, 4 H, J = 10 Hz, CH2), 1.40 (br s, 4 H, CH2). HR-ESI-MS for C24H39N16: 551.3544 
found: 5551.3549. ESI-MS [M+H]+:30% [M+2H]2+: 100%.
Bis-acetylene ligand 59:
EtO
HN NH
OEt
⋅ 2 HCl
N
N
N
H2N NH
HN
NH2
1)
    Et3N, EtOH
    0−25 °C, 18 h
2) HCl
               (55%)66 59
53
NH
HN
NH
HN NH2N
N N
H
N
HNN
N
N
H2N NH
NH
⋅ 4 HCl
A 25-mL, two-necked, round-bottomed flask equipped with a magnetic stir bar 
containing a white suspension of 0.402 g (1.37 mmol) of compound 53 in 10 mL of 
anhydrous EtOH is cooled in an ice-water bath under a nitrogen atmosphere. To the 
suspension was added 0.45 mL (3.23 mmol) of Et3N to produce a colorless clear 
solution. A solution of 0.711 g (3.02 mmol) of compound 66 (prepared by Long Luu) in 2 
mL of EtOH was added dropwise using a pipette. The reaction mixture was allowed to 
warm to 25 °C slowly and stirred for 24 h. The reaction was monitor by TLC (n-
BuOH:AcOH:H2O = 3:1:4; Rf = 0.2). The white suspension was filtered and washed with 
EtOH (20 mL). The white solid was dissolved in 5 mL of MeOH and chromatographed 
on short silica gel (~200 mL) column starting with 1:9 (v/v) CH2Cl2:MeOH mixture. Once 
the impurities were removed, the eluent was acidified with a gradient of 0.10–0.15 mL of 
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4 M HCl in dioxane (per liter of eluent) to afford the desired product. The product-
containing fractions were combined, filtered, and concentrated in vacuo to afford 0.561 
g (55%) of product as a white tetra·HCl salt (m.p. > 200 °C (decomp.)). 
Rf(AcOH:H2O:MeOH = 3:6:1) = 0.45. 1H NMR (DMSO-d6): 10.32 (s, 2 H, NH), 9.86 (s, 2 
H, NH), 9.48 (s, 2 H, NH), 7.99 (s, 4 H, ArH), 6.78 (br t, 4 H, Het-NH, rotamers), 6.23 (br 
t, 4 H, Het-NH, rotamers), 3.97 (br s, 4 H, CH2C≣C), 3.49 (m, 4 H, N=CNHCH2), 3.23 
(br s, 4 H, Het-NHCH2), 3.02 (s, 2 H, C≣CH), 1.66 (br s, 4 H, CH2), 1.57 (br s, 4 H, 
CH2). 13C  NMR (DMSO-d6): 166.6, 166.2, 165.6, 165.3, 161.5, 132.8, 128.6, 82.5, 72.2, 
42.6, 29.2, 26.5, 24.8. ESI-MS [M+H]+:5% [M+2H]2+: 100%.
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ABSTRACT
Myotonic dystrophy type 2 (DM2) is an incurable
neuromuscular disease caused by expanded CCUG
repeats that may exhibit toxicity by sequestering
the splicing regulator MBNL1. A series of triamino-
triazine- and triaminopyrimidine-based small mol-
ecules (ligands 1–3) were designed, synthesized
and tested as inhibitors of the MBNL1–CCUG inter-
action. Despite the structural similarities of the
triaminotriazine and triaminopyrimidine units, the
triaminopyrimidine-based ligands bindwith lowmicro-
molar affinity to CCUG repeats (Kd! 0.1–3.6 mM)
whereas the triaminotriazine ligands do not bind
CCUG repeats. Importantly, these simple and small
triaminopyrimidine ligands exhibit both strong inhib-
ition (Ki! 2mM) of the MBNL1–CCUG interaction
and high selectivity for CCUG repeats over other
RNA targets. These experiments suggest these com-
pounds are potential lead agents for the treatment
of DM2.
INTRODUCTION
Myotonic dystrophy (DM) is an RNA-mediated disorder
that affects both skeletal and smooth muscles as well as
internal organs such as the heart, lung and eye lens (1).
Two major types of DM have been identified: types 1
(DM1) and 2 (DM2). It was discovered that both DM1
and DM2 are caused by unstable nucleotide repeat se-
quences in DNA. DM1 is caused by expansion of the
CTG repeat (from 80 to >2000 repeats) in the 30-untrans-
lated region (30-UTR) of the dystrophia myotonin protein
kinase (DMPK) gene on chromosome 19 (2), whereas
DM2 is caused by expansion of the CCTG (from 75 to
11 000 repeats) in intron 1 of the ZNF9 (zinc-finger protein
9) gene on chromosome 3 (3). The corresponding
expanded transcripts, r(CUG)n and r(CCUG)n for DM1
and DM2, respectively, form inclusion complexes that se-
quester muscleblind-like (MBNL) proteins in the nucleus.
A member of a family of structurally and functionally
similar proteins, MBNL is expressed at high level in
skeletal muscles and is known to be directly involved in
causing DM. MBNL1 is involved in the regulation of
RNA splicing, editing and translation (4). The sequestra-
tion of MBNL1 proteins results in misregulated, alterna-
tive splicing of several pre-mRNAs, including the cardiac
troponin T (cTNT), fast skeletal troponin T (Tnnt3),
insulin receptor (IR) and chloride channel (ClC-1)
pre-mRNAs. It is proposed that these errors in alternative
splicing, in turn, cause the multisystemic clinical features
of DM (5). It has been suggested that agents that bind
selectively to the pathogenic RNAs might reverse the
phenotype by inhibiting MBNL1 protein from binding,
thereby allowing the protein and mRNAs to function
normally (6,7). Indeed, antisense oligonucleotides that
target the CUG repeat were shown to reverse the pheno-
type of DM1 in a mouse model (8,9).
With the knowledge that disrupting the MBNL1–CUG
repeat complex might provide a therapeutic strategy to
treat DM1, recent efforts have focused on small molecules
that target CUG repeats (10–13). An ideal candidate
should also reverse the splicing defects observed in DM.
For example, pentamidine is capable of rescuing four dif-
ferent pre-mRNAs affected by CUG repeats as well as
displacing MBNL1 from CUG ribonuclear foci (10). In
this regard, we have developed a simple, low molecular
weight ligand (ligand 1) that exhibits high selectivity in
binding the CUG base triplet and, further, inhibits the
MBNL1–CUG interaction with micromolar IC50 values
(Figures 1 and 2) (12). As an alternative-splicing regulator,
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MBNL1 binds to other stem–loop structures containing
pyrimidine–pyrimidine mismatches, including the pre-
mRNAs discussed above. Therefore, it is essential to de-
velop ligands that bind selectively to the pathogenic RNAs
in preference to the natural targets of the MBNL1 and
other nucleic acids. Indeed, achieving RNA and sequence
selectivity is particularly difficult given the presence of a
large amount of genomic DNA in the nucleus. The
majority of work to date has focused on DM1, however
recently, Disney and coworkers (14) reported oligomeric
ligands that target expanded CCUG repeats in DM2.
Specifically, a trimeric ligand with three kanamycin A
units was shown to bind strongly to CCUG RNA and
inhibit the MBNL1–CCUG interaction. A subsequent
report showed that the flexibility of the ligand backbone
plays a critical role in determining affinity and selectivity
(15). Despite these important advances, alternative
approaches are likely needed given the challenges in de-
veloping clinically useful therapeutic agents.
In examining the interaction of CUG repeats with
ligand 1, the triaminotriazine moiety was found to be im-
portant for the selective binding of U–U mismatches,
whereas the acridine unit provided binding affinity for
the CUG RNA (12). Stacking of the two heterocyclic
units, which was observed by 1H NMR, is likely to increase
the mismatch selectivity by significantly reducing the
ability of the acridine to function as an unselective RNA
intercalator. Although the binding mode is not known,
ligand 1 was designed to intercalate between the U–U
and G–C base pairs and simultaneously form a base
triplet with the triaminotriazine unit inserted between
the U–U mismatch (Figure 1). Therefore, small molecule
ligands structurally similar to ligand 1 (IC50=43 mM for
MBNL1–CUG) were explored. Herein, we report on ef-
forts toward a similar approach, to develop p-stacked
intercalators that specifically recognize CCUG repeats
and inhibit the MBNL1–CCUG interaction.
MATERIALS AND METHODS
Materials
RNA oligonucleotides were purchased from Dharmacon
RNAi Technologies, Inc. with 20-deprotection, desalting
and HPLC purification. DNA sequences were purchased
from Integrated DNA Technologies, Inc. with standard
desalting. The RNA oligonucleotides were dissolved
in Ambion RNA Storage Solution (pH 6.4) to give
1–2mM stock solutions. DNA sequences were dissolved
in TE buffer (pH 7.6) to give 1–2mM stock solutions. The
oligonucleotide concentration was determined by its ab-
sorbance at !max=260nm at 25
!C on a Shimadzu UV-
2501PC spectrophotometer. The concentration of each
single-stranded sequence was calculated using Beer’s law
with extinction coefficient (e260) provided by the supplier.
RNA and DNA duplexes were freshly prepared by mixing
the required volumes of the corresponding ssRNA and
ssDNA, respectively. The solution was annealed by
heating in a water bath at 95!C for 2min and slow
cooling to 25!C. Final duplex solutions were prepared
by adding MOPS buffer (100mM; pH 7.0), NaCl
solution (5.0M) and diluting to the required concentra-
tions by adding AccuGENE Molecular Biology Grade
Water and 1 or 10% (v/v) DMSO to give 20mM MOPS
and 300mM NaCl solutions.
Protein expression and purification
An expression vector for a truncated MBNL1 comprised
of amino acids 1–272 was obtained from Maurice
S. Swanson (University of Florida, College of Medicine,
Gainesville, FL, USA). This MBNL1 construct is com-
prised of the four zinc-finger motifs of MBNL1 and a
hexahistidine tag (C-terminus) and binds RNA with simi-
lar affinity as the full-length MBNL1. The protein
was expressed and purified as described previously (16).
Figure 1. (a) Design principle of ligand 1 and (b) two possible binding modes with different groove preference of ligand 1 binding to T–T/U–U
mismatch.
Figure 2. Ligand 1 inhibits the MBNL1–CUG interaction by binding to the U–U mismatches of the pathogenic RNA. MBNL1 is released and
resumes its alternative splicing functions for more than 12 known pre-mRNAs.
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The molecular weight was confirmed by MALDI-TOF
mass spectrometry, the concentration was determined by
Bradford protein assay (Bio-Rad), and the purity
determined by silver-stained SDS–PAGE.
Electrophoretic mobility shift assay
RNAs were labeled with [g-32P]-ATP using T4 poly-
nucleotide kinase (New England Biolabs) and were puri-
fied by phenol extraction and precipitation from ethanol.
Labeled RNA (5 ml, 5 nM) was heated at 95!C for 2min,
placed on ice for 10min and diluted to 125ml in RNA
storage buffer [66mM NaCl, 6.7mM MgCl2, 27mM
Tris–HCl (pH 7.5)]. For assays with competitor tRNA,
bulk yeast tRNA was added to the RNA solution to
give a final concentration of "100 nM. MBNL1 was seri-
ally diluted in binding buffer [175mM NaCl, 5mM
MgCl2, 20mM Tris–HCl (pH 7.5), 1.25mM 2-mercapto-
ethanol (BME), 12.5% glycerol, 2mg/ml bovine serum
albumin (BSA), 0.1mg/ml heparin]. Protein (5 ml) and
RNA (5 ml) solutions were combined. The reaction mixture
was incubated at room temperature for 25min and loaded
onto a 6% polyacrylamide gel (80 : 1) at 4!C. The gels
were run for 1 h at 360V in 22.5mM Tris–borate buffer
(pH 8). Gels were visualized on a Molecular Dynamics
Storm PhosphorImager. The apparent Kd values (assuming
a 1:1 stoichiometry) were obtained by fitting fraction RNA
bound versus protein concentration using the following
equation: fraction RNA bound=1/[1+(Kd/[protein]total)].
All measurements were performed with >10-fold excess
of protein over RNA so that [protein] would be approxi-
mately equal to [protein]total.
Inhibition assays using gel electrophoretic mobility
shift assay
The inhibition of the MBNL1–RNA complex was investi-
gated using the above procedure, but with addition of the
small molecule to the RNA–protein complex after 25min
of incubation. The reaction mixture was incubated for an
additional 10–15min at room temperature. The inhibition
assays were performed in the presence of 1 or 10% (v/v)
DMSO (depending on the solubility of ligand). The IC50
values were determined by fitting to the equation: B=!B
exp(#0.69[ligand]/IC50)+Binitial, where B is the radio-
activity (cpm) of the RNA, !B=Bfinal#Binitial, [ligand]
is the ligand concentration, IC50 is the concentration of
ligand, at which (F=0.5!B+Binitial). The apparent in-
hibition constant (Ki) was determined using the
equation: Ki=IC50$ (Kd/[protein]total), where Kd is the
dissociation constant of the MBNL1–RNA complex and
[protein] is at least 7-fold greater than the Kd.
Thermal denaturation studies
The melting temperatures of the duplexes were measured
on a Shimadzu UV-2501PC spectrophotometer equipped
with a temperature controller. The absorbance of each
RNA or DNA solution (10 mM duplex) with 20mM
MOPS (pH 7.0), 300mM NaCl and 10mM EDTA was
annealed and cooled to 0!C. The absorbance of each sam-
ple was monitored at 260 nm from 0!C to 90!C at a ramp
rate of 1!C/min. The melting temperature (Tm) of each
sample was determined from the maximum point of the
first derivative of the melting curve with Origin 7.0.
Isothermal titration calorimetry studies
Isothermal titration calorimetry (ITC) measurements were
performed at 25!C on a MicroCal VP-ITC calorimeter. A
typical experiment consisted of titrating 10 ml of a ligand
solution (500mM) from a 250ml syringe (stirred at 300 rpm)
into a sample cell containing 1.42ml of a RNA or DNA
solution (10–20 mM) with a total of 30 injections (1ml for
the first injection and 10 ml for the remaining injections).
The initial delay prior to the first injection was 60 s. The
duration of each injection was 24 s and the delay between
injections was 400 s. All experiments were performed in
triplicate. Data analysis was carried out with Origin 5.0
software (MicroCal). Binding parameters, such as the dis-
sociation constant (Kd), enthalpy change (!H) and entropy
change (!S), were determined by fitting the experimental
binding isotherms with appropriate models. The ligand
stock solution was 50mM in DMSO. The buffer solution
for ITC experiments was MOPS (20mM; pH 7.0),
NaCl (300mM) and 1% (v/v) DMSO to balance the
DMSO in the ligand solution.
Synthetic procedures
1H and 13C NMR spectra for structural characterization
were recorded on a Varian Unity Inova 500 spectrometer
(1H: 500MHz; 13C: 125MHz). Unless otherwise stated, all
NMR measurements were carried out in CDCl3 at room
temperature. Chemical shifts were reported as parts per
million (ppm) in scale using residual peaks of DMSO-d6
(1H: 2.50; 13C: 39.52) as internal standard. Coupling con-
stants (J) were reported in Hertz. Mass spectra were
obtained by the Mass Spectrometry Laboratory, School
of Chemical Sciences, University of Illinois.
All non-aqueous reactions were carried out under dry
N2 atmosphere with oven-dried (115
!C) glassware. Unless
otherwise stated, all solvents and reagents were of reagent
quality, purchased commercially and used without further
purification. The progress of reaction was monitored by
thin layer chromatography (TLC) performed on Merck
pre-coated silica gel 60F254 plates, and compounds were
visualized by UV and subsequently with a spray of 5%
(w/v) phosphomolybdic acid hydrate in ethanol with sub-
sequent heating. Flash chromatography was carried out
on columns of Macherey-Nagel MN Kieselgel 60M
(230–400mesh) silica gel or Sigma-Aldrich Brockmann I,
standard grade ("150mesh) alumina.
Ligand 2
A mixture of 163mg (0.830mmol) of 5-(4-aminobutyl)-
2,4,6-triaminopyrimidine (17), 334mg (0.996mmol) of
6-chloro-2-methoxy-9-phenoxyacridine and 0.17ml
(0.98mmol) of DIPEA in 6ml of DMF was heated to
90!C in an oil bath for 48 h. The reaction mixture was
cooled to room temperature and concentrated in vacuo.
The residue was purified by flash chromatography on alu-
mina using CH2Cl2 :MeOHmixture (9 : 1 gradient to 4 : 1) to
afford 279mg (0.638mmol, 77%) of ligand 2 as a yellow so-
lid. 1H NMR (DMSO-d6): d 8.36 (d, J=9.5Hz, ArH, 1H),
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7.87 (d, J=2Hz, ArH, 1H), 7.83 (d, J=9.5Hz, ArH,
1H), 7.60 (d, J=2Hz, ArH, 1H), 7.40 (dd, 2.5 and
9.5Hz, ArH, 1H), 7.32 (dd, 2 and 9Hz, ArH, 1H), 6.91
(t, J=5.5Hz, AcrNH, 1H), 5.40 (s, NH2, 4H), 5.11 (s,
NH2, 2H), 3.92 (s, OCH3, 3H), 3.73 (q, J=7Hz, NHCH2,
2H), 2.21 (t, J=7.5Hz, PymCH2, 2H), 2.78 (quin,
J=7.5Hz, CH2, 2H) and 1.37 (quin, J=8Hz, CH2,
2H). 13C NMR (DMSO-d6): d 162.0, 160.7, 155.0, 150.4,
148.2, 146.2, 133.4, 130.8, 127.2, 126.5, 124.2, 122.6, 116.9,
114.5, 100.6, 85.6, 55.7, 49.6, 30.4, 25.4 and 22.8. ESI-MS
(m/z): 438.2 ([M+H]+, 100%). ESI-HRMS (m/z): [M+H]+
calcd for C22H25N7OCl, 438.1809, found, 438.1814.
Ligand 3
A mixture of 72.3mg (0.369mmol) of 5-(4-aminobutyl)-
2,4,6-triaminopyrimidine, 145mg (0.442mmol) of 9-chloro-
N-[2-(dimethylamino)ethyl]-4-acridinecarboxamide (18) and
1.80 g (19.1mmol) of phenol was heated to 120!C in an oil
bath for 5 h. The reaction mixture was cooled to room
temperature and diluted with 150ml of 2M NaOH
solution. The suspension was stirred for 10min at 0!C.
The solid was filtered and purified by flash chromatog-
raphy on alumina using CH2Cl2 :MeOH mixture (9 : 1
gradient to 4 : 1), to afford 148mg (0.304mmol, 80%)
of ligand 3 as a yellow solid. 1H NMR (DMSO-d6):
d 12.46 (t, J=4.5Hz, CONH, 1H), 8.61 (dd, J=1 and
7Hz, ArH, 1H), 8.56 (d, J=8.5Hz, ArH, 1H), 8.43
(d, J=8.5Hz, ArH, 1H), 7.96 (d, J=9Hz, ArH, 1H),
7.76 (t, J=7.5Hz, ArH, 1H), 7.52 (s, AcrNH, 1H),
7.45–7.37 (m, ArH, 2H), 5.43 (s, NH2, 4H), 5.13 (s, NH2,
2H), 3.86 (t, J=6.5Hz, CONHCH2, 2H), 3.57 (q, J=
5.5Hz, AcrNHCH2, 2H), 2.55 (t, J=6Hz, PymCH2, 2H),
2.31 [s, N(CH3)2, 6H], 2.21 (quin, J=7.5Hz, 2H),
1.82 (quin, J=7Hz, CH2, 2H), 1.37 (quin, J=8Hz,
CH2, 2H).
13C NMR (DMSO-d6): d 165.2, 162.0, 160.7,
153.2, 147.7, 146.7, 133.8, 130.9, 128.5, 128.2, 127.3, 124.2,
122.5, 120.7, 115.6, 114.7, 85.5, 58.0, 49.8, 45.2, 37.2, 30.1,
25.3 and 22.8. ESI-MS (m/z): 488.3 ([M+H]+, 100%).
ESI-HRMS (m/z): [M+H]+ calcd for C26H34N9O,
488.2886, found, 488.2888. Anal. calcd for C26H37N9O3·
2H2O: C, 59.64, H, 7.12, N, 24.07. Found: C, 60.87, H,
6.85, N, 23.97.
RESULTS
Binding of ligand 1 to CCTG and CCUG sequences
Binding studies of ligand 1 were initially performed with a
DNA duplex containing a single (CCTG)2 step (Figure 3a).
Using ITC, it was found that ligand 1 binds strongly to
the CCTG duplex with a 3 : 1 stoichiometry and Kd(1)=
14 mM, Kd(2)=0.11mM and Kd(3)=37 mM. Job analysis
and circular dichroism titration studies support the 3 : 1
stoichiometry (see Supplementary Data). The binding to
RNA was examined using the 11-mer shown in Figure 3b.
In contrast to the results with the DNA oligonucleotide,
ligand 1 binds CCUG comparatively weakly; a single
Kd=79 mM was obtained. The CCUG repeat is capable
of forming a slipped structure containing U–U and C–C
mismatches separated by C–G base pairs as shown in
Figure 4 (19). For this reason, the binding of ligand 1 to
the slipped sequence was also investigated by ITC using
the 11-mer shown in Figure 3c. A 2 : 1 complex was ob-
served with low-micromolar Kd values: Kd(1)=3.5mM
and Kd(2)=7.0 mM (Figure 3c).
To determine whether ligand 1 can inhibit the MBNL1–
CCUG interaction, an electrophoretic mobility shift assay
Figure 3. ITC binding studies of ligand 1 using (a) a DNA sequence containing a CCTG repeat, (b) an RNA sequence containing a CCUG repeat
(RNA A) and (c) an RNA containing a slipped-CCUG motif (RNA B).
Figure 4. Two possible stem–loop structures for CCUG repeats with two consecutive C–U mismatches (left) or alternating C–C and U–U
mismatches in the slipped form (right).
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was performed using a (CCUG)6 RNA. The Kd values for
the complexes formed between (CCUG)6 and MBNL1
were determined in the absence and presence of 100 nM
of competitor tRNA to be 15±2nM and 30±4nM, re-
spectively (Figure 5). These values are in good agreement
with literature values (19). No significant inhibition of the
MBNL1–RNA interaction was observed with ligand 1 up
to a concentration of 250mM (see Supplementary Data).
Development of ligands 2 and 3
The high affinity of ligand 1 for U–U mismatches and
moderate affinity for C–C mismatches led us to explore
similar ligands that recognize C–U mismatches in CCUG
repeats. To this end, a structurally similar analog 2 was
synthesized and studied (Scheme 1). The ability of ligand 2
to bind CCUG and CCTG repeats was examined by ITC,
however, these studies were hampered by poor water solu-
bility. To achieve the high ligand concentration needed for
ITC studies, ligand 2 required more than 10% (v/v)
DMSO. With as little as 1% (v/v) DMSO, a 500 mM
solution of ligand 3 could be prepared in a 300mM
NaCl solution (MOPS buffer; pH 7), presumably because
it contains a water-solubilizing substituent. Because ex-
periments with ligand 2 were performed in the presence
of 10% DMSO, the melting temperature (Tm) of
(CCUG)6 was measured in the presence and absence of
10% DMSO. The stability of the RNA was found to be
identical within experimental error in the presence of 1–
10% DMSO. In addition, the Tm of (CCUG)6 was con-
centration independent suggesting the formation of a
hairpin not a duplex. The hydrolytic stability of
(CCUG)6 RNA in the presence of ligands 2 and 3 was
also evaluated. The (CCUG)6 RNA was incubated with
ligands 2 and 3 for at least 4 h at room temperature and
the RNA was evaluated by denaturing polyacrylamide gel
electrophoresis (see Supplementary Data). No cleavage of
the RNA was observed under these conditions. Therefore,
the RNA is stable to hydrolytic cleavage in all of the
binding and inhibition experiments reported herein.
Affinity and selectivity of ligand 3 for RNA
The affinity and selectivity of ligand 3 for binding to
CCUG RNA was evaluated by measuring the affinity
of ligand 3 for several oligonucleotides (Figure 6).
Scheme 1. Synthesis of ligands 2 and 3.
Figure 5. (a) Gel electrophoretic mobility shift assay of MBNL1 binding to (CCUG)6 RNA. (b) MBNL1 binding to (CCUG)6 in the presence of
100 nM tRNA. Control lane 1 (C1): RNA only. Control lane 2 (C2): RNA+MBNL1. (c) Plots of fractions of (CCUG)6 bound as a function of
MBNL1 concentration in the presence (green) and absence (blue) of 100 nM tRNA.
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The stabilities of these RNAs were evaluated by melt-
ing curves obtained by UV spectroscopy and are
reported in Table 1. The duplexes containing C–U
(RNA C), U–U (RNA D), C–C (RNA E), A–A (RNA
F) and G–G (RNA G) were designed to evaluate the
ability of ligand 3 to selectively recognize the mismatches
that are most likely found in the poly(CCUG) RNA
compared to related mismatched sequences. The binding
of ligand 3 to the DNA analog of the DM1 sequence
containing a T–T mismatch (DNA H) and the 18-nt
fragment of the human cTNT (hcTNT) pre-mRNA, a
natural target of MBNL1 (RNA I) was also evaluated. To
investigate the non-specific binding of ligand 3 to nucleic
acids in general, its affinity toward tRNA and herring
sperm DNA (hsDNA) was measured (Table 1).
ITC was used to measure the affinity of ligand 3 for the
duplexes (Table 1). For (CCUG)6 RNA, ligand 3 bound
with low micromolar affinity Kd(1)=5.2±0.6 mM and a
significantly weaker Kd(2)=478±85 mM. Ligand 3 binds
to RNA A, which contains a single CCUG site, i.e. two
proximal U–C mismatches (RNA A), similarly, exhibiting
a low micromolar affinity Kd(1)=3.6±0.8 mM and
Kd(2)=258±37 mM. The affinity for the slipped-
CCUG structure (RNA B) was significantly higher, with
first and second Kd values of 0.13±0.04mM and
10±5 mM, respectively. For comparison purposes, the
Kd values for the duplexes containing a single C–U
(RNA C, Kd=85±30 mM), U–U (RNA D, Kd=25±
13 mM) and C–C mismatches (RNA E, Kd=0.77±
0.28 mM) were measured.
Completing the picture, the binding of ligand 3was mea-
sured to duplexes F and G containing A–A and G–G
mismatches, respectively, and to DNA H with a CTG
site relevant in DM1 (20). The purine–purine mismatches
were bound weakly by ligand 3 (Kd> 100 mM) whereas the
CTG sequence (DNA H), was bound with a low micro-
molar affinity (Kd=1.4±1.5mM). Ligand 3 was found to
bind weakly (Kd=334±11 mM) to the 18-nt fragment of
hcTNT pre-mRNA (RNA I) and tRNA (Kd=2400±
2100 mM). Finally, ligand 3 bound herring sperm DNA
with Kd=36±7 mM.
Inhibition of the MBNL1–CCUG complex by
ligands 2 and 3
Despite the limited solubility of ligand 2 under the ITC
conditions, its ability to inhibit MBNL1 binding to RNA
could be determined because of the lower concentrations
required for gel electrophoretic mobility shift assays.
Table 1. Dissociation constants (Kd) and Tm values for all tested nucleic acids with ligand 3
a
Nucleic
acids
Specific target Tm (
!C)b Kd(1) Kd(2) Kd(3) Selectivityc
(CCUG)6 C–U pairs
d 61 5.2±0.6 478±85 – 1.4
A C–U pairs 53 3.6±0.8 258±37 – 1.0
B C–C and U–U 54 0.13±0.04 10±5 202±14 0.04
C Single C–U pair 62 85±30 231±55 – 24.0
D U–U 63 25±13 271±83 – 6.9
E C–C 62 0.77±0.28 162±8 – 0.2
F A–A 62 118±8 2270±360 – 33.0
G G–G 67 103±26 7690±280 – 29.0
H T–T 51 1.4±1.5 102±25 – 0.4
I – – 334±11 – – 93.0
tRNA – – 2400±2100 – – 670.0
hsDNA – – 36±7e – – 10.0
aKd values are reported in mM.
bConcentrations of duplexes are 10 mM; additional 1% (v/v) DMSO has negligible effect on the stability of the
duplexes (!Tm< 2!C). cSelectivity is the ratio of Kd(1) of the particular nucleic acid to that of RNA A. dm-fold predicts two 2" 2 nt internal loops.
eLigand 3 bound to about every 10 bp.
Figure 6. Nucleic acids studied in ITC experiments (tRNA and herring sperm DNA are not shown). The structures shown represent the most stable
structures predicted by m-fold. Note that RNA I is most likely single stranded under the conditions used to perform the binding or complex
inhibition experiments.
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Both ligands 2 and 3 were found to significantly destabil-
ize the MBNL1–CCUG complex. The IC50 of ligands 2
and 3 were determined by incubating varying concentra-
tions of the ligands with a constant concentration of
MBNL1–CCUG complex and evaluating the results
using gel shift assays. The Ki of these ligands was
determined using the equation Ki= IC50! (Kd/[pro-
tein]total), in which Kd is the dissociation constant of the
MBNL1–RNA complex and the concentration of
MBNL1 is in large excess of the Kd value. The comparison
of Ki values, rather than the IC50 values, under different
conditions is important in order to compare the effects of
the conditions on the behavior of the ligands independent-
ly of the effects of the varying conditions on the Kd of the
MBNL1–CCUG complex. Importantly, ligands 2 and 3
do not bind to MBNL1 as measured by ITC.
To evaluate the specificity of ligands 2 and 3 for CCUG
RNA, the inhibition experiments were performed in the
presence of competitor RNA sequences. For ligand 2, the
Ki value is increased only slightly to 3.4±0.9mM in the
presence of 100 nM tRNA (Figure 7a and c). Evaluation
of ligand 3 provided IC50 values of 52±8 mM and
35±3 mM in the absence and presence of 100 nM
tRNA, respectively, with a Ki of 2.2±0.3 mM and
2.8±0.3mM, respectively (Figure 7b and c). The selectiv-
ity of ligands 2 and 3 for the target sequences (CCUG)6
relative to (CUG)12 (i.e. DM2 versus DM1) and their
relative abilities to inhibit MBNL1 binding to the same
sequences were also evaluated. Ligand 2 inhibited binding
to (CCUG)6 and (CUG)12 with similar Ki values of 2.4 and
4.8mM, respectively, whereas ligand 3 exhibited a "7-fold
higher inhibition of the MBNL1–CCUG interaction
compared to the MBNL1–CUG interaction. The ability
of ligand 3 to destabilize complexes formed between
MBNL1 and cTNT (RNA I, Figure 6) was also evaluated.
cTNT is the 18-nt fragment (19) of the hcTNT pre-mRNA,
which is a natural target of MBNL1. Ligand 3 only
weakly inhibited the MBNL1–cTNT interaction. Table 2
summarizes the inhibition studies of ligands 2 and 3.
Finally, the ability of simple triaminopyrimidine
(ligands 4 and 5) and triaminotriazine (ligands 6 and 7)
recognition wedges to inhibit MBNL1 binding was ex-
amined (Figure 8). Consistent with our previous results
for DM1, wedges without tethered intercalators did not
destabilize the MBNL1–CCUG complexes (Figure 8).
DISCUSSION
The multisystemic clinical features of DM2 resemble those
of DM1, although patients with DM2 do not suffer from
the severe congenital form of disorder that occurs in DM1
(21). The prevalence of DM2 can be as high as in DM1
(1 in 8000) depending on the ethnicity of the population
(22). As noted in the introduction, the phenotype of
Figure 7. (a) Gel electrophoretic mobility shift assay of ligand 2 with (CCUG)6 RNA in the presence of 100 nM tRNA. Control lane 1 (C1): RNA
only. Control lane 2 (C2): RNA+MBNL1. (b) Gel electrophoretic mobility shift assay of ligand 3 with (CCUG)6 RNA in the presence of 100 nM
tRNA. Control lane 1 (C1): RNA only. Control lane 2 (C2): RNA+MBNL1. (c) Plots illustrating inhibition of MBNL1–(CCUG)6 complex with
ligand 2 (green) and 3 (blue).
Table 2. Summary of inhibition studies of various RNAs with ligands 2 and 3
RNAa tRNA (nM) Kd (nM) [MBNL1] (nM) 2 3
IC50 (mM) Ki (mM) IC50 (mM) Ki (mM)
(CCUG)6 – 15±2 350 59±5 2.5±0.2 52±8 2.2±0.3
100 30±4 350 40±11 3.4±0.9 35±3 3.0±0.3
(CUG)12 – 150±20 1000 37±11 5.5±1.4 118±40 18±5
cTNTb(I) – 1.0±0.2 15 101±26 6.7±1.6 >250 >17
aRNA concentrations were 0.1 nM.
b18-nt fragment of the cTNT pre-mRNA (RNA I in Figure 6).
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the disease can be reversed by inhibiting the interaction of
MBNL1 and CUG repeats (9,10). For example, Berglund
and coworkers (10) showed that pentamidine
(IC50=58 mM) was able to rescue the missplicing of the
IR and cTNT in HeLa cells. Based on these studies, it is
likely that small molecule ligands with similar IC50 values
that are selective inhibitors of the MBNL1–CCUG inter-
action will serve as good leads for development of a thera-
peutic agent to treat DM2. Therefore, small molecule
ligands structurally similar to ligand 1 (IC50=43 mM for
MBNL1–CUG) were explored.
In comparison to CUG repeats, targeting CCUG
repeats represents a particular challenge because neither
an NMR nor X-ray structure of RNA containing CCUG
repeats is available. The CCUG repeat structure is pre-
dicted by m-fold to be comprised of two C–G base pairs
and two C–U mismatches (23), although alternative struc-
tures cannot be ruled out (24). For example, Warf and
Berglund (19) have examined an alternative, slipped
CCUG structure containing alternating C–C and U–U
mismatches separated by C–G base steps (Figure 4).
Although a less stable form, it was found that MBNL1
bound this slipped structure with !1.5-fold higher affinity
than to the structure containing two C–U mismatches.
The triaminotriazine unit in ligand 1 was designed to
form a base triplet with a U–U mismatch. Whether the
designed complex forms is not known, but ligand 1 binds
r(CUG)4 and r(CUG)2 sequences with Kd=0.43mM and
Kd=2.1 mM, respectively, whereas the values for r(CAG)2
and r(CGG)2 sequences were Kd> 300 mM (12). Ligand 1
does bind with moderate affinity (Kd=14 mM) to
r(CCG)2 sequences, which contain a C–C mismatch.
The high affinity of ligand 1 for U–U mismatches and
moderate affinity for C–C mismatches led us to explore
the use of ligand 1 to recognize CCTG and CCUG.
Previously, it was found that ligand 1 bound the CTG
sequence with a 1:1 stoichiometry (12). In sequences con-
taining CTG repeats, there was a definite negative
cooperativity for adjacent sites. In contrast, ligand 1
appears by ITC fitting, CD titration studies and Job
analysis to bind the CCTG sequence in 1 : 3 stoichiometry.
Although care must be taken not to overinterpret the Kd
values obtained from ITC fitting, the tight binding re-
flected in the Kd(2) value may indicate a conformational
change with formation of a 1 : 1 complex. Thus, the posi-
tive cooperativity could result from the first ligand induc-
ing formation of two C-bulges and a central T–T
mismatch, the latter site providing the same tight binding
observed at CTG sites, whereas the C-bulge recognition
would be comparatively weaker (25). This C-bulge and
T–T mismatch structure, which is suggested to be a po-
tential drug target, is recently observed by NMR spectros-
copy for CCTG repeats (26).
The strong binding of ligand 1 for CCTG-containing
DNA did not translate into strong binding for an RNA
oligonucleotide containing a CCUG repeat (Ligand 1
binds CTG and CUG with similar affinity; see ref. 12).
Furthermore, no inhibition of MBNL1 binding to
(CCUG)6 was observed. Although the detailed structure
of the CCUG repeat is currently unknown, it has been
proposed to adopt an A-form helical conformation,
similar to that of the CUG repeat (6,27). At this time it
is not known why ligand 1 is unable to recognize strongly
the CCUG repeat. Nonetheless, the fact that ligand 1 is
capable of strong and selective CUG binding in RNA and
is able to inhibit binding of MBNL1 suggested that it
should be possible to discover and develop ligands exhibit-
ing similar behavior with CCUG sequences. This was the
impetus for exploring ligands 2 and 3.
To improve the ability of ligand 1 to bind to CCUG
RNA, structurally similar ligands such as 2 were pursued.
Ligand 2 is identical to 1, but with a triaminopyrimidine
moiety that forms a C-linked Janus-wedge. It was an
appealing recognition unit to explore because 5-(4-amino-
butyl)-2,4,6-triaminopyrimidine (17) was a known com-
pound, allowing 2 to be easily synthesized by the same
route as used for ligand 1. Unfortunately and somewhat
surprisingly, ligand 2 exhibited very limited water solubil-
ity compared to the structurally similar ligand 1. The
limited solubility of 2 prevented it from being studied by
Figure 8. (a) Chemical structures of wedge molecules. (b) Gel electrophoretic mobility shift assay showing that only p-stacked intercalators inhibit
the MBNL1–CCUG complex. Control lane 1 (C1): RNA only. Control lane 2 (C2): RNA+MBNL1. Control lane 3 (C3): RNA+MBNL1 with 10%
DMSO. Except when otherwise noted, all lanes contain 350 nM MBNL1, 100 mM ligands and 10% DMSO.
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ITC with <10% DMSO. Ligand 3 was prepared with a
more water-soluble intercalator, N-[2-(dimethylamino)
ethyl]acridine-4-carboxamide (DACA) in place of the
9-amino-6-chloro-2-methoxyacridine unit and this allowed
the triaminopyrimidine motif to be examined.
Ligand 3 bound to (CCUG)6 and RNA A with similar
affinity and stoichiometry. Specifically, both sequences fit
a binding model with a single, reasonably tight binding
site (3–5 mM) and a second, significantly weaker binding
site (250–480 mM). The tighter binding is presumably
associated with one of the two CCUG sites in (CCUG)6
and the single CCUG site in RNA A (Supplementary
Data). Potential weaker sites in (CCUG)6 include the re-
maining CCUG site, (CCUG)2 loop region and GC stem
regions. In fact, titration with RNA A, lacking the second
CCUG site and loop, give an ITC curve with better curva-
ture. This suggests the residual heat at the end of the ti-
tration for (CCUG)6 likely arises from a general, non-
specific binding of the weaker sites. Indeed, the affinity
is similar to that observed for ligand 3 binding to the
single-stranded hcTNT pre-mRNA (RNA I). Overall the
data are consistent with ligand 3 binding to only one of
the two C–U mismatches and a single CCUG site when
two sites are neighboring. The origin of this latter effect is
unclear.
Similar to the preference exhibited by MBNL1 (19),
ligand 3 binds with !40-fold higher affinity to the
slipped-CCUG structure (RNA B) than to the duplex con-
taining adjacent C–U mismatches (RNA A). These results
are in good agreement with the Kd values for the duplexes
containing the single U–U (RNA D) and C–C mismatches
(RNA E), suggesting that ligand 3 binds strongly to the
C–C mismatch in the slipped structure and to the U–U
with a reduced affinity.
Surprisingly, ligand 3 does not bind strongly
(Kd=85±30 mM) to RNA C, which contains a single
C–U step with two adjacent CG steps. Ligand 3 also
binds weakly (Kd> 100 mM) to the purine–purine
mismatches in duplexes F and G. The binding of ligand
3 to DNA containing a CTG sequence (DNA H), which is
one of the targets of DM1 (20), occurs with low
micromolar affinity (Kd=1.4±1.5 mM). The difference
in binding affinity of ligand 3 toward analogous RNA
and DNA duplexes (RNA D, U–U; Kd=25 mM) and
(DNA H, T–T; Kd=1.4mM) may result from structural
differences between B-form DNA and A-form RNA.
Importantly, ligand 3 not only binds CCUG, it inhibits
MBNL1 binding to CCUG with low micromolar Kd
values. Together with the ITC results, these data suggest
that ligand 3 is a good lead ligand for targeting either the
CCUG or CCUG-slipped repeat structures implicated as
the causative agent of DM2. Finding agents that complex
CCUG and inhibit MBNL1 binding is a challenge, but
finding agents that are highly selective is perhaps even
more difficult and likely more important given the diffi-
culty in developing highly selective agents targeted to
nucleic acids. The selectivity profile of ligand 3 has been
examined in several different contexts and can be found in
Tables 1 and 2. For example, it is notable that ligand 3
binds (CCUG)6 >600-fold tighter than it does tRNA.
Thus, even in the presence of tRNA, ligand 3 is capable
of disrupting the MBNL1–CCUG interaction with min-
imally diminished Ki values. It is also significant that
ligand 3 does not inhibit the interaction between
MBNL1 and its natural target, the 18-nt fragment of
hcTNT pre-mRNA (IC50> 250 mM).
Developing a systematic structure–activity relationship
is beyond the scope of the current study, but the data from
the gel electrophoretic mobility shift assays using simple
wedge recognition compounds 4–7 indicate that the
acridine unit is critically important. These results agree
with the previously proposed p-stacked intercalator
model wherein the acridine is responsible for affinity
whereas the selectivity is dictated by the nature of the
wedge motif. In this regard, it is intriguing that the
small structural difference between triaminotriazine and
triaminopyrimidine units leads to the preferential
binding to CUG for the former and to CCUG for the
latter. It is likely that the basicity difference between
triaminotriazine (pKa! 5) (28) and triaminopyrimidine
(pKa! 6.7) (29) plays an important role and this is an
aspect that merits additional study.
Finally, the broadest finding from the current study is
that ligands 2 and 3 exhibit among the highest docu-
mented selectivity for CCUG and, thus, represent an ex-
cellent starting point for the development more selective
and potent inhibitors of MBNL1 binding. Because of the
presence of multiple repeating units in the toxic RNAs
that cause DM1 and DM2, an obvious approach
involves oligomerization of these or analogous ligands
(11,14). This is an approach that has already proven ef-
fective. For example, Disney reported that the oligomer-
ization of a DNA dye (Hoechst 33258) and kanamycin A,
ligands that exhibit only moderate selectivity for the CUG
and CCUG sequence, respectively, result in oligomers of
better affinity and selectivity (11,14,15). The use of
intercalators presents an inherent limitation on selectivity
because an unstacked intercalator can non-selectively
complex a wide range of duplex DNAs and RNAs.
Developing new ligands where the recognition wedge
remains stacked or in close proximity to the intercalator,
or where the intercalator is replaced by a different unit
that provides affinity, may obviate this potential source
of poor selectivity. These and other approaches to
optimize this class of RNA binding agents are under
active investigation and will be reported in due course.
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Investigating the Binding Mode of an Inhibitor of the MBNL1·RNA Complex
in Myotonic Dystrophy Type 1 (DM1) Leads to the Unexpected Discovery of
a DNA-Selective Binder
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The development of small molecules that recognize
specific DNA and RNA sequences or structures re-
mains a critical challenge. If cell-permeable, such
agents might allow the regulation of genes for thera-
peutic purposes or the targeting of DNA or RNA sites
known to play some other roles in causing disease. A
few general approaches to the recognition of
double-helical DNA,[1] base mismatches,[2] G-quar-
tets,[3] and other targets[4] have emerged over the
past two decades. However, many difficulties remain.
For example, it is often difficult to obtain high selec-
tivity for DNA over RNA or vice versa.[5] We reported
that ligand 1 binds CUG and CTG sites with similar
high affinity and selectivity in RNA and DNA oligonu-
cleotides, respectively.[6] Herein we show that ligands
2 and 3, with one or two N-methyl groups, respec-
tively, selectively abolish RNA binding, with 3 giving
a more than threefold increase in DNA affinity that
could allow DNA-targeted gene therapy for myotonic
dystrophy type 1 (DM1).[7]
This work arose from the well-supported hypothe-
sis that DM1 originates in the sequestration of the al-
ternate splicing regulator protein, muscleblind-like 1
(MBNL1), by abnormally long CUG triplet repeats. It
has been suggested that ligands able to bind selec-
tively to these pathogenic triplet repeats might re-
verse the DM1 phenotype by inhibiting the
MBNL1·RNA complex, allowing the splicing regulator
to resume its normal function.[8] Much less attention
has focused on agents that might shorten or halt the
expansion of the CTG repeats found in the DMPK
gene but this DNA sequence has been identified as
a potential target for molecular therapy.[9] Thus, we
developed ligand 1,[6] which selectively binds CTG
and CUG sites and inhibits the MBNL1·CUG com-
plex.[10]
The design of ligand 1 was based on the X-ray crystal struc-
ture of r(CUG)6 determined by Berglund,
[11] which showed the
CUG repeat in a standard A-form helical structure with the U!
U mismatch flanked by G!C pairs. The triaminotriazine unit
was selected as a Janus wedge[12–14] to form a base triplet with
U!U (Figure 1A). Critical to the design was the assumption
that the two heterocycles would p-stack, reducing the nonspe-
cific intercalation (Figure 1B). Insertions from the minor and
Figure 1. A) Ligand 1 contains a triaminotriazine unit designed to selectively target T!T
and U!U mismatches. B) Proposed binding mode of ligand 1 to CUG (or CTG) repeats.
Figure 2. Three potential modes of binding: A) Minor groove triplet binding. B) Major
groove triplet binding. C) A stretched U!U wobble pair with a bridging water molecule.
D) Minor groove stretched wobble binding. R=CH3 (DNA) or H (RNA).
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major groove were considered, but the former was in line with
the intercalation preference of 9-aminoacridine.[15]
The data collected for ligand 1 was consistent with the bind-
ing model shown in Figures 1 and 2A. However, a de-twinned
CUG repeat structure with high-resolution hydration details[16]
led us to consider other possible binding modes. In particular,
there was concern that the minor groove base-triplet model
(Figure 2A) required the lengthening of the C1’!C1’ distance
of the U!U from 10.4 to 13.8 !. Although the RNA minor
groove is wide and shallow, 3.4 ! is a significant increase in
the C1’!C1’ distance (Figure 2A) and may signal a distortion in
the DNA or RNA backbone that is energetically unfavorable.[17]
This distance is even longer than that of a G!A purine-purine
Figure 3. A series of N-methylated versions (2–6) of ligand 1, and RNA and
DNA duplexes containing a r(CUG)2 and d(CTG)2 motifs, respectively, for
structure–activity relationship (SAR) studies.
Figure 4. Snapshots of minimized structures (Amber) from the 10 ns MD
simulations of A) the major groove triplet binding and B) the minor groove
stretched wobble binding (see also the Supporting Information).
Table 1. Dissociation constants [mm] of ligands 1–6 with r(CUG)2 and
d(CTG)2 containing U!U and T!T mismatches, respectively.
Ligand r(CUG)2 d(CTG)2 hsDNA
[b]
1 2.1"0.2 0.39"0.08 55"16
2 n.b.[a] 0.8"0.4 n.b.[a]
3 n.b.[a] 0.12"0.04 n.b.[a]
4 14"5 2.2"0.5 n.b.[a]
5 n.b.[a] 50"30 n.b.[a]
6 n.b.[a] n.b.[a] n.b.[a]
[a] n.b. : no measurable binding and a lower limit of Kd>200 mm is as-
signed. [b] Herring sperm DNA.
Figure 5. Analysis of the C1’!C1’ distance of 10 ns MD simulations of A) the
major groove triplet binding and B) the minor groove stretched wobble
binding. The average C1’!C1’ distance for all the base pairs is reported in
black, whereas C1’!C1’ distance of the U!U pair involved in the binding
with the triaminotriazine ring is reported in gray.
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pair (12.5 !).[18] In fact, repeated
attempts to model r(CUG)6·1
with the ligand in the minor
groove failed to yield a stable
complex.
Modeling showed that the
water molecule bridging the two
uracil bases in a stretched
wobble pair (Figure 2C) could
be replaced by the triazine unit
in the minor groove (Fig-
ure 2D).[19] This led to a smaller
structural reorganization of the
original pair (Figure 2D). Further,
modeling of a major groove
base triplet suggested a C1’!C1’
distance even closer to that in
the X-ray structure (Figure 2B).
In absence of direct structural in-
formation, an extended “methyl
scanning” approach[20] appeared
to be ideal to distinguish be-
tween models in Figure 2A
and 2D. Thus, N-methylated ana-
logues 2–6 were synthesized
and tested using isothermal ti-
tration calorimetry (ITC) with
both d(CTG)2 and r(CUG)2 (Figure 3). The ability to inhibit the
MBNL1·CUG interaction was examined by electrophoretic mo-
bility shift assays (EMSA). These methods were supplemented
with molecular dynamics (MD) simulations.
The methyl scanning method was possible because the
number of hydrogen bonds differ significantly in the base trip-
let (Figure 2Aand B) and the stretched wobble binding modes
(Figure 2D). In particular, the wobble binding mode has two,
possibly three, free N!H groups, whereas only a single N!
H group is free in the triplet binding modes.
The possibility of base-triplet recognition through the major
groove was also considered, because simple modeling indicat-
ed the C1’!C1’ distance to be minimally adjusted from 10.4 to
10.1 ! (Figure 2B). Indeed, an unconstrained 10 ns MD simula-
tion showed ligand 1 could fit satisfactorily in the major
groove (Figure 4A and Video S1). The MD simulation of the
minor groove stretched wobble binding was also performed
(Figure 4B and Video S2). Although fewer hydrogen bonds are
formed, the unconstrained simulation led to a stable structure.
The average C1’!C1’ distance of the U!U mismatch is moder-
ately lengthened by 0.4 ! (11.8 vs. 10.4 !, see Figure 5).
The d(CTG)2 recognition by 1–6 was measured by ITC and all
Kd values are collected in Table 1. Ligand 3 was found to bind
more than threefold stronger than ligand 1 (Kd=0.12 mm for 3
vs. 0.39 mm for 1), whereas ligands 2, 4, and 5 each bound
d(CTG)2 but progressively more weakly than 1.
[21] Ligand 6, car-
rying three methyl groups, showed no measurable binding to
d(CTG)2. Because of the limited aqueous solubility, we were
only able to assign a lower limit of Kd>200 mm. The combined
ITC and modeling results are consistent with Watson–Crick-
type recognition of the stretched wobble pair (Figure 2C). An
unconstrained 10 ns MD simulation further suggested the
weakly bound thymine could be flipped-out from the dsDNA
(Video S3 and Figure S3). In contrast to the results with
d(CTG)2, ligand 3 did not bind under similar conditions to
r(CUG)2 (Figure 6, Table 1) and, indeed, the single N-methyl
group in 2 was enough to eliminate ligand binding. The only
CUG-binding, N-methylated ligand was 4, and even its Kd was
seven times weaker than that of 1. All methylated ligands also
showed reduced affinity towards herring sperm DNA (hsDNA).
The ability of the recognition unit to stack on the intercalator
is enhanced by methylation which in turn reduced the nonspe-
cific intercalative binding to duplex DNA.[22]
Figure 6. ITC profiles for complexation of ligand 3 with duplex containing the A) T!T and B) U!U mismatches.
Figure 7. EMSA screening of ligands 1–6 showing only ligands 1 and 4
inhibit MBNL1·CUG interaction. [r(CUG)12]=0.2 nm, [MBNL1]=460 nm, [li-
gand]=100 mm, 10% DMSO (except lane 2), Tris·borate (pH 8.3). The struc-
ture of r(CUG)12 used in the assay is shown on the right.
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To assess the potential of these ligands for drug develop-
ment, their binding affinity to various DNA and RNA duplexes
was studied by ITC (Table S1). All methylated ligands showed
reduced affinity toward the duplexes, including hsDNA. The
ability to complex other mismatches was also measured. In
general, these ligands exhibited high selectivity (up to 1600-
fold) for DNA over RNA mismatches. The ligands were also
found to bind weakly to purine-purine mismatches. Interest-
ingly, all the methylated ligands bind quite strongly (Kd=0.13–
2.0 mm) to d(CCG)2, a trinucleotide repeat sequence associated
with Fragile XE syndrome[23] and chronic lymphocytic leuke-
mia,[24] thus suggesting a potential molecular therapeutic ap-
proach to these diseases that warrants additional study.
The ability of ligands 1–6 to inhibit MBNL1 binding to
r(CUG)12 was measured by EMSA, and the results paralleled the
ITC data. Thus, only ligands 1 and 4 showed inhibition
(Figure 7). Although nothing can be said about the groove
preference from these experiments, the MD simulations favor
major groove triplet formation (see above), and it is known
that loop and mismatch structures can enhance the accessibili-
ty of the major groove.[25]
The combined experimental and computational approach
described herein suggests that this class of ligands bind DNA
and RNA by significantly different modes. Thus, it is proposed
that ligands 1 and 4 recognize the U!U mismatch in RNA
through formation of a major groove base triplet (Figure 8A)
whereas ligands 1–5 bind the T!T mismatch in DNA through
the stretched wobble pair (Figure 8B). These binding modes
also explain the decreased binding to U!U by 4 (Kd=14 mm vs.
2.1 mm for 1) and to T!T by 5 (Kd=50 mm for 5 vs. 0.39 mm for
1). Thus, the C!NH(Me) bond rotation[26] leads to unfavorable
binding for one or more of the rotamers.[27]
In conclusion, we have used the methyl scanning method
combined with MD simulations to indirectly investigate the
possible binding modes by which ligands 1–5 recognize CUG
and CTG sites in RNA and DNA, respectively. Beyond informing
on the binding mode, the ability to substitute the amino
groups of ligand 1 suggests these as sites for further modifica-
tions that might enhance the selectivity and efficacy of these
lead compounds in treating DM1.
More significant was the unexpected discovery of DNA-se-
lective ligands for CTG. Whereas ligand 1 binds both CUG and
CTG with similar strength, ligand 3 showed a more than three-
fold increase in affinity to CTG
with negligible binding to RNA.
It was also found that these li-
gands showed reduced binding
toward DNA and RNA duplexes
(i.e. , without mismatches) upon
methylation, potentially opening
an avenue for a DNA-targeted
molecular therapy of DM1.[7]
Competitive binding to the cor-
responding CUG transcript
would be expected to reduce
the effectiveness of this ap-
proach and could also compli-
cate efforts to assess the DNA-targeted approach. More broad-
ly, this study increases our knowledge of how small molecules
can selectively recognize nucleic acids.
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Orthogonality in organic, polymer, and supramolecular
chemistry: from Merrifield to click chemistry
Chun-Ho Wong and Steven C. Zimmerman*
The concept of orthogonality has been applied to many areas of chemistry, ranging from wave
functions to chromatography. But it was Barany and Merrifield’s orthogonal protecting group strategy
that paved the way for solid phase peptide syntheses, other important classes of biomaterials such as
oligosaccharides and oligonucleotides, and ultimately to a term in widespread usage that is focused on
chemical reactivity and binding selectivity. The orthogonal protection strategy has been extended to the
development of orthogonal activation, and recently the click reaction, for streamlining organic
synthesis. The click reaction and its variants are considered orthogonal as the components react
together in high yield and in the presence of many other functional groups. Likewise, supramolecular
building blocks can also be orthogonal, thereby enabling programmed self-assembly, a superb strategy
to create complex architectures. Overall, orthogonal reactions and supramolecular interactions have
dramatically improved the syntheses, the preparation of functional materials, and the self-assembly of
nanoscale structures.
1. Introduction
As with many terms in chemistry, the term orthogonality, as
applied to protecting groups, began with a very precise definition
in a limited setting. Thus, in the context of his revolutionary
advance in peptide synthesis, Merrifield first reported the term
in 1977 as a protecting group removal strategy.1 It was a simple
but powerful concept that one of multiple protecting groups
could be removed in the presence of all others by using a
cleavage reaction with a different mechanism.
Since then the usage of the term orthogonality has
broadened dramatically. Indeed, the term is now used in
supramolecular chemistry for systems where two non-covalent
interactions occur with no crosstalk as well as in accelerated
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polymer and dendrimer syntheses. Recently, the widely-used,
copper-catalyzed alkyne!azide coupling (CuAAC) has been
described as a highly orthogonal reaction and in biological
contexts as a bioorthogonal conjugation method. Although the
click reaction by itself does not fit the classical Barany and
Merrifield’s definition of orthogonality (vide infra), its use in
this context is pervasive and the clearest indication that as a
chemical term orthogonality has achieved polysemic status.2
This feature article traces the history of orthogonal chemistry
and summarizes its current application in several areas of
chemistry with a focus on levels of orthogonal complexity.
2. Chemoselectivity
. . .‘‘The ability to discriminate among the reactive sites is
referred to as chemoselectivity.’’. . .
Trost (1983)3
Although orthogonality predates chemoselectivity, it is helpful to
discuss the latter term first. Chemoselectivity was coined by Trost
in 1983 to describe the ability of a chemical reagent to discrimi-
nate among reactive sites.3 For example, in compound 1 the
reaction with the sodium salt of dimethyl malonate in DMF
occurs exclusively with displacement of the bromide to give 2
(Fig. 1).3,4 But in the presence of tetrakis(triphenylphosphine)-
palladium(0), the allylic acetate is activated and undergoes displace-
ment to 3with no formation of 2. The high chemoselectivity of these
two reactions originates from their quite different mechanisms.
Chemoselectivity may also be achieved with a single mecha-
nism and two structurally similar sites, provided that there is
precise control of the reaction conditions. An example would be
two acetal groups that cleave in acid, but have graduated
reactivity; so increasing acidity entirely removes one and then
the other. This strategy commonly employed in protecting
group chemistry is referred to as themodulated lability approach
(Fig. 2a).5 This approach takes advantage of the reactivity
difference of functional groups A and B toward a mild and
more forcing reagent in the same type of reaction. Indeed, the
early peptide synthesis developed by Merrifield used the
1000 : 1 reactivity difference of the t-butyloxycarbonyl (Boc)
and benzyl groups toward TFA to allow differential deprotection
of the growing peptide at the amino terminus and without
deprotecting the peptide side chains.6 The use of a stronger
acid (e.g., HF) removes both groups and cleaves the peptide
from the resin. In this and the previous example, it is not
possible to reverse the order of the deprotection steps. Thus,
the sequence of the reaction is controlled by the different
reactivity of the two functional groups.
3. Orthogonal protecting group chemistry
. . .‘‘An orthogonal system is defined as a set of comple-
tely independent classes of protecting groups. In a system
of this kind, each class of groups can be removed in any
order and in the presence of all other classes.’’. . .
Barany and Merrifield (1977)1b
3.1 Orthogonality vs. chemoselectivity
The orthogonal reactions developed by Barany and Merrifield
involve two protecting group removal steps that occur with high
chemoselectivity (Fig. 2b). In practice, each of the deprotection
reactions occurs by a different mechanism designed so that each
is able to effect removal of one protecting group exclusively.
Thus, each reaction is chemoselective so each may occur in any
order. As shown in Fig. 2b, the use of either sequence affords the
same product. Orthogonality can be considered as a subset of
chemoselectivity. However, the terms ‘‘orthogonal’’ and ‘‘chemo-
selective’’ are often used interchangeably in the literature. In
addition, terms such as partial or quasi-orthogonal are occa-
sionally seen, sometimes referring to partial chemoselectivity.
3.2 Increasing complexity: multiple dimensions
The discovery of the 9-fluorenylmethoxycarbonyl (Fmoc) group
by Carpino meant that for the first time an amino protecting
group could be removed under mildly basic conditions.7
Because the conditions are orthogonal to the acidic t-Bu
removal and high yielding, the Fmoc!t-Bu strategy (orthogonality-
based; Fig. 3) has largely replaced Merrifield’s classic peptide
Fig. 1 Synthetic scheme showing chemoselective reaction of compound 1 at
either the bromide or allylic acetate sites.3,4
Fig. 2 Three examples of chemoselective transformation of two functional
groups: (a) modulated lability approach, (b) sequential orthogonal transforma-
tions and (c) simultaneous transformations. Functional groups A and B can be on
two separate molecules.
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synthesis using the Boc!benzyl strategy (modulated lability-
based). The Fmoc and t-Bu groups represent an excellent pair of
orthogonal protecting groups.
The number of ‘‘dimensions’’ of an orthogonal system can
be increased. For example, in his Nobel Lecture, Merrifield
described a pentapeptide containing three orthogonal protect-
ing groups (Fig. 4).6 The peptide is linked to the resin by an
o-nitrobenzyl (ONb) group and protected by two additional
functional groups (t-Bu and Dts) that can each be cleaved
without affecting the other.
Another way in which the complexity of a set of orthogonal
reactions can be increased is by conducting their operation
simultaneously in a single flask (Fig. 2c). This scenario repre-
sents a more stringent example of chemical orthogonality
because beyond the reagents being selective for their respective
functionality they must not affect one another.8 This type of
transformation, illustrated in Fig. 2c, can offer higher effi-
ciency, with reduced time and waste; allowing us to envision
a multistep synthesis where all the reagents are added at once.
The simultaneous, multi-functionalization of macromolecules
and the dual labeling of cellular targets for imaging are already
possible and will be discussed below (vide infra).
Higher dimensional orthogonal systems are possible. Indeed,
some synthetic targets benefit from multiple orthogonal pro-
tecting group strategies. For example, the challenges in oligo-
saccharide synthesis are significant because the many hydroxyl
groups have similar reactivity. A wider range of orthogonal
protecting groups is now available and this enabled Wong and
co-workers to report the synthesis of a library of oligosacchar-
ides containing 38 416 members.9a The four dimensional sys-
tem consisted of chloroacetyl, p-methoxybenzyl, levulinyl, and
t-butyldiphenylsilyl protecting groups that were selectively
deprotected using four different mechanisms: basic hydrolysis,
acidic hydrolysis, hydrazinolysis, and fluoride-based deprotec-
tion, respectively (Fig. 5).9a Later, this orthogonal strategy was
combined with a one-pot sequential strategy for the prepara-
tion of branched oligosaccharides.9b
Boons and co-workers reported another set of orthogonal
protecting groups for oligosaccharides that are chemoselec-
tively removed using DDQ oxidation, Pd-catalysis, hydrazino-
lysis, and fluoride-based desilylation.10 It was also found that
the selected protecting group pattern on the mannose rings is
important for obtaining high yields and selective b-mannosylation.
Reviews on protecting group strategies and the influence on
stereoselectivity in oligosaccharide synthesis are available.11
3.3 Chromatic orthogonality
. . .‘‘Orthogonality is defined as the possibility of making
one functional group react selectively in the presence of
others under specific conditions. . .a differentiation
based on the color of a light beam could be named
chromatic orthogonality.’’. . .
Bochet (2004)12
A powerful approach to spatiotemporal orthogonal deprotec-
tion avoids reagent-based reactions, using photolytic cleavage
reactions instead to achieve the desired chemoselectivity.
Deprotection can be performed using a wide variety of photo-
labile groups (e.g., o-nitrobenzyl, p-hydroxyphenacyl, benzo-
phenone)13 in the presence of other reagent-based protecting
groups. In general, photolabile groups form an orthogonal
system with a wide range of chemical-based protecting groups
Fig. 3 A general representation of an Fmoc!t-Bu strategy (orthogonality-
based) for peptide synthesis.
Fig. 4 Three orthogonal protecting groups removed independently by acid
(t-Bu), reductive cleavage (Dts), and light (ONb).6
Fig. 5 An orthogonal set of four protecting groups used for the synthesis of a
library of oligosaccharides.9a
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(e.g., silyl and allyl groups) because light can be absorbed with
considerable selectivity. Indeed, many functional groups do not
absorb light from common laboratory light sources and many
that do are not photoreactive. It is further possible to create a
set of photolabile groups that each react with light of a different
wavelength ! a type of orthogonality referred to as chromatic
orthogonality.12,14 For example, the 30,5 0-dimethoxybenzoin
and 2-nitroveratryl esters shown in Fig. 6a are photo-
deprotected at 254 and 420 nm, respectively. The approach
was later refined with a pair of o-nitrobenzyl-based photolabile
groups that can be photo-deprotected orthogonally by fine-
tuning using both substituent- and isotopic effects on quantum
yields (Fig. 6b).15
The use of orthogonal protecting group strategies is now
commonplace in the synthesis of a range of complex molecules.
These include natural products and biomolecules such as oligo-
saccharides, glycoproteins, and nucleic acids. The high level of
dimensionality is most evident in Kocien´ski’s classification of a
large number of protecting groups into 13 orthogonal sets;
members of each set are removable by a unique mechanism.16
4. Orthogonal coupling reactions
Avoiding protection!deprotection steps can dramatically
streamline the construction of complex molecules.17,18 The
potential of this approach was made particularly apparent in
Baran’s seminal report of a protecting-group-free synthesis of
hapalindole Q in 2004.19 The use of orthogonal coupling
reactions is one powerful strategy for avoiding protecting
groups. As with orthogonal protecting groups, this approach
is not limited to a pair of reactions, rather multiple reactions
can be orthogonal and performed in any order.
4.1 Orthogonal glycosylation
. . .‘‘We investigated the possibility of using two sets of
chemically distinct (orthogonal) glycosyl donors and acti-
vation conditions. . . The chosen set of reactions is there-
fore shown to be orthogonal.’’. . .
Ogawa et al. (1994)20
To our knowledge, the earliest example of an orthogonal
coupling strategy is the orthogonal glycosylation reported by
Ogawa and co-workers in 1994 (Fig. 7).20 In this approach, two
distinct anomeric groups (phenylthio and fluoride) can be
orthogonally activated without affecting one another. This
approach has also been adopted in solid phase oligosaccharide
syntheses21,22 and in the production of a combinatorial library
of oligosaccharides.23
4.2 Orthogonal dendrimer syntheses
. . .‘‘It was anticipated that both pairs of functional
groups and their resulting coupling products would be
inert to the conditions of the other coupling reaction,
orthogonality that would allow 4 and 5 to be employed
consecutively in either order.’’. . .
Zeng and Zimmerman (1996)24
The second reported example of an orthogonal coupling
approach to prepare a complex molecule came in the context of
polymer synthesis. Our group disclosed the first orthogonal
dendrimer synthesis featuring two AB2-type monomers (i.e.,
AB2 and CD2) that couple in a convergent approach utilizing
alternating Mitsunobu esterification and Sonogashira coupling
steps.24 Because these two reactions are orthogonal, deprotec-
tion or activation steps could be avoided for the first time
(Fig. 8). Thus, each coupling reaction added one layer to the
dendrimer. The approach was extended with the use of AB4 and
CD4 monomers (Fre´chet’s branched-monomer approach),
25 so
that each orthogonal coupling reaction adds two layers to
the dendrimer (Fig. 9). This remains the fastest dendrimer
synthesis to date in terms of number of steps from the
monomer units. Indeed, the MW of 4 and 5 are just 592 and
416, respectively, but they combine in three synthetic steps to
produce a sixth generation dendrimers with a MW = 20896. This
is a rate of growth (MW per step) not even observed in nature.
By using the Mitsunobu esterification and Sonogashira
coupling reactions, the layers of the dendrimer alternate.
Similarly, Majoral and co-workers reported an orthogonal
dendrimer synthesis in a divergent approach using alternating
hydrazone formation and Staudinger reaction.26 To produce a
homogeneous dendrimer, where the layers are chemically identical,
Yu and co-workers combined the Horner!Wadsworth!Emmons
and Heck reactions as two orthogonal coupling reactions so
that the linkages prepared are all vinylene-type.27
Although the orthogonality aspect of click reactions will be
discussed in Section 4.5, it should be noted here that click
Fig. 6 Examples of photolabile groups for wavelength-selective deprotections.14b,15
Fig. 7 Orthogonal glycosylation developed by Ogawa and co-workers.20
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chemistry is emerging as an efficient method to construct
dendritic structures.28 Hawker et al. reported several
approaches involving the use of CuAAC29 and thiol!ene reac-
tions30,31 coupled to ‘‘non-click’’ reactions to construct dendri-
tic structures. They also reported the use of two orthogonal
click reactions (CuAAC and thiol!ene reactions) to accelerate
the dendrimer synthesis such that a G6 dendrimer can be
prepared in a single day (Fig. 10).32 Recently, Monteiro demon-
strated the use of two orthogonal click reactions ! CuAAC and
nitroxide radical coupling (NRC) ! to prepare dendrimers in
either convergent or divergent approaches.33 Under appropriate
conditions, it is possible to synthesize G3 dendrimers with a
variety of building blocks in a one-pot setting. Other orthogonal
click syntheses of dendrimers are also reported.34,35
4.3 Chemical ligation of peptides
Although peptides containing up to 100 amino acids are now
synthesized routinely, larger peptides and proteins (i.e., >150
amino acids) cannot be readily prepared in high yield and
purity because the peptide coupling efficiency decreases with
sequence length. Chemical ligation provides a convenient
method to link two peptide segments covalently.36,37 In parti-
cular, the native chemical ligation has been widely adopted
because it produces a natural peptide bond (Fig. 11).38 The
method uses a Cys!thioester ligation with an entropically
favored intramolecular transacylation. At pH 7!8, the thioester
is reactive toward thiols, not hydroxyl nucleophiles. Internal
cysteine residues can reversibly react with the thioester but this
reaction is unproductive. As a result, the C-terminal thioester
Fig. 8 Orthogonal synthesis of a G4 dendron using alternating Mitsunobu and
Sonogashira couplings.24
Fig. 9 Rapid synthesis of a G6 dendron using a combination of orthogonal coupling strategy and branched-monomer approach.24
Fig. 10 Accelerated divergent synthesis of a G6 dendrimer using two ortho-
gonal click reactions.32
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will permanently connect only to the N-terminal cysteine,
forming a native peptide linkage. The reaction therefore is
highly chemoselective. As with other highly chemoselective
reactions (see click reactions; Section 4.5), the chemical ligation
of peptides has been termed orthogonal ligation.36
4.4 Orthogonal catalysis
The concept of orthogonal reactivity can also be applied to
catalysis and catalytic cycles. For example, Buchwald and
co-workers developed Pd- and Cu-based catalysts that effect
chemoselective C- or N-arylation reactions, respectively (Fig. 12).39
Likewise, switching metal catalysts from Pd- to Cu-based
allowed the selective N- and O-arylation, respectively, of various
aminophenols.40 The site of arylation of aminoalcohols can
also be controlled by the choice of ligands with high selectiv-
ities from 15 : 1 to >50 : 1.41 In each of these systems the two
chemoselective transformations are expected to be orthogonal
even if orthogonality was not demonstrated experimentally.
In orthogonal catalysis there are also different levels of
complexity from the sequential catalytic transformations just
described to systems where two or more catalytic cycles operate
simultaneously. The latter arguably represents the most
demanding of all orthogonal systems because each entire
catalytic cycle must be fully orthogonal. Thus, the substrate
and product and each reactive intermediate and catalytic
species must be compatible unless the kinetics of the cycles
are vastly different in which case a few of the species may not be
present at the same time. Chung and co-workers reported a
three-step, one-pot synthesis of fenestranes using Co nano-
particles and Pd(II) catalysts in which the two catalysts operate
simultaneously (Fig. 13).42 The first step is carried out prior to
the addition of the palladium catalyst. Nonetheless, this is an
example of one-pot, orthogonal catalysis made possible by the
mutual independence of the Pd(II) catalyst for the allylic
alkylation in the second step and the Co catalyst for the last
Pauson!Khand reaction. Fogg and dos Santos have termed
such processes orthogonal tandem catalysis.43 Similarly, Hidai,
Uemura and co-workers reported the use of ruthenium and
platinum as orthogonal tandem catalysts to synthesize a series
of substituted furans.44 Another impressive example is the
synthesis of branched polyethylenes using three catalysts that
operate simultaneously in a one-pot procedure (Fig. 14).45
Polyethylenes of different properties can be prepared simply
by varying the mole ratios of the catalysts.
4.5 Click reactions, orthogonal click reactions, and
bioorthogonality
The objective of this section is not to provide a comprehensive
review of click chemistry but to focus on its relationship to
orthogonality. In discussing click reactions generally, Sharpless
noted that ‘‘although click reaction components are necessarily
highly reactive, their chemoselectivity profiles are quite narrowly
defined, that is, the reactions are ‘‘orthogonal’’ to an unusually
broad range of reagents, solvents, and other functional groups’’.46
Thus, he correctly noted the implicit orthogonality of click
reactions as originating in the high reactivity of the coupling
components with one another but broad tolerance of other
reagents and functional groups. The prototypical click reaction,
the copper-catalyzed alkyne!azide cycloaddition (CuAAC),
illustrates these ideas well. It is a highly chemoselective reac-
tion that proceeds in high yield under mild conditions46 yet the
azide and alkyne groups are relatively unreactive.
Fig. 11 Cys!thioester ligation as an example of orthogonal ligation.38
Fig. 12 Orthogonal Pd- and Cu-based couplings of oxindoles via C- and
N-arylation, respectively.39
Fig. 13 One-pot three-step orthogonal tandem catalysis in the synthesis of
fenestranes by Co nanoparticles and allyl palladium chloride.42
Fig. 14 Orthogonal-tandem catalysis for the preparation of branched polyethylenes
in the presence of three catalysts.45
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The low reactivity profile of organic azides47,48 and terminal
alkyne groups is illustrated in Fig. 15a and b, respectively. Thus,
Lin and Walsh prepared a series of glycopeptide antibiotics by
the chemoselective click reaction of various azido sugars with
an alkyne-containing cyclic peptide (Tyc3PG; Fig. 15a).49 The
azide group is carried through several steps prior to reaction
with the alkyne group. Analogously, Gin reported the synthesis
of a cyclodextrin analog by double click reaction of a trisaccharide
carrying both click partners.50 In this example, the terminal
alkyne is carried through six steps prior to the cyclization
reaction (Fig. 15b).
4.5.1 Orthogonal functionalization of polymers using click
chemistry. The orthogonality of the click reaction is well illu-
strated in the post-functionalization of polymers. Indeed, click
methodology has the ability to create new polymers by introdu-
cing functionality at polymer chain ends or along the back-
bone.51 Preparation of alkyne- or azide-containing polymers and
their subsequent click modifications will not be covered here;
readers are directed to several recent reviews.52 This section
focuses on orthogonal, simultaneous, one-pot post-polymeriza-
tion modifications of polymers using click reactions. This
approach minimizes the number of synthetic steps and reduces
the number of work-up and purification operations.53,54
Hawker reported the one-pot, simultaneous and cascade func-
tionalization of polymers.55 Both strategies combined CuAAC and
an esterification reaction as a highly orthogonal pair. For example,
a simultaneous functionalization was performed on a water-
soluble polymer containing acetylene- and hydroxyl-moieties for
CuAAC and esterification, respectively (Fig. 16).55 NMR and IR
analysis of the product polymer indicated >95% conversion for
both reactions. The cascade-type functionalization occurs when a
side-chain modification adds new functionality that can undergo
a further transformation. The authors described the reaction of a
polymer carrying active ester groups with propargylamine and an
organic azide under CuAAC conditions. The amide formation
reaction and alkyne click can occur in any order to furnish the
cascade-functionalized polymer.
Lyon described a related approach to the formation of multi-
responsive gels.56 Thus, EDC-based amidation and the CuAAC
reaction were the orthogonal reactions used to link fluorescein
and rhodamine dyes simultaneously to methacrylate-based
microgels. Both FT-IR and epifluorescence microscopy demon-
strated the synthesis of the desired materials.
Yang and Weck reported the one-pot, simultaneous polymer
modification using two orthogonal click reactions ! CuAAC
and hydrazone formation.57 The polymer modification is highly
modular with a wide range of substrates including those with
biological interest (Fig. 17). Quantitative functionalization was
observed by NMR and IR analysis.
Tunca and co-workers reported an analogous process using
the CuAAC and Diels!Alder reaction.58 In this report, two end-
functionalized polymers (maleimide!PMMA and acetylene!
PEG) were attached to polystyrene polymers containing anthra-
cene and azide moieties with >90% grafting efficiency based on
NMR analysis. In an approach that has been reviewed recently, the
combination of Diels!Alder and CuAAC has been used to prepare
Fig. 15 Two examples illustrating the orthogonality profiles of alkynes and
azides under a wide range of conditions.49,50
Fig. 16 Simultaneous functionalization of a water-soluble terpolymer through
CuAAC and activated ester-based functionalizations.55
Fig. 17 One-pot dual post-polymerization functionalization using two click
reactions (CuAAC and hydrazone formation).57
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polymers of different architectures, including star polymers, cyclic
polymers, and dendrimers.59 The one-pot, cascade functionaliza-
tion of polystyrene using a combination of CuAAC and Diels!
Alder reactions was also reported by Yagci and co-workers.60
A final example of polymer-based click chemistry comes from
Tunca who reported a combination of three orthogonal reactions
(CuAAC, Diels!Alder, and NRC) in a one-pot preparation of
linear tetrablock copolymers (Fig. 18).61 The isolated yields of
the polymers were 50!55%, with GPC and NMR analysis show-
ing the Mn values of the isolated polymers to be in good
agreement with the sum of the Mn of the reactant polymers.
4.5.2 Click chemistry beyond CuAAC. As seen above,
CuAAC is a powerful reaction with a wide range of applications.
The high chemoselectivity of the CuAAC allows it to form a
highly orthogonal reaction pair with many other reactions.
Indeed, there are only a few reactions reported not to be fully
compatible with CuAAC and these often involve the instability
of organic azides toward heat, light, or phosphine.62 It has been
reported that the copper catalyst may be partially poisoned by
nucleophilic thiol species63 and that it is not fully compatible
with oxime formation.64 Residual copper can also be proble-
matic in certain applications.65
The radical-mediated addition of thiols to terminal alkene
groups, called the ‘‘thio-click’’ by Schlaad in 2007,66 has
emerged as a useful complement or alternative to the CuAAC
reaction. Radical ‘‘thio-click’’ reactions can be initiated ther-
mally and photochemically where the latter has a higher
efficiency.67 The utility of the thiol!ene, thiol!yne, and
thiol!Michael addition reactions is evident in their widespread
applications, including in polymer and materials synthesis and
as a tool in chemical biology studies.59,68,69 Nitroxide radical
coupling is also considered a click-like reaction.59,70 As noted
previously, CuAAC and NRC form an orthogonal reaction pair
allowing the preparation a variety of polymeric G3 dendrimers
with Mn > 20 000 in a one-pot fashion.
33
4.5.3 Orthogonal dynamic combinatorial libraries using
click-type chemistry.
. . .‘‘The resulting double-level dynamic libraries are there-
fore named orthogonal. . .the two processes, in principle, do
not interfere, and analogously to the orthogonal protecting
groups in organic chemistry’’. . .
Lehn et al. (2001)71
Together with the CuAAC reaction, certain imine-forming con-
densations46 have been classified by Sharpless as fulfilling the
criteria of a click reaction. Similar to the CuAAC process, these
condensation reactions can be orthogonal to a range of other
reactions, but a key difference is that imine formation is reversible
under some conditions. With this orthogonal and reversible
nature, Eliseev and Lehn reported the first double-level, dynamic
combinatorial library (DCL) based on the orthogonality of two
reversible processes: imine formation and metal!ligand
exchange.71 Other pairs of orthogonal exchange reactions have
been reported, for example hydrazone formation!disulfide
exchange72 and imine formation!nitrone formation.73 The
complexity of DCLs has also been raised to a triple-level with
the use of three orthogonal exchange processes. Thus, Otto and
Nitschke reported a DCL with imine, disulfide, and metal!ligand
exchanges.74 Furlan and co-workers reported a DCL with hydra-
zone, disulfide, and thioester exchanges.75 For more details,
readers are directed to several recent reviews.76
4.5.4 Bioorthogonal ligation using click chemistry.
. . .‘‘Selective chemical reactions that are orthogonal to the
diverse functionality of biological systems are now recog-
nized as important tools in chemical biology. . .these
bioorthogonal reactions have inspired new strategies’’. . .
Bertozzi et al. (2004)77
The past decade has seen an increasing focus on developing
highly chemoselective reactions in biological settings. These
click reactions were termed bioorthogonal and have proven
useful new tools for studying biological processes by function-
alizing biomolecules selectively.78 Beyond working in aqueous
medium, bioorthogonal reactions may need to occur on or
within living cells and ultimately in organisms.79 One example
is the modified Staudinger reaction reported by Saxon and
Bertozzi in 2000,80 which involves the selective functionaliza-
tion of cell surface glycoproteins (Fig. 19). Thus, Jurkat cells
were incubated with N-azido-acetylmannosamine so that they
displayed azido groups on their surface. The Staudinger!
Bertozzi ligation, as it is now known,81 shows no cross-reactivity
between the phosphine and cellular disulfide bonds. Although
the Staudinger!Bertozzi ligation is relatively slow (kobs E
10!3 M!1 s!1),82 the reaction has shown to be applicable in
bacterial cultures83 and in mice.84
The CuAAC reaction was also applied to cellular bio-
labeling.85 The issue of copper cytotoxicity can be circumvented
by using polytriazole ligands86 to accelerate the reaction and
protect the cells from reactive oxygen species (ROS) generated by
the Cu-catalyzed reduction of oxygen. Nonetheless, considerable
Fig. 18 One-pot tetrablock copolymer synthesis using CuAAC, Diels!Alder, and nitroxide radical coupling reactions.61
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cell death would be expected when the copper concentration is
above the maximum tolerated level of ca. 500 mM.78c
To overcome the toxicity of copper ions, Bertozzi and co-
workers developed a number of cyclooctynes for the copper-
free, strain-promoted alkyne!azide cycloaddition (SPAAC).78
The triple bond in the cyclooctyne (OCT) ring is more reactive
(strain-promoted) than common terminal alkyne groups and
allows the cycloaddition to occur under physiological condi-
tions without the presence of copper catalyst. Boon’s dibenzo-
cyclooctynes (DBCO) were also found to undergo SPAAC and
were applied successfully to live cell labeling.87 The rates of the
first generation cyclooctyne derivatives were found to be com-
parable to that of Staudinger ligation, and about 70!80-fold
slower than the standard CuAAC reaction.78,79
Computational studies88 provided insights into the origin of
the rate enhancement (e.g., electronic vs. strain effects) for a
range of click partners (Fig. 20).89 With a difluoro substituted
cyclooctyne moiety (DIFO), the rate of SPAAC is found to be
comparable to CuAAC under pseudo-first-order conditions.90
Similarly, the DBCO systems reported by Boons and Popik were
found to have similar reaction rates.91 Apparent drawbacks of
these systems are their lengthy syntheses and hydrophobicity.
The latter can limit aqueous solubility and lead to membrane
or serum proteins localization. Sletten and Bertozzi reported
the dimethoxyazacyclooctyne (DIMAC) system as having an
improved log S value (!2.7 vs. !3.1 for OCT) and hence
showing higher water-solubility.92 DIMAC also showed much
less non-specific background labeling compared to its parent
compounds. The system does require a 9-step sequence from a
known pyranoside (overall yield B6%) and the rate is compar-
able to that of cyclooctyne.92
The tetrazine-based inverse-electron-demand cycloaddition
is receiving considerable attention as a new member in the bio-
orthogonal reaction toolbox because of its faster reaction rate
(see Fig. 20).93 Schultz and Lemke showed the incorporation of
trans-cyclooctene (TCO) containing lysine into proteins and the
subsequent Diels!Alder reaction with fluorogenic tetrazine-
functionalized dyes in living cells.94 The strain-promoted
inverse-electron-demand Diels!Alder cycloaddition (SPIEDAC)
occurs with a rate constant as high as 35 000 M!1 s!1. An even
higher rate constant (380 000 M!1 s!1) was recently reported in
a study on in vitro DNA labeling using (E)-bicyclo[6.1.0]non-4-
ene95 derivatives.96 In general, tetrazine cycloadditions with
cyclooctynes94 and norbornenes97 also proceed more rapidly
compared to the same reaction with organic azides.98
The broad range of rate constants in Fig. 20 (note logarith-
mic scale) suggests that some of the bioorthogonal reactions
can be used simultaneously without cross talk. Indeed, Ja¨schke
recently reported a one-pot, in vitro dual labeling of DNA using
CuAAC and tetrazine-based cycloaddition as an orthogonal
reaction pair.96 Also very recently, Hilderbrand reported the
use of two copper-free cycloadditions (DBCO!azide and
TCO!tetrazine) as an orthogonal reaction pair for selective
multi-target imaging of cancer cells (Fig. 21).99
The development of ‘‘photo-click’’ chemistry offers spatio-
temporal control over the reaction initiation.78b Thus, Lin
and co-workers developed the photo-initiated high efficiency
bioconjugation of proteins using 2,5-diaryltetrazoles.100
Fig. 19 Bioorthogonal Staudinger!Bertozzi ligation.80
Fig. 20 Comparison of range of rate constants of bioorthogonal reactions.
Numbers in parentheses are the largest rate constants reported in the series.
Rate constants depend on the actual conditions and substituents on the
substrates; the ranges are served as ballpark comparison only. Structures repre-
sented the best in the series. Adapted with permission from ref. 89.
Fig. 21 Two orthogonal click cyclization reactions can be used simultaneously in
a biological setting.99
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The diaryltetrazole undergoes nitrogen extrusion to form a
nitrile!imine dipole that undergoes a [3 + 2]-cycloaddition
with alkene dipolarophiles (Fig. 22).100a Boons and Popik also
developed a photo-inducible system in which the dibenzo-
cyclooctyne ring is masked by a cyclopropenone motif.91 The
photo-triggered decarbonylation offers the ability to label living
organisms in a spatio-temporally controlled manner. This
system has also been applied successfully in the modification
of surfaces (vide infra).101
5. Orthogonality (fidelity) in supramolecular
chemistry
5.1 Metal!ligand coordination combined with hydrogen
bonding
. . .‘‘From a synthetic point of view it is important that the
two types of interactions [metal!ligand coordination and
hydrogen bonding] are ‘‘orthogonal’’, that is, mutually
compatible.’’. . .
Reinhoudt et al. (1997)102a
The orthogonality discussed thus far is based on chemical
reactions, i.e., two highly chemoselective functional group
inter-conversions. The concept of orthogonality can be extended
to non-covalent interactions. Indeed, the remarkable complexity
of biological systems is built upon a series of intricate non-
covalent interactions that are an exceptional example of a high-
dimension orthogonal system. Because supramolecular systems
are at equilibrium, the orthogonality is continually being tested,
unlike the case of an irreversible chemoselective reaction.
Although this possible complication can be a challenge, it also
represents an opportunity because unwanted supramolecular
interactions may self-correct. So there is a proofreading mecha-
nism possible in self-assembling systems in general.
Reflecting on some of these ideas, Reinhoudt reported in
1997 the first discrete nanostructure assembled by two different
supramolecular interactions (Fig. 23).102a Metallo-dendrimers
as large as 28 kDa were characterized making these among the
largest discrete self-assembled polymers (dendrimers) known.102b
The importance of the orthogonality between the metal!ligand
coordination and hydrogen bonding was explicitly recognized
by Reinhoudt (see the above quote). The pincer coordination103
seen in Fig. 23 is now extensively used in combination with other
hydrogen bonding recognition modules by the Weck group.104
Other commonly used coordination complexes include 2,20-
bipyridine (bpy) and 2,20 : 60,200-terpyridine (tpy) metal com-
plexes that are orthogonal to many of the same hydrogen
bonding modules used with the Pd!pincer complex. These
units have been particularly useful in the design of main-chain
and side-chain modified supramolecular polymers.105 For
example, Schubert et al. reported the formation of hydrogen-
bonded, metallo-supramolecular polymers containing the UPy
hydrogen bonding module and terpyridine as end-groups in the
presence of the Zn(II) ion.106 The same concept was applied to
telechelic polymers to yield high molecular weight supra-
molecular polymers.107 Noting that the UPy dimer is stable
only in non-polar solvents, Schmuck prepared a monomer
containing a terpyridine and a guanidiniocarbonyl pyrrole
carboxylate zwitterion.108 The zwitterion is known to form a
highly stable dimer in DMSO (Ka > 10
8 M!1)109 and the resulting
polymer is observed in both DMSO and aqueous solutions
displaying typical ring-chain equilibrium.110 The self-assembly
of the hydrogen-bonding and metal-coordination is found to be
fully reversible. This orthogonal approach to supramolecular
polymers has been reviewed recently.111
5.2 Orthogonal hydrogen bonding interactions
. . .‘‘These non-standard nucleotides and the pairs that
they form have had particular value as ‘orthogonal
binders’, recognition elements that bind with DNA-like
specificity, but without interference by natural DNA.’’. . .
Benner et al. (2007)112
The very high fidelity of DNA replication is often associated
with highly selective hydrogen bonding.113 In fact, DNA replica-
tion is not perfect and the high fidelity originates not only in
base-pair selectivity but also in shape complementarity113b,c
and subsequent proofreading processes.114 The issue of selectivity
in the pairing of DNA bases and their analogs has been
examined in multiple contexts. Benner and co-workers have
developed base analogs as a way to expand the ‘‘genetic alphabet,’’
Fig. 22 Photo-triggered functionalization of O-allyl-tyrosine-containing
Z-domain protein by photo-click chemistry.100a
Fig. 23 Reinhoudt’s self-assembled dendrimer featuring orthogonal Pd!pincer
coordination and cyanuric acid (CA)!melamine hydrogen bonded rosette motifs.102a
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to create a new base that is orthogonal to A!T and G!C.115 Jorgensen
used computational methods to explore the origin of base-pair
stability and proposed that, in addition to the number of hydrogen
bonds, the stability could be explained by the arrangement of the
donor and acceptor groups and particularly the resultant differ-
ences in ‘‘secondary electrostatic interactions’’ (Fig. 24).116
We reported in 1992117a the first experimental data that
supported the Jorgensen proposal and have since collected
considerable additional data and this knowledge has been used
in the design of more highly orthogonal and more stable DNA
base-pair analogs.117b,c For example, the UG!DAN hetero-
complex118"121 and DeAP dimer122,123 represent two hydro-
gen-bonded pairs that are highly orthogonal and significantly
more stable than DNA base-pairs (Fig. 25, see also Section 5.3).
Minakawa, Matsuda and co-workers found that these quadruply
hydrogen bonded base pairs, depending on the sequence
arrangement, are capable of increasing the thermal stability
of oligonucleotides.124 Leigh and co-workers reported in 2011 a
highly stable AAAA!DDDD quadruple hydrogen bonded
complex with Ka > 10
12 M"1 in CH2Cl2.
125
One area that has not been fully explored is the degree of
orthogonality between the various hydrogen bonding modules
represented by the arrays in Fig. 24. Nonetheless, these modules
have proven quite useful in a wide range of orthogonal assembly
studies. For example, we reported the orthogonal self-assembly
of two dendritic systems consisting of bis-ureidodeazapterin (6)
and pyrimido-naphthyrdinone (7) units (Fig. 26).123 Strikingly
no mixing of the two heterocycles was observed even though the
AAD and DDA arrays in 7 could interact with the AADD array in
6 with the formation of three hydrogen bonds.
Related areas where these high-affinity and high-fidelity
hydrogen-bonded complexes have been applied are, e.g., in
the formation of main-chain supramolecular polymers, in the
noncovalent side-chain modification of polymers, and the
formation of supramolecular polymer blends. An example of
the latter involves two immiscible polymers (PS and PBMA),
prepared with a few mol% of UG and DAN units on the polymer
backbone of PBMA and PS, respectively.120,126 The properties
(such as Tg and viscosity) of the supramolecular blend were
found to be tunable and thermoreversible. The same recogni-
tion pair was reported to form supramolecular alternating
block copolymers with PEG and PBMA blocks.121 Again, the
properties of the copolymers and the polymeric structures are
found to be reversible because of the supramolecular nature of
the recognition process.
Weck and co-workers demonstrated the orthogonal nature
of UG!DAN and Hamilton receptor!cyanuric acid (Hamilton
receptor!CA) and applied the units for the preparation of
supramolecular ABC triblock copolymers.127 The triblock copolymer
can be prepared by stepwise additions of each block or by a
Fig. 24 Possible arrangement of hydrogen bond donor and acceptor groups in
triply and quadruply hydrogen bonded complexes and ranges for measured
association constants.116,117d
Fig. 25 Four stable quadruply hydrogen-bonded complexes each with different
motifs: UG!DAN heterocomplex,118"121 DeAP dimer,122,123 Minakawa and
Matsuda’s novel deoxyribonucleotides,124 and Leigh’s AAAA!DDDD complex.125
Fig. 26 Orthogonal self-assembly of hexameric dendrimers. Gn = Freche´t-type
dendron.123
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one-pot self-assembly. Recently, Lu¨ning reported the use of
Hamilton receptor!CA and complementary ADDA!DAAD units
for orthogonal assembly of a G2 supramolecular dendrimer.128
Weck reported the supramolecular side-chain functionalization
of copolymers using a combination of Hamilton receptor!CA
and T!DAP motifs (Fig. 27) but noted non-specific interactions
between the Hamilton receptor and T.127 Similarly, hydrogen-
bonding and metal coordination might not be fully orthogonal,
depending on the particular system.129,130 Reviews on side-chain
supramolecular polymers can be referred to for more details.131,132
5.3 Quantifying orthogonality in supramolecular systems
In the case of orthogonal reactions, the extent of orthogonality
can be measured by the degree of chemoselectivity, which, in
turn, is measured by the chemical yield of desired and unde-
sired products. In supramolecular systems, the extent of ortho-
gonality can be directly observed. For example, in a remarkable
example of ‘‘self-sorting’’ Isaacs has reported the 1H NMR
spectrum of a multicomponent supramolecular mixture.133
The self-assembling systems, including Rebek’s calixarene capsule,
Meijer’s ureido-pyrimidinone dimer, Reinhoudt’s rosette, and
Isaacs’s cucurbituril dimer, all faithfully formed their designed
complex without interference from the other components. The
same group has defined different types of self-sorting and exam-
ined quantitatively the process under thermodynamic control
using a combination of simulation and experiment.134"136
As a framework for discussing and quantifying supramole-
cular orthogonality, we defined the fidelity (F) of a supramole-
cular system as the mole fraction of desired complexes
(Fig. 28).119,137,138 If each of the possible equilibrium constants
can be measured or estimated, F can be calculated analytically
at all concentrations and stoichiometries of interest. Impor-
tantly, a three-dimensional fidelity plot allows these systems
to be understood in considerable detail (Fig. 28). To better
measure the inherent orthogonality of a system, F at a 1 : 1
ratio of the compounds or complexes of interest was measured
and this was termed intrinsic fidelity (intrinsic orthogonality).137
Two fidelity plots that examine the orthogonality of a pair of
complexes are illustrated in Fig. 28. First, using a mixture of
triply hydrogen-bonded complexes G!C and T!DAP, high fidelity
(F > 0.96) is observed over a broad concentration range
(1.0"10"6 M), indicating that the hydrogen-bonding arrays in
G!C and T!DAP are capable of leading to highly selective
binding. This is consistent with the fact that the homodimer-
izations and other undesired complexations are relatively weak
(o10 M"1). Similarly, a quadruply hydrogen-bonded system
consisting of UG!DAN and (DeAP)2 forms a very high fidelity
system (F Z 0.99) over a wide range of concentrations and
stoichiometries.119 Again, although both complexes are quadruply
hydrogen-bonded, the difference in the arrays (DAAD!ADDA and
DDAA!AADD) contributes significantly to the orthogonality in the
recognition process.
6. Orthogonal surface modifications
The modification of surfaces is important in many areas,
including the fabrication of microelectronics, optoelectronics,
and sensors.139 Modified surfaces also play a key role in various
aspects of biological engineering, for example as scaffolds for
tissue engineering, stem-cell differentiation, and cell culture.140
Fig. 27 Weck’s supramolecular polymer side-chain functionalization displaying
orthogonal self-assembly of Hamilton receptor!CA and T!DAP motifs.127
Fig. 28 Fidelity plots for mixtures of (a) G!C and T!DAP and (b) UG!DAN and
(DeAP)2 complexes. Concentrations are expressed in molar (M). Adapted with
permission from ref. 119. Copyright (2005) American Chemical Society.
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Various lithographic techniques allow the creation of patterned
surfaces with micron to nanometer scale features. The ability to
orthogonally alter the surface chemistry allows precise control
over the properties and patterns that are displayed.
6.1 Surface modifications by self-assembly
In 1989 Whitesides and co-workers reported the formation of
patterned self-assembled monolayers, employing an orthogo-
nal set of hard!soft acid!base interactions.141 In particular,
the selective adsorption of alkanethiols on gold and organic
acids on alumina surfaces was observed on gold surfaces with a
micro-patterned silver overlay (Fig. 29). Two additional orthogonal
self-assembly systems were reported, one using alkanethiols on
gold and carboxylic acids or alkane phosphonic acids on indium
tin oxide (ITO)142 and the second system alkane disulfides on gold
and alkane isocyanides on platinum.143 The latter system did not
achieve full orthogonality as it requires a non-equimolar solution
of the disulfide and isocyanide (40 : 1) to achieve selective surface
functionalization because of the undesired competitive adsorp-
tion of isocyanide on a gold surface.143
Recently, Hoeppener reported the self-assembly of Si and Au
nanoparticles (NPs) and hydroxyl-containing micelles on a
multi-functionalized silicon substrate with !NH2, !SH, or
!CO2H groups, with potential selectivity based on their
chemical reactivity.144 Full orthogonality was not possible
because undesired interactions such as adsorption of Au NP
onto the ammonium surface occur. To avoid cross reactivity,
the functionalization was done in a sequential manner: (1) self-
assembly of negative charged Si NP on the ammonium func-
tionalized surface, (2) Au NP on the thiol surface, and (3)
hydroxyl-containing micelles on the carboxylic acid surface.
6.2 Surface modifications via click chemistry
Not surprisingly CuAAC has emerged as a powerful method to
covalently attach various entities to surfaces. By combining
with other orthogonal reactions, CuAAC has further allowed
selective surface functionalization to give patterned surfaces.
For example, Gleason used capillary force lithography (CFL) to
create a nanopattern of amine and alkyne groups from a bilayer
consisting of 50 nm thick non-crosslinked poly(propargyl
methacrylate) (PPMA) film laid by initiated chemical vapor
deposition (iCVD) on top of a 100 nm thick poly(allylamine)
(PAAm) film using plasma enhanced chemical vapor deposition
to achieve cross-linking.145 The functionalization was accom-
plished in one step with a solution of a Cu(I) salt, tetramethyl-
rhodamine-5-carbonyl azide and 5/6-carboxyfluorescein,
succinimidyl ester (Fig. 30).145 The orthogonal coupling of
alkyne to azide and amino group to NHS-ester was evident in
the microscopic images showing the red and green fluores-
cence in the same pattern created by the CFL.
Maynard reported the use of two orthogonal click reactions
to pattern proteins on surfaces (Fig. 31).146 The initial patterned
surface was prepared by electron-beam lithography.147 Sub-
sequently, oxo-myoglobin was attached to the hydroxyl-amine-
coated areas through oxime formation followed by the attachment
of ubiquitin azide using CuAAC (Fig. 31). The simultaneous
immobilization of three different proteins (streptavidin, bovine
serum albumin, and myoglobin) on surface patterned with
biotin, maleimide, and aminooxy functionalities was also
reported.148 Similarly, Chi used CuAAC and thiol!ene reactions
as an orthogonal set of coupling reactions to pattern proteins
into nanostripes on Si wafers.149
Hawker reported a novel set of orthogonal copper-free,
thermal reactions for selective surface modification through
thermal microcontact printing (mCP).150 Three different dyes
were anchored to the surface using orthogonal thermal azide!
alkyne cycloaddition (TAAC) and acyl ketene formation followed
by nucleophile trapping. It was found that acyl ketene was
formed at 150 1C from its precursor and reacted with amines
but not azides; the azide was shown to be stable even at 150 1C.150
Another example of surface modification using a copper-
free, dibenzocyclooctyne-based SPAAC was reported by Popik
Fig. 29 Orthogonal surface self-assembly based on hard!soft acid!base principle.141
Fig. 30 Simultaneous dual surface functionalization using a combination of
CuAAC and carbodiimide chemistry. Reproduced with permission from ref. 145.
Copyright (2008) American Chemical Society.
Fig. 31 (a) Dual protein patterning using oxime formation followed by CuAAC.
(b) Overlay of myoglobin (green) and ubiquitin (red) fluorescence images. (c)
Ubiquitin reacts with alkyne patterns. (d) Myoglobin reacts with aminooxy
patterns. Scale bar = 5 mm. Adapted with permission from ref. 146.
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and co-workers.151 This DIBO-based immobilization has also
been applied successfully to functionalize microbead surfaces.151
One of the appealing features of the DIBO system is that the
reactive triple bond can be masked as a cyclopropenone motif
(Fig. 32a).101 Photo-decarbonylation can be easily performed
upon irradiation at 350 nm, thereby revealing the reactive triple
bond for copper-free cycloaddition (Fig. 32b). Spatially con-
trolled immobilization can be achieved simply using a shadow
mask. Areas protected by the mask will not undergo cyclo-
addition, thus allowing spatial functionalization on a surface
substrate (Fig. 32c!e). Bowman and co-workers also reported
the spatiotemporally controlled alkyne!azide cycloaddition
using the photochemical reduction of Cu(II) to Cu(I) with
photolithographic techniques.152
6.3 Surface modifications via supramolecular interactions
An extremely active area of research applies the principles of
Section 5 ! orthogonal supramolecular connections ! to the
patterning of surfaces and the formation of functional mono-
and multi-layers. This area has been reviewed very recently by
Yilmaz and Huskens and, thus, will not be covered here.153
7. Conclusions
The concept of orthogonality has come a long way from the
protecting group strategy first described by Barany and Merrifield
in 1977. Indeed that very same notion of two chemoselective
reactions operating with a complete lack of interference from
one another has become pervasive in organic chemistry.
Indeed, the complexity has multidimensional protecting group
strategies available and one can envision a similar development
in orthogonal coupling reactions and orthogonal catalytic cycles.
Ultimately, this would facilitate more efficient syntheses and per-
haps even lead to a day when multi-step synthesis can be carried
out in a single pot with simultaneous addition of the reagents.
The orthogonal approach has moved well beyond the realm
of synthetic organic chemistry into materials and polymer
chemistry and also become a powerful tool for chemical
labeling of biomolecules within living cells. The remarkable
rate at which click chemistry and bioorthogonal reactions have
been adopted is testimony to their powerful ability to link two
entities in high yield and without interference even in complex
systems. The expansion of the click chemistry toolbox by having
additional orthogonal click reactions will undoubtedly further
accelerate progress in many of the areas described herein.
Where will the next big advance come? Predictions along these
lines are always challenging, but more sophisticated strategies
for controlling the spatial and temporal aspects of orthogonal
processes, especially in synthetic organic and biological
contexts, would represent a major advance.
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